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Abstract 
 
 
Cannabinoids show potential as new treatments for inflammatory bowel disease (IBD), 
exerting several favourable effects in the gut, including anti-inflammatory and anti-
motility effects. The main difficulty with cannabinoids is their psychotropic side effects, 
but access to the brain may be prevented by conjugating the cannabinoid to a bulky 
group such as a dendrimer. The aims of this thesis were to investigate the mechanism by 
which cannabinoids reduce gut motility and to investigate whether cannabinoids protect 
the intestine from inflammatory-damage. A further aim was to determine whether 
cannabinoids remain pharmacologically active when conjugated to a dendrimer.  
 
All cannabinoids used (apart from arachidonoylcyclopropylamide and (-)WIN 55,212-
2) caused a concentration-dependent reduction in the size of electrically-stimulated 
contractions in the guinea-pig ileum. The responses were not blocked by CB1, CB2, CBe 
(putative endothelial cannabinoid receptor) or GPR55 antagonists, suggesting that none 
of these receptors were involved in mediating cannabinoid responses. PSN 375963 
reduced carbachol-induced contraction, suggesting that the GPR119 may be present on 
ileum smooth muscle. (+)WIN 55,212-2 was shown to protect the guinea-pig ileum 
from hydrogen peroxide-induced damage but this protection was not blocked by CB1, 
CB2, CBe or GPR55 antagonists, suggesting that the protective effects were not 
mediated through these receptors. Conjugation of JWH007 to a spacer (GA003) 
abolished activity in the guinea-pig ileum and the conjugation of JWH007 to a spacer 
and dendrimer (GA006) was found to be toxic in the macrophage assay. 
 
These studies show that cannabinoid-mediated inhibition of guinea-pig ileum 
contractions is not mediated through the CB1, CB2, CBe or GPR55 receptor. These 
receptors were not involved in the (+)WIN 55,212-2 mediated protection against 
hydrogen peroxide-induced damage in the ileum. The approach of attaching a dendrimer 
to JWH007 to prevent central nervous system (CNS) penetration does not appear to be a 
feasible approach because the cannabinoid-dendrimer was unexpectedly cytotoxic. 
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1. Introduction 
 
1.1 Overview of thesis 
 
Therapeutics currently available to treat inflammatory bowel disease (IBD) and Irritable 
Bowel Syndrome (IBS) are limited either by their lack of efficacy or their severe side 
effects, and there is a need for safer, more effective treatments to be developed. 
Cannabinoids may potentially be developed as a new class of therapeutics for IBD. 
They exert several beneficial effects in the gut such as reducing inflammation, motility 
and secretions, alleviating visceral pain (Izzo and Sharkey, 2010) and enhancing 
epithelial wound healing (Wright et al., 2005). The main barrier to a cannabinoid-based 
therapeutic is the resulting psychotropic side effects, but this could be overcome by 
conjugating the cannabinoid to a dendrimer to prevent the cannabinoid from crossing 
the blood brain barrier. Dendrimers are bulky polymers with tree-like branching 
structures. The size of the dendrimer can be selected so that it is small enough to be 
absorbed across the intestine but large enough to prevent central nervous system (CNS) 
penetration. Dendrimer properties and in vivo dendrimer distribution are discussed in 
more detail in chapter 5. 
  
The mechanisms by which cannabinoids reduce motility in the gut have not been fully 
elucidated and one of the main aims of this thesis was to examine the receptors involved 
in these effects. Additionally, as this has not been the subject of any earlier research, 
these studies investigated whether cannabinoids protect the intestine against 
inflammatory damage. The final aim of this thesis was to test whether cannabinoids 
retain their pharmacological efficacy when conjugated to a dendrimer 
 
 
 
 
3 
This introduction reviews the current literature concerning the pharmacology of plant, 
synthetic and endogenous cannabinoids, as well as the latest evidence regarding the 
mechanisms by which cannabinoids modulate the immune response and reduce 
inflammation and motility in the gut. 
 
1.2 Cannabis sativa  
 
The plant Cannabis sativa, commonly known as marijuana, was first used for 
medicinal, recreational and religious purposes 5000 years ago (Pertwee, 2006) and is 
now the most popular illegal drug in the United States with 46.1% of 17-18 year olds 
being users (Klein, 2005). The plant is widely known for its psychotropic effects which 
include relaxation and euphoria at low doses (which accounts for its recreational use) 
and impairment of thinking, perceptual and psychomotor function at high doses (Smita 
et al., 2007).  
 
Marijuana contains at least 66 compounds known as cannabinoids, the cannabinoid ∆9-
Tetrahydrocannabinol (THC) being mainly responsible for the psychotropic effects 
(Pertwee, 2006). In addition to phytocannabinoids, endogenous cannabinoids and 
cannabinoid receptors have now been discovered in mammals and are discussed in more 
detail below (section 1.3).  
 
In addition to use for its psychotropic effects, marijuana has been used to relieve the 
symptoms of several diseases ranging from rheumatism and epilepsy to tetanus and 
gonorrhoea. There is also anecdotal evidence that marijuana may be effective in 
relieving the symptoms of Crohn’s disease and diabetic gastroparesis (Klein, 2005). 
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Also, antiperistaltic, antisecretive and antiulcer activity has been exhibited by THC 
(Pinto et al., 2002a).  
 
1.3 The endocannabinoid system 
 
Endogenous cannabinoid receptors and agonists have been discovered in mammals and 
two types of cannabinoid receptors (CB1 and CB2) have been cloned (Howlett et al., 
2002).There is also evidence for the existence of other cannabinoid receptor types 
(Gomez-Ruiz et al., 2007). CB1 receptors are found in the central nervous system and 
some peripheral tissues whereas CB2 receptors are mainly found on immune cells, 
reviewed by Pertwee (2005) and Pertwee et al (2002). These receptors are coupled to G 
proteins and there is evidence that an allosteric site is present on the CB1 receptor which 
modulates cannabinoid affinity for the binding site (Price et al., 2005). The CB1 receptor 
seems to be highly conserved across species, in contrast to the CB2 receptors which 
show more variation between species (Gomez-Ruiz et al., 2007). 
 
Of the endogenous agonists that have been found, anandamide (Hanus et al., 2001) and 
2-arachidonoyl glycerol (2-AG) (Sugiura et al., 1997; Sugiura et al., 1996) have been 
the most extensively studied. These agonists have been found to differ in efficacy for 
the two receptor types (Pertwee, 1999). 2-AG is an agonist at the both receptors and is 
more active as a CB2 receptor agonist than anandamide (Gomez-Ruiz et al., 2007). 
Anandamide acts as a partial or full agonist at the CB1 receptor, depending on the tissue 
and response being measured and can act as a low-efficacy agonist or an antagonist at 
CB2 receptors (Gomez-Ruiz et al., 2007). Other endogenous cannabinoids include 
noladin ether (2-arachidonoyl ether), N-arachidonoyl dopamine (NADA) and 
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virodhamine which vary in efficacy at cannabinoid receptors and whose biological 
function is unknown (Gomez-Ruiz et al., 2007).  
 
“Endocannabinoid-like” substances also exist such as palmitoylethanolamide (PEA) and 
oleoylethanolamide (OEA). These compounds possess low affinity for the CB1 and CB2 
receptor (Bradshaw et al., 2005; Devane et al., 1992; Lambert et al., 1999) but can 
enhance the action of endocannabinoids at their receptors, in a process known as the 
entourage effect (Gomez-Ruiz et al., 2007). These compounds are N-acylethanolamines 
and it is thought that, in a similar way to anandamide, they are synthesised from a 
molecule similar to N-acyl phosphatidylethanolamine (NAPE) and broken down by 
fatty acid amide hydrolase (FAAH) (Alexander and Kendall, 2007). There is evidence 
that OEA and PEA may exert pharmacological effects through non-CB1 and non-CB2 
receptors (Brown, 2007). OEA reduces food intake and alters metabolism, and studies 
have suggested that these effects may involve activation of the vanilloid receptor 
transient receptor potential cation channel, subfamily V, member 1 (TRPV1), 
peroxisome proliferator - activated receptor (PPARα) (Fu et al., 2003; Su et al., 2006; 
Thabuis et al., 2008) or the orphan receptor GPR119 (Ning et al., 2008; Overton et al., 
2006). PEA, on the other hand, has anti-inflammatory effects which may be mediated 
through stimulation of the orphan receptor GPR55 (Ryberg et al., 2007), PPARα (Lo 
Verme et al., 2005c) or potentiation of anandamide actions at several receptors (Costa et 
al., 2008). The effect of OEA and PEA on the non-CB1, non-CB2 receptors has been 
discussed in more detail in section 1.7.2. 
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1.4 Synthesis of endocannabinoids 
Endocannabinoids are formed and released on demand (Elphick et al., 2001; Kreitzer et 
al., 2001; Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001) in response to increased 
intracellular calcium (Best et al., 2010) and therefore are not stored in synaptic vesicles, 
in contrast to other neurotransmitters. Anandamide is produced by the hydrolysis of the 
membrane pre-cursor NAPE, catalysed by the enzyme phospholipase D (NAPE-PLD) 
(Okamoto et al., 2004). Prior to this, NAPE is synthesised by the transfer of arachidonic 
acid from phosphatidylcholine to phosphatidylethanolamine (Cadas et al., 1997; see 
figure 1.1). Variants of this pathway have been described in the stomach and the mouse 
leukemic monocyte-macrophage cell line RAW 264.7 (Gomez-Ruiz et al., 2007). It is 
now thought that there may be alternative pathways for the synthesis of anandamide as 
NAPE-PLD knockout mice do not have lower levels of anandamide (Leung et al., 2006; 
se figure 1.1). Studies have suggested that phopsho-anandamide may be formed by the 
subsequent hydrolysis of NAPE by a phospholipase-C like enzyme and then hydrolysed 
to anandamide by an enzyme such as tyrosine phophatase N22 (Liu et al., 2006). 
Another pathway for anandamide production may be the cleavage of two acyl groups 
from NAPE by α/β hydrolase 4, followed by hydrolysis of glycerophospho-anandamide 
to anandamide by a phosphodiesterase (Simon et al., 2006). It is also possible that 2-
lyso-NAPE may be formed from NAPE by phospholipase A2 and converted to 
anandamide by lyso-phospholipase D (Sun et al., 2004). 
 2-AG, on the other hand, is produced from 1,2-diacylglycerol (DAG) by DAG lipase 
(DAGL). Two isozymes of DAG lipase, DAGL-α and DAGL-β, have been found in the 
adult brain (Bisogno et al., 2003). DAG can be produced from phosphoinositides or 
from phosphatidic acid (Gomez-Ruiz et al., 2007). 
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Figure 1.1 Pathways for anandamide synthesis. 
 
1.5 Endocannabinoid uptake mechanisms 
There is evidence that termination of anandamide’s action occurs via uptake into cells. 
This is followed by intracellular hydrolysis to arachidonic acid and ethanolamide 
(Gomez-Ruiz et al., 2007; see figure 1.2) which is catalysed by FAAH (Maccarrone et 
al., 1998; Piomelli et al., 1999).The mechanism of anandamide uptake is controversial 
as an endocannabinoid transporter has not yet been identified. Suggested mechanisms 
include diffusion facilitated by a membrane transporter, diffusion driven by intracellular 
hydrolysis of anandamide, diffusion driven by intracellular sequestration of anandamide 
and endocytosis (Gomez-Ruiz et al., 2007). 
 
 phosphatidylcholine phosphatidylethanolamine  
 
arachidonic  
acid 
 NAPE 
 2-lyso-NAPE 
         ? 
 phospho-anandamide  
                ? 
glycerophospho-anandamide  
                            ? 
Anandamide 
Phospholipase A2 ? 
Phospholipase C 
-like 
Enzyme ? 
Phospholipase D 
α/β hydrolase ? 
 lyso-phospholipase D ?  tyrosine phosphatase  N22 ?  
Phosphodiesterase ? 
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1.6 Metabolism of endocannabinoids  
Inside the cell, whereas anandamide undergoes hydrolysis to arachidonic acid and 
ethanolamide, catalysed by FAAH, 2-AG undergoes hydrolysis to arachidonic acid and 
glycerol, catalysed by a monoacylglycerol-lipase (MAGL). FAAH can also catalyse the 
hydrolysis of 2-AG, but MAGL is thought to be mainly responsible. Additionally, 2-AG 
is a substrate for α/β hydrolases, which could also be responsible for the hydrolysis of 
this endocannabinoid (Blankman et al., 2007). 
Non-FAAH amidases, the FAAH homologue FAAH-2 (Wei et al., 2006) and N-
acylethanolamide acid amidase (NAAA) (Tsuboi et al., 2005) which inactivate N-acyl-
ethanolamines, have been discovered. Anandamide and 2-AG, however, are not 
inactivated by these enzymes (Tsuboi et al., 2005; Wei et al., 2006). 
O-phosphorylcholine derivatives of N-acylethanolamines have been discovered in 
FAAH null mice (Mulder et al., 2006), and, although it is not clear how these are 
formed, this could represent a mechanism for FAAH-independent inactivation of 
anandamide and other N-acylethanolamides (De Petrocellis et al., 2009).  
The endocannabinoids anandamide and 2-AG are metabolised by cyclooxygenases and 
lipoxygenases, which are involved in the general metabolism of eicosanoids (Hampson 
et al., 1995; Ueda et al., 1995; Yu et al., 1997) as well as cytochrome P450 enzymes 
(Bornheim et al., 1995). Prostamides are formed by the oxidation of anandamide by 
cyclooxygenase 2 (COX-2) and subsequent conversion by prostaglandin synthases (see 
figure 1.2). The action of these enzymes on 2-AG, on the other hand, produces 
prostaglandin glycerol esters (Kozak et al., 2000). The prostamide metabolites of 
anandamide may produce various pharmacological effects, for example the inhibition of 
immune cells such as macrophages (Correa et al., 2008) and the increase in  pulmonary 
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artery pressure (Wahn et al., 2005). Prostaglandin metabolites of 2-AG also possess 
pharmacological effects, such as the mobilisation of intracellular Ca2+ (Nirodi et al., 
2004).  2-AG and anandamide may also be converted to hydroperoxy- and hydroxyl-
derivatives by lipooxygenases or epoxyeicosatetraenoyl-anandamides by cytochrome 
p450 oxygenases (see figure 1.2). Most of these metabolites are still active at 
cannabinoid receptors, but there is  currently no evidence that they are produced in vivo 
(De Petrocellis et al., 2009). 
 
Figure 1.2 Metabolic pathways of anandamide. 
 
1.7 Cannabinoid pharmacology 
 
1.7.1 Cannabinoid receptor ligands 
 
Cannabinoid agonists can be divided into three different classes, endocannabinoids 
(found endogenously in mammals), phytocannabinoids (found endogenously in plants) 
and synthetic cannabinoid ligands. Synthetic cannabinoid antagonists have also been 
designed. Some of these antagonists are neutral whereas others are inverse agonists 
O-phosphorylcholine 
 derivative of 
 anandamide  
Anandamide 
Prostamides  hydroperoxy- 
 and hydroxyl- 
derivatives of  
anandamide 
Epoxyeicosatetraenoyl 
-anandamides  
arachidonic acid  
and ethanolamide  
FAAH  
independent 
mechanism 
COX-2 FAAH LOX CYP 
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(reduce the constitutive activity of the receptor).  Cannabinoids differ in their selectivity 
at the CB1 and CB2 receptors: the common cannabinoid agonist and antagonists and 
their affinities for the CB1 and CB2 receptors are shown in table 1.1 overleaf.  
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Ligand Classification CB1 ki 
 value (nM) 
CB2 ki 
value (nM) 
Reference 
ACEA Selective CB1 
agonist 
1.4 >2000 (Hillard et al., 1999) 
ACPA Selective CB1 
agonist 
2.2 715 (Hillard et al., 1999) 
Methanandamide Selective CB1 
agonist 
17.9 
20 
 
868 
815 
 
(Lin et al., 1998) 
(Khanolkar et al., 1996) 
Rimonabant Selective CB1 
antagonist 
11.8 
12.3 
5.6 
 
 
973 
702 
>1000 
 
 
(Felder et al., 1995) 
(Showalter et al., 1996) 
(Rinaldi-Carmona et al., 
1994) 
AM281 Selective CB1 
antagonist 
12 4200 (Lan et al., 1999a) 
AM251 Selective CB1 
antagonist 
7.49 2290 (Lan et al., 1999b) 
JWH133 Selective CB2 
agonist 
677 3.4 (Huffman et al., 1999) 
SR144528 Selective CB2 
antagonist 
70 
305 
437 
50.3 
>10000 
0.28 
0.3 
0.6 
1.99 
5.6 
(Ruiu et al., 2003) 
(Rinaldi-Carmona et al., 
1998) 
(Rinaldi-Carmona et al., 
1998) 
(Iwamura et al., 2001) 
(Ross et al., 1999) 
AM630 Selective CB2 
antagonist 
5152 31.2 (Ross et al., 1999) 
JWH007 Non-selective CB1 
/ CB2 agonist 
9.5 2.9 (Huffman et al., 2005) 
 
HU210 Non-selective CB1 
/ CB2 agonist 
0.0608 
0.1 
0.73 
0.524 
0.17 
0.22 
(Felder et al., 1995) 
(Rhee et al., 1997) 
(Showalter et al., 1996) 
CP 55,940 Non-selective CB1 
/ CB2 agonist 
5 
3.72 
1.37 
 
 
1.8 
2.55 
1.37 
 
 
(Ross et al., 1999) 
(Felder et al., 1995) 
(Rinaldi-Carmona et al., 
1994) 
 
(+)WIN  Non-selective CB1 
/ CB2 agonist 
9.94 
4.4 
62.3 
 
16.2 
1.2 
3.3 
 
(Rinaldi-Carmona et al., 
1994) 
(Hillard et al., 1999) 
(Felder et al., 1995) 
 
O-1602 
 
 
Selective GPR55 
agonist 
>30000 >30000 (Ryberg et al., 2007) 
(-) CBD GPR55 
antagonist/ CB1 
antagonist/CB2 
inverse agonist 
4350 
>10000 
2860 
>10000 
(Showalter et al., 1996) 
(Bisogno et al., 2001) 
Abnormal-CBD Selective CBe 
agonist 
>100000 >10000 (Showalter et al., 1996) 
O-1918 Selective CBe 
antagonist 
>30000 >30000 (Jarai et al., 1999) 
PSN 375963 GPR119 agonist Reported not 
to bind 
? (Lambert et al., 2007) 
 
Table 1.1 Affinities of commonly used cannabinoid agonists and antagonists/inverse agonists at the CB1 
and CB2 receptor. 
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1.7.2 Non-CB1 / CB2 targets for cannabinoid receptor ligands 
 
One of the major problems with using selective cannabinoid agonists and antagonists as 
tools in pharmacological studies is that they may not be as selective as first thought. It is 
now emerging that cannabinoids may have several other pharmacological targets apart 
from the CB1 and CB2 receptors. For example, the so-called selective CB1 antagonist 
rimonabant has been shown to target a number of other receptors apart from CB1 and 
has also been shown to directly alter ion channel conductance. These effects of 
rimonabant have been reported at concentrations used in pharmacological studies which 
means that results from these studies should be interpreted with caution (see table 1.5). 
The evidence for additional targets for cannabinoids (including putative novel 
cannabinoid receptors) has been discussed below. 
GPR55 receptor 
The orphan G protein receptor GPR55 has been proposed as a novel cannabinoid 
receptor as it activated by several cannabinoids (Brown, 2007). There have been some 
suggestions that GPR55 may be the putative CBe receptor but the evidence is not 
entirely consistent with this theory (See CBe receptor section below). Some researchers 
suggest that GPR55 is not a cannabinoid receptor at all, as cannabinoids do not 
consistently activate the GPR55 receptor (see table 1.2 a, and b). Some authors have 
suggested that lysophosphatidylinositol (LPI) is more likely to be the endogenous ligand 
as it has been reported to activate this receptor in every assay studied so far (Godlewski 
et al., 2009). 
GPR55 mRNA has been found to be expressed in the human brain (high levels have 
been found in the dorsal striatum, caudate nucleus and putamen) and it has been 
suggested that GPR55 may have a role in pain signalling and influence memory, 
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learning and motor functions. GPR55 transcripts have also been identified in peripheral 
tissues including ileum, testis, spleen, tonsil, breast, adipose tissue (Brown, 2007; 
Sawzdargo et al., 1999) and endothelial cell lines (Waldeck-Weiermair et al., 2008). 
 
Ligand Activity Cell type Measured response Reference 
Anandamide No effect(1µM) hGPR55-
HEK293 
ERK 
phosphorylation 
(Oka et al., 
2007; Oka et al., 
2009) 
nM range hGPR55-
HEK293 
[35S]GTPγS Assay (Ryberg et al., 
2007) 
µM range hGPR55-
HEK293 
RhoA activation (Ryberg et al., 
2007) 
µM range hGPR55-
HEK293 
Ca2+ mobilisation (Lauckner et al., 
2008) 
µM range HUVEC Ca2+ mobilisation (Waldeck-
Weiermair et al., 
2008) 
µM range HUVEC ERK 
phosphorylation 
(Waldeck-
Weiermair et 
al., 2008) 
No effect hGPR55-
HEK293 
Ca2+ mobilisation (Henstridge et 
al., 2009b)  
2-AG No effect(1µM) hGPR55-
HEK293 
ERK 
phosphorylation 
(Oka et al., 
2007; Oka et al., 
2009) 
nM range hGPR55-
HEK293 
[35S]GTPγS Assay (Ryberg et al., 
2007) 
No effect (5µM) hGPR55-
HEK293 
Ca2+ mobilisation (Lauckner et al., 
2008) 
No effect hGPR55-
HEK293 
Ca2+ mobilisation (Henstridge et 
al., 2009b)  
LPI nM range hGPR55-
HEK293 
ERK 
phosphorylation 
(Oka et al., 
2007; Oka et al., 
2009) 
µM range DRG neurons Ca2+ mobilisation (Lauckner et al., 
2008) 
µM range HUVEC Ca2+ mobilisation (Waldeck-
Weiermair et al., 
2008) 
nM range hGPR55-
HEK293 
Ca2+ mobilisation (Henstridge et 
al., 2009b)  
µM range hGPR55-
HEK293 
NFAT activation (Henstridge et 
al., 2009b)  
µM range hGPR55-
HEK293 
RhoA activation (Henstridge et 
al., 2009b)  
Table 1.2a Activity of cannabinoids at the GPR55 receptor. 
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Ligand Activity Cell type Measured response Reference 
(+)WIN No effect (1µM) hGPR55-
HEK293 
ERK 
phosphorylation 
(Oka et al., 
2007) 
No effect (1µM)  hGPR55-
HEK293 
[35S]GTPγS Assay (Johns et al., 
2007) 
No effect (30µM) hGPR55-
HEK293 
[35S]GTPγS Assay (Ryberg et al., 
2007) 
No effect (5µM) hGPR55-
HEK293 
Ca2+ mobilisation (Lauckner et al., 
2008) 
AM281 No effect (30µM) U2OS cells 
expressing 
GPR55 
Β-arrestin assay (Kapur et al., 
2009) 
Agonism (3 to 
30µM) 
hGPR55-
HEK293 
Elevation of 
intracellular Ca2+ 
(Henstridge et 
al., 2009a and b) 
rimonabant 
 
No effect (10µM) GPR55-
expressing 
microglial cells 
(BV2) 
Elevation of 
intracellular Ca2+ 
(Eldeeb et al., 
2009) 
No effect (30µM) U2OS cells 
expressing 
GPR55 
Phosphorylation of 
ERK 
(Kapur et al., 
2009) 
Agonist (EC50 
3.9µM) 
U2OS cells 
expressing 
GPR55 
Β-arrestin assay (Kapur et al., 
2009) 
Agonist  (10µM) hGPR55-
HEK293 
G-protein 
dependent 
activation of 
PKCΔII 
(Kapur et al., 
2009) 
Antagonist hGPR55-
HEK293 
Ca2+ mobilisation (Lauckner et al., 
2008) 
Antagonist mouse DRG 
neurons 
Ca2+ mobilisation (Lauckner et al., 
2008) 
Abnormal-CBD nM range hGPR55-
HEK293 
[35S]GTPγS Assay (Johns et al., 
2007) 
µM range hGPR55-
HEK293 
[35S]GTPγS Assay (Ryberg et al., 
2007) 
No effect(3µM) hGPR55-
HEK293 
Ca2+ mobilisation (Lauckner et al., 
2008) 
(-)CBD Antagonist hGPR55-
HEK293 
[35S]GTPγS Assay (Ryberg et al., 
2007) 
0-1602 nM range  HEK293 [35S]GTPγS Assay (Johns et al., 
2007) 
nM range HEK293 [35S]GTPγS Assay (Ryberg et al., 
2007) 
µM range HEK293 RhoA activation (Ryberg et al., 
2007) 
µM range  HUVEK Ca2+ mobilisation (Waldeck-
Weiermair et al., 
2008) 
No effect (10µM) hGPR55-
HEK293 
Ca2+ mobilisation (Oka et al., 
2009) 
No effect (10µM)  hGPR55-
HEK293 
ERK 
phosphorylation 
(Oka et al., 
2009) 
Table 1.2b Activity of cannabinoids at the GPR55 receptor continued.  
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GPR119 receptor 
 
The GPR119 receptor is an orphan G protein-coupled receptor which has been proposed 
as a novel cannabinoid receptor .The receptor is closely related to the cannabinoid 
receptors (Oh et al., 2006) and the endocannabinoid-like OEA is a known ligand for 
GPR119 (Milman et al., 2006), although anandamide is only a weak agonist for this 
receptor (Overton et al., 2006). The effects of other cannabinoids on this receptor have 
also been tested and are shown in table 1.3. Several selective GPR119 agonists have 
been designed such as PSN 375963 (EC50 8.4 ± 2.7µM at human GPR119 in the yeast 
fluorimetric assay) and PSN 632408 (EC50 5.6 ± 0.99µM at human GPR119 in the yeast 
fluorimetric assay) (Overton et al., 2006) but unfortunately no GPR119 antagonists 
have been developed yet, so it is difficult to confirm the involvement of this receptor in 
any functional studies. 
 
GPR119 mRNA has been found mainly in the pancreas and gastrointestinal tract (Chu 
et al., 2007; Lauffer et al., 2009) and in some brain tissues (Overton et al., 2008). 
Immunohistochemical studies in the pancreas have shown that the GPR119 receptor is 
present in polypeptide-releasing cells (Sakamoto et al., 2006) and co-localised with 
insulin in the islet of Langerhans cells (Chu et al., 2007). In the intestine, the GPR119 
receptor was found to be co-localised with glucagon-like peptide (GLP-1) in 
proglucagon positive cells of the villi (Chu et al., 2007).   
 
Studies have suggested that the GPR119 receptor is involved in controlling glucose 
tolerance and obesity. GPR119 agonists improved glucose tolerance by increasing 
insulin secretion from pancreatic cells in vitro and in vivo in diabetic mice (Chu et al., 
2008). OEA and PSN 632408 decreased food intake and body weight gain in mice (Lan 
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et al., 2009; Overton et al., 2006). However, as there is no GPR119 antagonist available 
at present, it is not clear whether the effects of these compounds are mediated through 
the GPR119 receptor. The effects of OEA could be mediated by the peroxisome 
proliferator-activated receptor alpha (PPAR α) receptor (see ‘Peroxisome proliferator-
activated receptors’ below), and PSN 632408 is also able to activate the GPR55 
receptor (Milman et al., 2006).  
 
Ligand GPR119 fold induction of 
yeast reporter 
Reference 
Anandamide 2 (Overton et al., 2006) 
PEA 20 (Overton et al., 2006) 
2-AG inactive (Overton et al., 2006) 
OEA 60 (Overton et al., 2006) 
methanandamide inactive (Overton et al., 2006) 
CP,55940 inactive (Overton et al., 2006) 
(+)WIN inactive (Overton et al., 2006) 
JWH133 inactive (Overton et al., 2006) 
Table 1.3 Activity of cannabinoids at the GPR119 receptor.  
 
CBe receptor 
 
There is also evidence for a non-CB1, non-CB2, non-vanilloid receptor in mesenteric 
vasculature (Jarai et al., 1999; Ralevic et al., 2001; Wagner et al., 1999), which has now 
been proposed as a novel cannabinoid receptor and is known as the ‘abnormal 
cannabidiol’ or the endothelial cannabinoid (CBe) receptor. 
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Abnormal cannabidiol (abnormal-CBD) is a cannabinoid which does not bind to CB1 or 
CB2 (see table 1.1). This compound, as well as anandamide and OEA, was found to 
dilate isolated mesenteric artery segments and the effects of anandamide and abn- 
cannabidiol  were antagonised by the cannabidiol analogue O-1918 (which also does 
not bind to CB1 or CB2 receptors) (Hoi et al., 2006; Offertaler et al., 2003). 
Vasorelaxation was also blocked by pertussis toxin suggesting that the receptor is Gi-
protein coupled. These results lead to the suggestion that a novel cannabinoid receptor 
(now known as the CBe receptor) is present in the mesentery and that abnormal-CBD 
cannabidiol, anandamide and OEA are agonists for this receptor whilst O-1918 is a 
selective antagonist (Hoi et al., 2006; Offertaler et al., 2003).  
 
The CBe receptor may also be involved in endothelial cell migration, as well as 
vasorelaxation. Abnormal-CBD cannabidiol was found to stimulate migration in an O-
1918-sensitive manner, suggesting that this effect was mediated through the CBe 
receptor (Mo et al., 2004). It is important to note that the CBe receptor has not been 
cloned yet and that its existence is only suggested from the results of functional studies. 
 
It has been suggested that the orphan receptor GPR55 is the putative CBe receptor, 
although the evidence is not entirely consistent with this idea. The evidence has been 
summarised by Ross (2009).  In support of the hypothesis that GPR55 is the CBe 
receptor, O-1602 and abnormal-CBD can elicit responses thought to be mediated by the 
CBe receptor as well as GPR55. Furthermore, both CBe and GPR55 receptor responses 
are sensitive to antagonism by rimonabant and cannabidiol. In addition, (R)-(+)-WIN 
55,212-2 mesylate ((+)WIN) does not bind to GPR55 and also does not elicit responses 
thought to be mediated by the CBe receptor. The evidence against this hypothesis is that 
O-1602 and abnormal-CBD exert haemodynamic effects in wild-type and GPR55-/- 
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mice. Also, CP 55,940 activates GPR55 but does not act at the CBe receptor (Ross, 
2009). 
 
More recently, the orphan receptor GPR18 has been suggested as the CBe receptor. In 
one study, N-arachidonoyl glycine and abnormal-CBD were found to mediate cellular 
migration in BV-2 microglia and GPR18 transfected HEK293, effects that were blocked 
by O-1918. In addition, GPR18 mRNA and immunocytochemical staining was found in 
the BV-2 microglia. Neither N-arachidonoyl glycine nor abnormal-CBD produced this 
effect in GPR55-transfected and wild-type HEK 293 cells (McHugh et al.,2010).  
Transient  receptor potential receptors 
Cannabinoids are also known to act on the family of transient receptor potential (TRP) 
receptors. Anandamide and methanandamide activate the vanilloid receptor 1 (TRPV1), 
and the selective CB1 agonist, arachidonoyl-2’-chloroethylamide (ACEA) is also a 
partial agonist at this receptor (Ross et al., 2001; Zygmunt et al., 1999). ACEA has been 
shown to stimulate calcitonin gene-related peptide (CGRP) release from rat ganglion 
sensory neurons, an effect that was blocked by TRPV1 antagonists (Price et al., 2004). 
Rimonabant has been shown to be a mixed TRPV1 agonist/antagonist, stimulating 
CGRP release at high concentrations but antagonising capsaicin-stimulated CGRP 
release at low concentrations (Price et al., 2004). 
Studies have shown that the transient potential cation channel, subfamily A, member 1 
(TRPA1) receptor is activated by Δ9 -tetrahydrocannabinol (THC), (S)-(-)-WIN 55,212-
2 mesylate (-)WIN and (+) WIN (Jordt et al., 2004). Both THC and cannabidiol (-)CBD 
were found to increase free intracellular calcium concentrations in HEK293 cells 
transfected with TRPA1 receptors (Jordt et al., 2004). THC and (+) WIN were found to 
induce inward currents in TRPA1-expressing oocytes (Hinman et al., 2006) and 
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Chinese hamster ovarian (CHO) cells, respectively (Akopian et al., 2008). THC has also 
been shown to activate vanilloid receptor 2 (TRPV2) receptors and induce calcium 
mobilisation in TRPV2-transfected HEK293 cells (Neeper et al., 2007). 
Cross regulation between the cannabinoid and vanilloid systems has been suggested by 
Gomez-Ruiz et al (2007). This is supported by evidence that anandamide is released 
following capsaicin activation of vanilloid receptors on primary sensory neurons which 
co-express vanilloid and cannabinoid receptors (Gomez-Ruiz et al., 2007). 
 
 Peroxisome proliferator-activated receptors 
 
Studies now suggest that cannabinoids can activate members of the PPAR family. 
Whereas the PPARδ (Barish et al., 2006) and PPARγ1 (Auboeuf et al., 1997) receptors 
are ubiquitously expressed, PPARγ2 is found in adipose tissue, PPARγ3 is found in 
macrophages (Auboeuf et al., 1997)  and PPARα is found in metabolically active 
tissues such as liver, heart and muscle (Stienstra et al., 2007). All PPARs are also 
expressed in the brain and peripheral nervous system (Cimini et al., 2005). This section 
focuses on PPARα and PPARγ as the effects of cannabinoids on PPARδ have not been 
extensively studied. 
 
Current evidence suggests that cannabinoids can activate PPARs to affect appetite, lipid 
metabolism, inflammation and vasodilatation. Indeed, OEA was shown to suppress 
appetite (Fu et al., 2003), stimulate lipolysis (Guzman et al., 2004) and reduce oedema 
in mice (Lo Verme et al., 2005). OEA was also found to be neuroprotective in a mouse 
model of cerebral artery occlusion (Sun et al., 2006). None of these OEA-mediated 
effects could be reproduced in PPARα knockout mice, suggesting this receptor was 
responsible for its effects (Fu et al., 2003; Guzman et al., 2004; Lo Verme et al., 2005; 
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Sun et al., 2006). Another endocannabinoid-like compound, PEA, was found to have 
similar effects on inflammation as OEA.These effects were also thought to be mediated 
through the PPARα receptor (LoVerme et al., 2006). Cannabinoids have also been 
shown to activate the PPARα receptor. The cannabinoid (+)WIN was shown to be 
neuroprotective via activation of the PPARα receptor, and the endocannabinoids 
anandamide, virodhamine and noladin are also known to activate PPARα. (Sun et al., 
2006). 
 
There is evidence that THC, anandamide and (+)WIN activate PPARγ to dilate blood 
vessels (O'Sullivan et al., 2005), reduce inflammation (Rockwell et al., 2004) and 
induce apoptosis respectively (Giuliano et al., 2009). Other cannabinoids which activate 
PPARγ are 2-AG, N-arachidonoyldopamine, HU210, CP 55,940, cannabidiol 
(O'Sullivan, 2007) and methanandamide (Eichele et al., 2009). 
 
The mechanism of action of cannabinoids at PPARs is not fully understood (O'Sullivan, 
2007)  – some studies suggest that cannabinoids bind directly to the receptors to alter 
gene expression (Fu et al., 2003; (Sun et al., 2006), whereas some studies suggest that 
cannabinoid metabolites activate PPARs (Rockwell et al., 2004). Another suggestion is 
that cannabinoids act at receptors on the cell membrane and activate signalling 
pathways which lead to the activation of PPARs (O'Sullivan, 2007). 
 
 
 
 
 
 
 
 
 
 
21 
Other receptors 
 
Cannabinoid agonists also target other non-cannabinoid receptors and channels, apart 
from TRP and PPAR, as illustrated by the cannabinoid (+)WIN and the antagonist 
rimonabant in tables 1.4 and 1.5 below: 
 
Ligand Receptor or channel Effect Concentration Reference 
Rimonabant acetylcholine 
(muscarinic) M1 + M4 
Displacement >1µM or >10µM (Christopoulos et 
al., 2001) 
adenosine A1 Antagonism 10µM (Savinainen et al., 
2003) 
adenosine A3 Displacement IC50 = 1.5 µM (as reviewed by 
Pertwee, 2010) 
α2A- adrenoceptors Displacement IC50 = 7.2 µM  (as reviewed by 
Pertwee, 2010) 
α2C- adrenoceptors Displacement IC50 = 3.6 µM  (as reviewed by 
Pertwee, 2010) 
angiotensin AT1 Displacement IC50 = 7.2 µM (as reviewed by 
Pertwee, 2010) 
5-HT6 Displacement IC50 = 2.8 µM  (as reviewed by 
Pertwee, 2010) 
imidazoline Antagonism 1µM (Molderings et al., 
1999) 
µ opioid Displacement IC50 = 3.0 µM  (as reviewed by 
Pertwee, 2010) 
µ opioid  Displacement IC50 = 4.1 µM (Kathmann et al., 
2006) 
µ opioid  Displacement IC50 = 5.7 µM (Cinar et al., 2009) 
κ opioid  Displacement IC50 = 3.9 µM  (as reviewed by 
Pertwee, 2010) 
prostanoid EP4 Displacement IC50 = 3.9 µM  (as reviewed by 
Pertwee, 2010) 
prostanoid FP Displacement IC50 = 2 µM  (as reviewed by 
Pertwee, 2010) 
prostanoid IP Displacement IC50 = 4.9 µM (as reviewed by 
Pertwee, 2010) 
tachykinin NK2 Displacement IC50 =2 µM  (as reviewed by 
Pertwee, 2010) 
L-type 
calcium(Cav1)channels 
Displacement IC50 = 6.1 µM (as reviewed by 
Pertwee, 2010) 
T-type 
calcium(Cav3)channels 
Inhibition 100 nM, 1 µM (Chemin et al., 
2001) 
potassium TASK-1 
channels 
Inhibition 10µM (Maingret et al., 
2001) 
potassium Kv channels Inhibition 10µM (Van den Bossche 
et al., 2000) 
potassium Kv channels Displacement IC50 = 2.5 µM  (as reviewed by 
Pertwee, 2010) 
type-2 sodium channels Displacement IC50 = 5.1µM (as reviewed by 
Pertwee, 2010) 
Table 1.4 Activity of rimonabant at other non-cannabinoid targets. 
 
 
 
 
22 
 
Ligand Receptor or 
channel 
Effect Concentration Reference 
(+)WIN  imidazoline activation 10 and 100 µM (Molderings et 
al., 2002) 
5-HT3 antagonism IC50 = 310 nM (Fan, 1995) 
5-HT3A antagonism IC50 = 104 nM (Barann et al., 
2002) 
glycine (α2) inhibition IC50 = 220 nM (Yang et al., 
2008) 
glycine (α3) inhibition IC50 = 86 nM (Yang et al., 
2008) 
potassium 
TASK-1 
channels 
inhibition 10 µM (Maingret et al., 
2001) 
potassium Kv 
channels 
inhibition 20 µM (Van den 
Bossche et al., 
2000) 
sodium channels potentiation 10 nM (Fu et al., 2008) 
sodium channels inhibition 10 µM (Okada et al., 
2005) 
type-2 sodium 
channels 
inhibition IC50 = 12.2, 14.4, 
21.1 µM 
(Nicholson et al., 
2003) 
type-2 sodium 
channels 
displacement IC50 = 19.5 µM (Nicholson et al., 
2003) 
 
 
Table 1.5 Activity of (+)WIN at other non-cannabinoid  targets.  
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1.8 Cannabinoid receptor signalling pathways 
 
CB1 and CB2 Receptor signalling 
Cannabinoids can activate multiple signalling pathways through activation of the CB1 or 
CB2 receptor. The signalling pathway activated varies depending on the coupling to the 
receptor (for example, the CB1 receptor preferentially couples to a subset of Gα i/o 
subunits) (Straiker et al., 2002), the tissue type (Breivogel et al., 2000; Breivogel et al., 
1997; Pacheco et al., 1994) and also the cannabinoid activating the receptor (functional 
selectivity) (Berg et al., 1998; Kenakin, 1995).  
Cannabinoid receptors can also activate more than one signalling pathway at the same 
time through activation of Gα and Gβγ subunits. Cross-talk can then occur between 
these signalling pathways (Howlett, 2005). Cannabinoids can also dimerise with other 
receptors to activate specific signalling pathways. For example, the CB1 receptor can 
form heterodimers with D2 dopamine receptors (Kearn et al., 2005). 
   
G proteins coupled to the CB1 and CB2 receptors include members of the G i/o family 
(Howlett, 2005) which are involved in several signalling pathways, including the 
negative regulation of calcium channels, positive regulation of inwardly rectifying 
potassium channels, activation of protein kinases and gene induction (Howlett et al., 
2000).  
Cannabinoids appear to mediate a number of opposing responses, including their effect 
on adenylyl cyclase. Usually, cannabinoids inhibit adenylyl cyclase (AC) via coupling 
of the receptor to Gi proteins leading to a decrease in levels of cyclic adenosine 
monophosphate (cAMP). However, CB1 receptors can couple to Gs proteins instead and 
increase cAMP. This could be because different cannabinoid agonists induce different 
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conformations of the CB1 receptor which possess different affinities for the various G 
proteins (Gomez-Ruiz et al., 2007). 
Similar cannabinoids can increase or decrease nitric oxide (NO) levels by activating 
constitutive nitric oxide synthase (NOS) and inhibiting inducible NOS respectively. 
Also, although cannabinoids decrease Ca2+ conductance through Ca2+ channels, they 
can also increase intracellular Ca2+. Stimulation of CB1 receptors or CB2 receptors can 
produce this increase in Ca2+ via activation of phospholipase C (PLC), leading to 
increased inositol 1,4,5-trisphosphate (IP3) levels and the release of Ca2+ from IP3 – 
sensitive stores. This release of Ca2+ may be linked to the stimulation of NOS which has 
Ca2+ -calmodulin-dependent isoforms (Fimiani et al., 1999). These signalling pathways 
have been simplified and shown in figures 1.3a and b. 
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Figure 1.3a Cannabinoid signalling at the CB1 and CB2 receptor (adapted from Bosier et al., 2010). 
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Figure 1.3b Cannabinoid signalling at the CB1 receptor continued (adapted from Turu et al., 2010).  
 
GPR55 and GPR119 receptor signalling  
The GPR55 receptor does not activate Gi/o or Gs proteins, unlike the CB1 receptor and 
CB2 receptor, suggesting that it activates different signalling mechanisms (Gomez-Ruiz 
et al., 2007). The GPR55 receptor seems to exhibit functional selectivity in a similar 
fashion to the CB1 receptor, where different cannabinoids activate different signalling 
pathways. The different signalling pathways activated by GPR55 are shown (figure  1.4 
overleaf). 
 
Signalling of the GPR119 receptor may be mediated through coupling of the receptor to 
the Gs protein as high levels of cAMP have been found in GPR119-expressing cells 
(Chu et al., 2007). Stimulation of AC and protein kinase A activity by GPR119 agonists 
has also been reported in GPR119-expressing cells (Chu et al., 2007; Overton et al., 
2006; Reimann et al., 2008; Semple et al., 2008) and there is evidence for the 
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involvement of K+ and Ca2+ channels in GPR119 signalling pathways (Ning et al., 
2008). 
 
 
Figure 1.4 Cannabinoid signalling at the GPR55 receptor continued (adapted from Ross, 2009).  
 
1.9 The therapeutic potential of cannabinoids in inflammatory bowel disease 
 
1.9.1 Inflammatory bowel disease 
 
The main forms of IBD are Crohn’s disease and ulcerative colitis, which are chronic 
conditions characterised by periods of remission and relapse. The aetiology of IBD is 
complex, involving a combination of susceptible genes (CARD 15, IBD 2-7), 
environmental factors such as exposure to certain food components and 
microorganisms, and an overaggressive immune response. IBD develops due to an 
inappropriate immune response to microorganisms which enter the intestine via the 
leaky epithelium. The antigens bind to toll-like receptors on the epithelial cell 
 
 
 
 
28 
membrane and the epithelial cells act as antigen presenting cells to dendritic cells. Next, 
T helper cells become activated and stimulate macrophages to secrete pro-inflammatory 
cytokines such as TNFα. Natural killer cells are also activated which secrete cytokines 
and are cytotoxic. The inflammatory mediators released then attract circulatory 
leukocytes to the tissue which produce chemokines including ROS which, in turn, cause 
more tissue damage (Kumar and Clark, 2009). 
 
Crohn’s disease can affect any area of the gastrointestinal tract (the ileocecal region is 
the most commonly affected), whereas ulcerative colitis is restricted to the colon 
(colitis) and/or rectum (proctitis). The clinical features are similar for both conditions 
and include anorexia, weight loss, abdominal pain, fever and diarrhoea (Kumar and 
Clark, 2009). The conditions can be differentiated by their histological features which 
are shown below in table 1.6. 
 
 Crohn’s disease Ulcerative colitis 
Inflammation Deep (transmural) 
Patchy 
Mucosal 
Continuous 
Granulomas Present Rare 
Goblet cells Present Depleted 
Crypt abscesses Scanty Common 
            Table 1.6 Histological features of IBD (adapted from Kumar and Clark, 2009) 
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1.9.2 The effects of cannabinoids on the immune response 
As IBD involves activation of an inappropriate immune response, it would be important 
for any successful therapeutic to be able to ‘dampen down’ this response. Cannabinoids 
have shown that they are able to modulate the immune response and the evidence is 
summarised below. 
Expression of the cannabinoid receptors CB1 and CB2 has been found throughout the 
immune system (Galiegue et al., 1995; Lee et al., 2001; Noe et al., 2000), although the 
CB2 receptor is reportedly more abundant in immune tissues than CB1 (Croxford et al., 
2005). CB2 mRNA expression has been found to vary according to immune cell type – 
its highest expression has been found in B cells and the lowest in T cells  (Galiegue et 
al., 1995; Lee et al., 2001; Noe et al., 2000).The expression of CB1 and CB2 receptors in 
the immune system has also been found to vary depending on the activation stimuli, 
activation state and the immune cell type used in studies (Croxford et al., 2005; Klein, 
2005).There is also evidence that the endocannabinoids anandamide and 2-AG are 
produced by macrophages, peripheral blood mononuclear cells and dendritic cells in 
response to stimulation by bacterial lipopolysaccharide (LPS) in vitro (Klein, 2005). 
Cannabinoids are thought to be important to maintain normal immune homeostasis and 
it has been found that mice that do not possess CB2 receptors show signs of immune 
dysregulationulation such as developing inflammatory bowel disease (Ziring et al., 
2006). 
The interactions between cannabinoids and immune cells are very complex and differ 
depending on the cell type, cell activation state, the activation stimuli, the cannabinoid 
ligand, and the concentration of the cannabinoid used (Croxford et al., 2005; Klein, 
2005). Several studies have shown that cannabinoids inhibit immune cell proliferation 
(Cencioni et al.; Klein et al., 1985; Schwarz et al., 1994; Yuan et al., 2002), ROS and 
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cytokine release (Kaplan et al., 2008; Ross et al., 2000; Sacerdote et al., 2005), 
antibody production (Eisenstein et al., 2007; Jan et al., 2007) and migration (Raborn et 
al., 2008; Sacerdote et al., 2000). Most of these inhibitory effects were reported to be 
CB2 receptor mediated (Yuan et al., 2002; Ross et al., 2000; (Cencioni et al.; Eisenstein 
et al., 2007; Raborn et al., 2008), although it must be noted that many of the studies 
only used one CB2 antagonist, and the concentrations of the cannabinoid and antagonist 
used were much higher than their binding affinity for the CB2 receptor (Ross et al., 
2000).  
Some studies have suggested that CB1, as well as CB2 receptors, may be involved in 
inhibiting cytokine release (Sacerdote et al., 2005) and inhibiting chemotaxis (Sacerdote 
et al., 2000). Non- CB1/ CB2 receptor mediated mechanisms are thought to be 
responsible for the cannabinoid-mediated inhibition of superoxide production by 
neutrophils (Naccache et al., 1982). Studies have investigated cannabinoid signalling 
pathways and have found that cannabinoids inhibit immune cell response, at least in 
part by suppression of AC/cAMP signalling pathway (Koh et al., 1995), resulting in 
decreased binding of transcription factors and nuclear factors to DNA, and therefore 
decreased gene transcription (Massi et al., 2006b). This signalling pathway is shown in 
figure 1.1a. 
Although most studies have reported cannabinoid-mediated inhibition of the immune 
response, cannabinoid-induced stimulation has also been observed. Cannabinoids have 
been shown to increase the proliferation of immune cells (Derocq et al., 1995), enhance 
migration (Croxford et al., 2005) and induce cytokine release. Most of these stimulatory 
effects have been reported for endocannabinoids and THC, although low concentrations 
of CP 55,940 and (+)WIN were found to increase proliferation of B cells (Derocq et al., 
1995). The CB2 receptor has been implicated in inducing migration (Croxford et al., 
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2005), whereas CB2 and non-CB1/CB2-receptor mechanisms have been reported to be 
involved in the pro-proliferative effects of cannabinoids (Derocq et al., 1998; Valk et 
al., 1997).  
Cannabinoids were shown to alleviate symptoms in models of inflammatory diseases 
and one of the reasons suggested for this is the Th1 suppressing/Th2 enhancing effect 
shown by cannabinoids. Th1 cytokines are thought to be involved in the pathogenesis of 
a number of autoimmune diseases such as multiple sclerosis, where inhibition of Th1 
cytokines is thought to be therapeutic. Several studies have suggested that cannabinoids 
alter the balance of Th1 to Th2 mediated immune responses (Croxford et al., 2005; 
Klein, 2005). 
 In vivo studies on mice infected with Legionella pneumophilia showed that 
cannabinoids suppressed the production of Th1 cytokines and enhanced the production 
of Th2 cytokines. CB1 and CB2 receptors were thought to be involved from the use of the 
selective cannabinoid receptor antagonists, rimonabant and SR144528 (Newton et al., 
1994; Klein et al., 2000). It was suggested that the CB1 receptor mediates the 
suppression of Th1 activity whilst the CB2 receptor mediates the enhancement of Th2 
activity. It was also suggested that this could be due to varying expression/ signalling of 
CB2 and CB1 receptors on Th1 and Th2 cells (Klein et al., 2004). 
The Th2 biasing effect shown by cannabinoids is thought to occur for a number of 
reasons, including differences in cannabinoid receptor expression on T helper (Th) cell 
subsets and antigen presenting cells, the reduction of Th1 cytokines from dendritic cells, 
the shift of B cell antibody production from IgM to IgE and the inhibition of Th1 
cytokines by production of Th2 cytokines (Tanasescu et al., 2010). 
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The cannabinoid (+)WIN reduced progression of clinical symptoms in a mouse model 
of chronic multiple sclerosis. This reduction was associated with a decrease in Th1 
mediated functions and inhibition of pro-inflammatory cytokine mRNA (Croxford et 
al., 2003). Similar benefits have also been reported from the use of cannabinoids in 
rheumatoid arthritis (Croxford et al., 2005). 
Cannabinoids have also shown to be effective in models of IBD, but it is unlikely that 
this is due to a Th1 suppressing/Th2 enhancing effect as ulcerative colitis is a Th2 driven 
disease and there is new evidence that Crohn’s disease may be Th17 driven. The effects 
of cannabinoids in IBD models are discussed in further detail below. 
 
1.10 Cannabinoid effects on intestinal inflammation and motility 
 
1.10.1 Cannabinoid effects on intestinal inflammation 
 
Studies using several animal disease models, including multiple sclerosis and 
rheumatoid arthritis, have demonstrated the anti-inflammatory effects of cannabinoids 
(Croxford et al., 2003; Croxford et al., 2005). Cannabinoids may also be useful as 
therapeutics for IBD as there is evidence from various studies that cannabinoids may 
produce anti-inflammatory effects in the intestine (Izzo et al., 2008; Izzo et al., 2010). 
They have also been shown to reduce inflammation-induced motility disturbances and 
protect cholinergic nerves from inflammatory damage (Jamontt et al., 2010).  
 
There is evidence that the anti-inflammatory effects of cannabinoids in the gut may be 
CB1 or CB2 receptor mediated. One study showed that selective CB1 and CB2 receptor 
agonists inhibited experimental colitis in mice induced by oil of mustard and dextran 
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sulphate sodium (Kimball et al., 2006). However, selective antagonists were not used to 
corroborate the CB1 and CB2 receptor effects. 
 
Another study reported that cannabinoids mediate their anti-inflammatory effects 
through the CB1 receptors. Authors found that when mice were treated with DNBS, 
inflammation was more pronounced in CB1(-/-) mice than CB1(+/+) mice, and treatment 
of the wild-type mice with rimonabant produced the same effects as the CB1 receptor 
knockout, ie stronger inflammation was produced. They also found that the non-
selective cannabinoid receptor agonist HU210 or genetic ablation of FAAH protected 
the mice against dinitrobenzene sulfonic acid (DNBS)-induced colitis. Additionally, this 
study found that spontaneous oscillatory action potentials were found in circular smooth 
muscle cells of CB1(-/-) but not CB1(+/+) colons after DNBS treatment, suggesting that 
CB1 receptors reduce smooth muscle irritation induced by inflammation (D'Argenio et 
al., 2006). A caveat in the study is that no selective CB1 agonists were used and the 
effect of HU210 was assumed to be CB1 receptor mediated without confirming this 
effect with selective CB1 agonists. 
 
Several studies have suggested that cannabinoids can reduce inflammation in the gut 
through a non-CB1/non-CB2 receptor(s). Studies have been carried out using the plant-
derived (-)CBD and the GPR55 agonist O-1602 in models of inflammation, neither of 
which binds to the CB1 or CB2 receptor. Firstly, a study using O-1602 showed that this 
cannabinoid protected against colitis and inhibited recruitment. This O-1602-mediated 
inhibition was still present in mice which did not express the CB1, CB2 or GPR55 
receptor (Schicho et al., 2011), suggesting this effect was non- CB1, CB2, GPR55 
mediated.  
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(-)CBD also inhibited inflammation through a non-CB1/non-CB2 mechanism in a mouse 
model of colitis. The cannabinoid reduced iNOS, IL-1β and IL-10 expression and 
without changing the levels of endocannabinoids. The levels of the endocannabinoids 
were measured as (-)CBD is a known FAAH inhibitor. The same study showed that      
(-)CBD reduced oxidative stress in vitro in caco-2 cells (Borrelli et al., 2009a). This 
suggests that (-)CBD reduces inflammation and oxidative stress through a non-
CB1/non-CB2 receptor(s). 
 
Another study showed that (-)CBD reduced inflammation and associated motility 
disturbances in a rat model of colitis (Jamnott et al., 2010). (-)CBD has been shown to 
inhibit the release of pro-inflammatory mediators which reduce smooth muscle function 
and decrease neurotransmitter release from the myenteric plexus (Collins, 1996; 
Esposito et al., 2007; Jacobson et al., 1997; Kaplan et al., 2008; Kinoshita et al., 2006; 
Watzl et al., 1991). This mechanism could be involved in reducing the motility 
disturbances. One problem with this study,  however, is that it did not investigate 
whether (-)CBD altered the levels of endocannabinoids in the gut, so it is not clear 
whether (-)CBD was exerting effects indirectly by inhibiting FAAH or whether it was 
working through a  non-CB1/non-CB2 receptor.  
 
In contrast to the above studies, McVey et al (2003) have reported that cannabinoids 
may also induce intestinal inflammation as anandamide and 2-AG were found to induce 
ileitis in rats, an effect mediated by the vanilloid receptor TRPV1. This suggests that 
any cannabinoid used therapeutically for inflammatory bowel disease should stimulate 
cannabinoid receptors but avoid stimulating the vanilloid receptor.  
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1.10.2  CB1 -mediated effects on intestinal motility 
 
Several studies have showed that cannabinoids reduce intestinal motility in animals and 
humans (Esfandyari et al., 2007; Colombo et al., 1998; Izzo et al., 1999; Izzo et al., 
2000a; Landi et al., 2002; Pinto et al., 2000b).These effects would be beneficial in IBD 
which is associated with an increase in intestinal motility and is accompanied by 
symptoms such as intestinal cramps and diarrhoea. 
 
The currently held view is that cannabinoids inhibit intestinal motility through 
activation of the CB1 receptor. However, much of this evidence relies on the use of the 
CB1 receptor antagonist rimonabant, which may not be as selective as first thought (see 
section 1.7.2 ).Also, there is now evidence for non-CB1, non-CB2 effects  on intestinal 
motility (Mang et al., 2001; Smid et al., 2007). The evidence for CB1, CB2 and non-CB1, 
non-CB2 –mediated effects have been reviewed below and in later sections.   
 
Firstly, studies have reported the presence of CB1 receptor mRNA in the guinea-pig 
myenteric plexus (Griffin et al., 1997) and in the myenteric and submucosal plexus of 
the rat intestine (reviewed by Pinto et al., 2002a). In addition, immunohistochemical 
studies using CB1 receptor antibodies have detected the presence of CB1 receptors in the 
neurones of the guinea-pig, rat and porcine enteric nervous system, reviewed by 
Pertwee (2001) and Pinto et al., (2002a). Studies in these animals have also shown an 
association between choline acetyltransferase and CB1 receptor distribution in the 
myenteric plexus, suggesting that CB1 receptors are present on cholinergic neurones 
within the enteric nervous system (Buckley et al., 1998). More specifically, there is 
immunohistochemical evidence that the CB1 receptors are present on excitatory 
neurones in the myenteric plexus .There is also evidence (Aviello et al., 2008b) for the 
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presence of CB1 receptors on intrinsic sensory neurones of the enteric nervous system 
(see figure 1.5). However, although the immunohistochemical evidence shows that the 
CB1 receptor is present in the enteric nervous system, it does not provide proof that this 
receptor is involved in cannabinoid-mediated inhibition of intestinal motility. 
 
 
Figure 1.5 Localisation of cannabinoid receptors in the intestine (adapted from Izzo, 2008). 
 
Researchers have also conducted studies on intestinal contractions in vitro and have 
demonstrated that cannabinoids can inhibit electrically stimulated contractions of 
guinea-pig ileum myenteric plexus-longitudinal and circular smooth muscle (Coutts et 
al., 1997; Izzo et al., 1998; Mang et al., 2001; Pertwee et al., 1996), as well as human 
ileum longitudinal and circular smooth muscle (Croci et al., 1998; Manara et al., 2002). 
The authors suggest that this inhibition is due to stimulation of pre-synaptic CB1 
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receptors (as this effect is antagonised by rimonabant), which results in a decrease in 
acetylcholine release and hence muscle contraction (Coutts et al., 1997; Croci et al., 
1998; Izzo et al., 1998; Mang et al., 2001; Pertwee et al., 1996).   
 
 
Studies have also shown that cannabinoids inhibit peristalsis of isolated intestinal 
segments, again reported to be CB1 mediated due to antagonism by rimonabant (Grider 
et al., 2009; Heinemann et al., 1999; Sibaev et al., 2009). Studies have shown that 
cannabinoids can inhibit all components of the peristaltic reflex, the intrinsic sensory 
neurons (Grider et al., 2009), the ascending excitatory reflex (Grider et al., 2009; 
Heinemann et al., 1999; Sibaev et al., 2009) and the descending inhibitory reflex 
(Grider et al., 2009). The intrinsic sensory neurons are activated when the intestine is 
distended by food, which leads to smooth muscle contraction (ascending excitatory 
reflex) and relaxation (descending inhibitory reflex) which allows food to be propelled 
along the intestine in an anal direction (Izzo et al., 2010). 
 
Cannabinoids have been shown to inhibit the ascending excitatory reflex by inhibiting 
cholinergic and non-cholinergic transmission (Grider et al., 2009; Heinemann et al., 
1999; Sibaev et al., 2009). Again, authors have concluded that this effect is CB1 
mediated from antagonism of the cannabinoid-mediated inhibition by rimonabant 
(Heinemann et al., 1999; Sibaev et al., 2009) or AM251 (Grider et al., 2009). 
 
Much of the evidence suggests that cannabinoids reduce peristalsis by inhibiting the 
ascending contraction, but there are also studies that have demonstrated cannabinoid-
induced effects on the descending relaxation pathway of peristalsis. One study (Grider 
et al., 2009) reported that cannabinoids inhibited the descending relaxation via 
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inhibition of vasoactive intestinal peptide (VIP) release, whereas the other (Heinemann 
et al., 1999) reported activation of the descending relaxation via stimulation of 
inhibitory motor neurones which operate through apamin sensitive K+ channels and 
nitric oxide release. The former study (Grider et al., 2009) implicated the CB1 receptor 
in the response due to its sensitivity to AM251. However, the presence of the CB1 
receptor on inhibitory motor neurones has not been confirmed by immunohistochemical 
studies (Aviello et al., 2008b).   
 
There is also evidence that cannabinoids reduce the release of CGRP from sensory 
neurons which usually occurs in response to distension of the intestine by ingestion of 
food. This was also reported to be CB1 mediated as this was antagonised by AM251 
(Grider et al., 2009) . 
 
In vivo studies from as early as 1989 have reported that cannabinoids inhibit rodent 
intestinal motility (Shook et al., 1989). Subsequent in vivo studies have demonstrated 
that cannabinoids inhibit intestinal motility in rodents in a rimonabant-sensitive manner 
(Colombo et al., 1998; Izzo et al., 1999; Izzo et al., 2000a; Landi et al., 2002; Pinto et 
al., 2002b). One study has also shown that cannabinoids do not reduce motility in CB1 
knockout mice. This led the authors to the conclusion that cannabinoids inhibit 
intestinal motility via stimulation of CB1 receptors.  
 
Studies have also investigated the effects of cannabinoids on mice and rats treated with 
croton oil, a substance which induces a state of intestinal inflammation and diarrhoea in 
rodents (Izzo et al., 2001b; Izzo et al., 2000b). These studies (Izzo et al., 2001b; Izzo et 
al., 2000b) found that cannabinoids inhibited intestinal motility in control and croton-oil 
treated mice, and that this inhibition was sensitive to rimonabant. The inhibitory effect 
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of cannabinoids was enhanced in croton oil-treated mice compared with control mice 
and it was suggested that this enhanced inhibition was due to an up-regulation of CB1 
receptors, as CB1 receptor expression seemed to be increased in the croton-oil inflamed 
intestine (Izzo et al., 2001b).  
The major problem with these pharmacological studies in vitro and in vivo is the over-
reliance on one so-called selective CB1 antagonist, usually rimonabant but sometimes 
AM251. Both rimonabant and AM251 have been reported to exert several non-specific 
effects at the concentrations used (micromolar range) in these studies (Pertwee., 2010). 
In addition, the studies used non-selective cannabinoids such as (+)WIN and 
anandamide rather than selective CB1 agonists such as ACPA and ACEA. This, together 
with the fact that the antagonists may not be as selective as first thought, casts doubt on 
the conclusion that cannabinoids inhibit intestinal motility through the CB1 receptor. 
The next section describes the evidence for the involvement of other receptors in 
cannabinoid-mediated inhibition of intestinal motility. 
 
1.10.3 CB2 -mediated effects on intestinal motility 	  
The presence of CB2 mRNA has been reported in the rat ileum (Storr et al., 2002) and 
human colon (Ligresti et al., 2003), and immunohistochemical studies have shown the 
presence of this receptor in the enteric nervous system of human (Wright et al., 2008) 
and rat ileum (Duncan et al., 2008). However, evidence is conflicting for the role of 
CB2 receptors in regulating intestinal motility.  
 
 In vitro studies on human and guinea-pig ileum have reported that cannabinoid-induced 
inhibition of intestinal motility is not affected by the CB2 receptor antagonist, SR144528 
(Croci et al., 1998; Izzo et al., 2000a). In vivo studies in mice and rats found that 
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cannabinoid-induced inhibition of intestinal motility was not antagonised by SR144528 
(Izzo et al., 1999; Izzo et al., 2000a).  In contrast, one study reported that a selective 
CB2 receptor agonist blocked defecation, suggesting that the CB2 receptor is present in 
the intestine and inhibits intestinal motility (Hanus et al., 1999). There is also recent 
evidence that the CB2 receptor may be involved in motility control, as anandamide 
stimulated VIP release in the rat myenteric plexus, and this response was antagonised 
by SR144528 (Kurjak et al., 2008). 
 
Another suggestion is that the CB2 receptor may be upregulated in the gut during 
inflammation (Wright et al., 2005), and may be involved in reducing intestinal motility 
under these conditions (Izzo, 2007). One study showed that when rat gastrointestinal 
transit was increased by lipopolysaccharide (an inflammatory stimulus), a selective CB2 
agonist, but not a selective CB1 agonist, reduced the transit back to normal level 
(Mathison et al., 2004).  This was supported by the Duncan et al (2008) study which 
showed that the selective CB2 agonist JWH133 reduced motility in LPS-treated rats and 
that this was reversed by the CB2 antagonist AM630. 
 
1.10.4 Non-CB1, non-CB2 mediated effects on intestinal motility 
 
Other studies have suggested that stimulation of non-CB1, non-CB2 cannabinoid 
receptors can alter intestinal motility. For example, in one study, anandamide inhibited 
acetylcholine release via stimulation of a non-CB2, non-CB1 receptor (Mang et al., 
2001). Also, there is other recent in vitro evidence to suggest that cannabinoids may 
inhibit intestinal contractions via non-CB1, non-CB2 mechanisms (Duncan et al., 2005; 
Makwana et al., 2010a). One study also showed that the non-selective cannabinoids 
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anandamide and 2-AG inhibited contractions of the human colon and that this was not 
altered by AM251, suggesting CB1 was not involved (Smid et al., 2007). 
 
There is also evidence that the endocannabinoid-like acylethanolamides OEA and PEA 
reduce intestinal motility (Aviello et al., 2008a; Capasso et al., 2001; Capasso et al., 
2005; Cluny et al., 2009). Both compounds are present in the gut as well as their target 
receptors, TRPV1 (OEA), PPARα (OEA and PEA), GPR119 (OEA) and GPR55 (PEA 
and OEA) (Borrelli et al., 2009b). It is unclear at the moment which receptors are 
involved in the PEA and OEA-mediated inhibition of motility but is unlikely to be CB1 
or CB2 as the compounds possess low affinity for these receptors and OEA reduced 
motility in  CB1 and CB2  knockout mice. The PPARα receptor also does not seem to be 
involved as OEA also inhibited GI transit in PPARα knockout mice (Cluny et al., 
2009).  
 
The endocannabinoid anandamide is also a ligand of vanilloid receptors found on 
primary afferent nerves, and anandamide was found to stimulate these receptors to 
increase acetylcholine release in the guinea-pig ileum. However, the vanilloid receptor 
antagonist capsazepine had no effect on inhibition of intestinal motility by anandamide 
in vivo (Izzo et al., 2001a). It was, therefore, suggested by (Pinto et al., 2002a) that 
vanilloid receptors do not have a role in the intestinal motility changes by anandamide. 
 
1.10.5 Pre-junctional vs post-junctional effects on intestinal motility 
 
Much of the evidence suggests that cannabinoids act only on pre-junctional CB1 
receptors to inhibit intestinal motility. Indeed, anandamide was not found to reduce 
contractions of guinea-pig and human ileum, guinea-pig myenteric plexus-longitudinal 
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and circular smooth muscle induced by exogenous acetylcholine, carbachol, substance P 
or histamine, as reviewed by Pertwee (2001). However, a 1997 study of cannabinoid 
effects on guinea-pig ileum myenteric neurones suggested that cannabinoids stimulate 
pre and post-synaptic CB1 receptors to inhibit fast cholinergic transmission (Lopez-
Redondo et al., 1997).  
 
Further studies are required to investigate the post-synaptic effects of a wider range of 
cannabinoids as most of the studies carried out relate to anandamide only (Lynn et al., 
1994; Mang et al., 2001). 
 
1.10.6 Cannabinoid signalling in the enteric nervous system 
 
Cannabinoid signalling within the enteric nervous system has not been extensively 
investigated. However, a recent study has been carried out on guinea-pig myenteric 
neurones which showed that endocannabinoids are produced by myenteric neurones, in 
addition to other studies that have shown that cannabinoids can be produced by immune 
cells in the gut wall as well as vascular endothelial cells (Boesmans et al., 2009).  
Anandamide appears to be the endocannabinoid which activates CB1 receptors in the 
enteric nervous system (Boesmans et al., 2009).  
  
Cannabinoids are known to reduce neurotransmitter release by inhibiting Ca2+ influx 
into the pre-synaptic terminal (Lovinger, 2008). In the study by Boesmans (2009), it 
was shown that in guinea-pig myenteric neurones cannabinoids reduced the 
spontaneous activity of excitatory and inhibitory neurones, reducing Ca2+ spike 
frequency and mitochondrial transport. Cannabinoids were also found to alter synaptic 
vesicle turnover (Boesmans et al., 2009). All these effects would reduce 
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neurotransmission (for example, the release of acetylcholine). Spontaneous activity of 
the neurones was also increased by the CB1 antagonists AM251 (10µM) and rimonabant 
(1 µM), leading to the suggestion that enteric nerve signalling is under the control of 
CB1.  However, the non-specific effects of rimonabant and AM251 at these 
concentrations have been documented (Pertwee., 2010). 
 
The CB1 receptor is coupled to the inhibition of adenylyl cyclase via Gi and the 
activation of K+ and inhibition of Ca2+  channels by Go and it has been suggested that all 
of these actions may contribute to cannabinoid-mediated inhibition of 
neurotransmission in the intestine (Galligan, 2009). However, this has not been 
investigated and there is no convincing evidence that CB1 is responsible for inhibiting 
motility at the moment. 
 
1.10.7 CNS effects of cannabinoids on intestinal inflammation and motility 
 
Although the enteric nervous system can function without input from the CNS,  
extrinsic sympathetic and parasympathetic nerves, as well as vagal and spinal  primary 
afferents, innervate the gastrointestinal tract and exert control over its functions in vivo. 
There is evidence for the presence of the CB1 receptor on cell bodies of afferent 
neurones in the dorsal root ganglia, nodose ganglia and vagal efferents (see figure 1.3) 
(Duncan et al., 2005). 
 
Cannabinoids have been shown to act peripherally to reduce intestinal motility (Coutts 
et al., 1997; Izzo et al., 1998; Mang et al., 2001; Pertwee et al., 1996) but it has been 
shown that cannabinoids also alter intestinal motility through activation of cannabinoid 
receptors in the CNS. An in vivo study showed that cannabinoids were more active 
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when administered intracerebroventricularly than when administered intraperitoneally 
(Izzo et al., 2000).These effects were blocked by the CB1 antagonist rimonabant, which 
led to the suggestion that the effects were CB1 mediated (Pinto et al., 2002a). 
 
Most of the studies in models of IBD reviewed above do not distinguish between the in 
vivo peripheral and central effects of cannabinoids on inflammation. However, one 
study showed that the peripherally-restricted CB1/CB2 agonist SAB378 had no effect on 
inflammation in mouse models of colitis, suggesting that central, as well as peripheral, 
cannabinoid receptor activation is required to mediate the anti-inflammatory effects of 
cannabinoids. SAB378 cannabinoid was found to reduce motility in these models, 
however, through activation of the CB1 receptor (Cluny et al., 2010a). This study has 
important implications for the concept of a cannabinoid-dendrimer conjugate which 
does not enter the CNS.  It suggests that such a compound would not reduce 
inflammation in patients with IBD as it would only act peripherally. However, this is 
the result of only one study and further investigations, distinguishing between the 
central and peripheral effects of cannabinoids in IBD, are required. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
1.11 Aims of thesis 
 
As  there is a need for more effective, safer drugs to treat IBD/IBS, cannabinoids 
may represent a new class of therapeutics for these disorders. Indeed, cannabinoids 
have been shown to have several beneficial effects on the gastrointestinal tract, 
including anti-inflammatory and anti-motility effects.  
 
The mechanisms by which cannabinoids reduce intestinal motility have not been 
fully established and so one of the aims of this thesis was to investigate the 
cannabinoid receptors involved  in the inhibition of guinea-pig ileum contractions 
and to determine whether they were located pre or post-synaptically.  
 
Several studies have showed that cannabinoids reduce intestinal inflammation but 
studies have not investigated whether cannabinoids protect the intestine against 
inflammatory damage. Another aim of this thesis was to determine whether 
cannabinoids were protective in in vitro models of inflammatory damage. 
 
The major problem with a cannabinoid-based therapeutic would be the resulting 
psychotropic side effects, but this may be overcome by conjugating the cannabinoid 
to a dendrimer that it is large enough to prevent penetration of the blood brain 
barrier. The effect of cannabinoid conjugation on pharmacological activity  has not 
been studied, and so the final aim of this thesis was to investigate whether novel 
cannabinoid-dendrimer conjugates retained activity in two pharmacological assays. 
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2. General methods 
 
2.1 Introduction 
 
The technique used most extensively throughout the thesis was electrical stimulation of 
the guinea-pig ileum (chapters 3, 4 and 5). Co-axial, transmural electrical stimulation of 
the guinea-pig isolated ileum is one of the oldest pharmacological techniques, used to 
examine the effects of drugs on the release of acetylcholine from cholinergic nerve 
endings (Scriabine et al., 1970). The method was first established by Paton (1955) and 
has since been modified by other research groups (Scriabine et al., 1970). Carbachol-
induced contraction of the ileum was used instead of electrical stimulation to investigate 
any direct effect of cannabinoids on ileal smooth muscle. Carbachol directly stimulates 
muscarinic receptors on smooth muscle to produce contraction and is non-hydrolysable 
(unlike acetylcholine). 
 
The Paton ileum technique was used to screen cannabinoid-dendrimer conjugates for 
CB1 potency as the literature indicated that cannabinoids reduced electrically-evoked 
contractions through the CB1 receptor. However, as the thesis progressed it became 
apparent that the CB1 receptor was not responsible for this effect and that another 
receptor may have been involved. 
 
Another assay was required to assess the potency of the cannabinoid-dendrimer 
conjugates at the CB2 receptor. The assay chosen was LPS-stimulation of TNFα release 
from RAW 264.6 macrophages. This assay was chosen as cannabinoids have been 
shown to inhibit the release of inflammatory mediators (including TNFα) from RAW 
264.7 macrophages (Fischer-Stenger et al., 1993; Jeon et al., 1996; Ross et al., 2000) 
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and this has been shown to occur through activation of the CB2 receptor (Ross et al., 
2000; Hao et al., 2010).  
 
LPS levels used in the literature vary (2-1000ng/ml) as well as the exposure period 
(between 2-24 hours) and bacterial strain (commonly Escherichia coli 055:B5 or 
026:B6) (Fischer-Stenger et al., 1993., Jeon et al., 1996; Kim et al., 2008; Lahat et al., 
2008., Peirce et al.,2010; Ross et al., 2000; Shen et al., 2009; Zhao et al.,2010; Eads et 
al., 2009; D’Souza et al., 1996; Zhang et al., 2007). The LPS level and the exposure 
period for the pharmacological assay used in the thesis were chosen from a pilot study 
(see 2.4 ‘Lipopolysaccharide (LPS)-stimulation of a macrophage cell line’ below). LPS 
used was from Escherichia coli 055:B5 as this is commonly used in the literature and 
produces reproducible results (Kim et al., 2008; Lahat et al., 2008; Zhang., 2007). 
 
2.2 Electrical field stimulation of the guinea-pig ileum 
 
Animal husbandry  
 
Male Dunkin-Hartley guinea-pigs (Harlan, UK) weighing 250-500g were housed and 
treated in accordance with the Animals (Scientific Procedures) Act 1986.  The animals 
were subjected to 12 hour light-dark cycles. Animals received Harlan global diet 
complete feed for guinea-pigs 2940 (Harlan, UK) and were allowed food and water ad 
libitum.  
 
Tissue preparation 
 
The guinea-pigs were killed by concussion followed by exsanguination. The abdomen 
was dissected and the ileum was excised (14cm from the caecum). The fat and 
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connective tissue was removed from the ileum, which was then cleaned with Krebs’ 
solution (see section 2.1.3 for composition).  
 
 Organ bath preparation 
 
A 2 cm long segment of ileum was used for this procedure. Cotton was threaded 
through each end of the ileum and the ileum was mounted onto an electrode (through 
the lumen) and secured at one end (see figure 2.1). The electrode was lowered into an 
organ bath filled with 50mls Krebs’ solution, maintained at 37°C and continuously 
aerated with carbogen (95% O2 and 5% CO2). The Krebs’ solution was prepared daily 
and composed of (in mM) NaCl 118, KCl 4.7, CaCl2.6H2O 1.3, MgSO4.7H2O 1.2, 
K2PO4 1.2, NaHCO3 25 and glucose 11.1. Approximately 0.5g of tension was applied to 
the ileum. The tissue was left to equilibrate for 10 minutes before electrical stimulation 
was applied. 
 
 
Figure 2.1 Set-up of the ileum 
ileum mounted 
onto electrode 
thread 
attached to 
ileum and 
transducer 
second 
electrode 
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tubing 
         
        stimulator 
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Electrical field stimulation  
 
Electrical pulses (at a frequency of 0.1Hz, pulse width of 1.0 ms) were delivered to the 
electrodes via a Harvard model 6012 stimulator (Massachusetts, USA) (see figure 2.1). 
The electrical stimulation of the ileum causes the release of acetylcholine from 
cholinergic nerve endings which contracts the ileum (Scriabine et al., 1970). The 
stimulus amplitude was found to produce strong, reproducible contractions of the ileum 
was 25 volts. The contractions were detected by the dynamometer UFI isometric 
transducer (Pioden Controls, Isle of Wight, UK) and amplified by a bridge amplifier 
(ADI instruments, Chalgrove, UK). The amplified signal was then displayed on a chart 
recorder (Labchart and Scope, ADI instruments, Chalgrove, UK). The equipment was 
calibrated daily. 
 
The ileum preparation was left for 30 minutes to allow the EFS-induced contractions to 
stabilise. The tissue remained viable for at least 3 hours, during which time all 
experiments were conducted. 
 
 Choice of cannabinoid vehicle in the ileum 
 
Cannabinoids are poorly soluble in water and so the recommended solvents for these 
drugs are ethanol or dimethyl sulfoxide (DMSO). DMSO had been previously been 
found by the laboratory group to significantly reduce the size of ileum contractions and 
so ethanol was chosen as the vehicle where possible.  
 
During the initial experiments with the cannabinoid (+)WIN, the ethanol vehicle caused 
a substantial reduction in the size of EFS-induced contractions of the ileum at high bath 
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concentrations (0.2-2.4%) but had no effect at lower concentrations (0.02-0.33%; see 
figure 2.2A and B below). Ethanol (at low concentrations) was then used as the vehicle 
for all other cannabinoid agonists and antagonists used in the ileum (in EFS and 
carbachol experiments). The only exceptions were AM281 and AM630, which were not 
soluble in ethanol at the concentrations required, and were instead dissolved in DMSO 
(0.02%).  
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Figure 2.2A and B The effect of (+) WIN dissolved in (A) ethanol (0.2-2.4%), (B)  ethanol (0.02-0.33%) 
and  vehicles alone on the size of EFS-induced contractions of the guinea-pig isolated ileum, expressed as 
percentage of baseline EFS response. The baseline size was measured immediately before the addition of 
(+) WIN. Each symbol represents the mean percentage; vertical bars indicate standard error of the mean 
(SEM); * P< 0.05, **P< 0.01 (one way ANOVA with  post-hoc Dunnett’s test).  
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2.3  Carbachol - induced contraction of the ileum  
 
To investigate any post-synaptic effects of cannabinoids on the ileum, the ileum was set 
up as described previously (see ‘Organ bath preparation’), but carbamoyl chloride 
(carbachol) was used to contract the ileum instead of electrical stimulation. Carbachol 
directly stimulates muscarinic receptors on ileum smooth muscle to produce contraction 
and is non-hydrolysable (unlike acetylcholine). 
 
A sub-maximal concentration (3x10-7M) suitable for use in pre-contracting sections of 
ileum was determined from the cumulative concentration-response curve shown in 
figures 2.3 A and B overleaf. The tissue was left for 20 minutes subsequent to the 
addition of carbachol to allow the contraction to stabilise. The contraction was sustained 
for at least 90 minutes, during which time all experiments were conducted. 
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Figure 2.3A The effect of carbachol on baseline tension of the guinea-pig ileum (n=3). Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM), data were 
analysed by one sample Student’s t test. 
 
 
Figure 2.3B Trace showing the effect of carbachol on baseline tension of the guinea-pig ileum. 
Concentrations (M) shown below: 
1 = 1x10-9                              4 = 3x10-8                   6 = 3x10-7                                   9= 1x10-5 
2 = 3x10-9                              5 = 1x10-7                   7 = 1x10-6 
3 = 1x10-8                              6 = 3x10-7                   8 = 3x10-6 
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2.4 Lipopolysaccharide (LPS)-stimulation of a macrophage cell line  
 
Cell line 
 
The RAW 264.7 mouse leukaemic monocyte – macrophage cell line (European Cell 
Culture Collection) was used for all experiments. Cells were supplied at passage 7.  
 
Resuscitation of cells 
 
Cells were thawed in a 37°C water bath and suspended in supplemented medium (pre-
warmed to 37°C). The cells were then centrifuged at 150g for 5 minutes and re-
suspended in supplemented medium and transferred to a T25 (25cm2 surface area) flask. 
The flask was incubated at 37°c in a 95% air and 5% CO2 humidified atmosphere. Cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
heat inactivated bovine serum and 100 units/ml penicillin and 100µg/ml streptomycin. 
Medium was replenished every 72 hours. 
 
 Sub - culture of cells 
 
At 80% confluency, medium containing cells in suspension was removed from the flask 
and retained. The adherent cells were scraped from the bottom of the flask and 
suspended in the spent medium. The cells were then centrifuged at 150g for 5 minutes 
and re-suspended in fresh supplemented medium and split between 3 T25 flasks (1:3 
ratio). The flasks were then incubated as above. 
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Freezing of cells 
 
Stocks of cells were frozen at passages 8,10,11. The medium containing suspension 
cells was removed from the flask and retained. The adherent cells were scraped from the 
bottom of the flask and suspended in the spent medium. The cells were then centrifuged 
(as in‘Subculture of cells’), re-suspended in cold freezing medium (10% DMSO, 20% 
FBS and 70% DMEM) and transferred to cryovials. The cryovials were frozen at -80°c 
overnight and then transferred to liquid nitrogen (-140°c). 
 
Cell counting 
 
A 100µl sample of cells was taken and transferred to a cuvette. This was made up to 
10mls with isotonic solution Isoton® and the cells were counted using a Coulter® Z2 
Counter set to read particles sized between 9 and 30 microns. The readings were taken 
three times and the average was calculated .This number was then multiplied by 200 to 
calculate the number of cells per ml. 
 
LPS-induced TNFα release from RAW 264.7 macrophages  
 
The cells were counted as above and seeded onto a 24 well plate (1.9cm2/well) at a 
density of 40,000 cells/cm2. Cells were grown for 96 hours, at which point the medium 
was removed from the wells and replaced with antibiotic-free medium containing LPS 
(5ng/ml). After an incubation period of 16 hours, the medium was removed from the 
wells and assayed for TNFα at a later date (see ‘TNFα measurement’ below). The 
concentration of LPS used was decided from the pilot study shown in figure 2.4. 
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Figure 2.4 LPS pilot study (n=1). RAW 264.7 macrophages were exposed to LPS at 5ng/ml for 8 hours 
and 5ng/ml and 10ng/ml LPS for 16 hours. Higher concentrations of 25-1000ng/ml LPS were also tested 
but the absorbance readings were too high and did not fall within the range of the standard curve. 
 
Cell Lysis 
 
At the end of the LPS exposure macrophages were lysed to remove their protein 
content. Lysis buffer (pH 7.5) was made up on the day of lysis and kept on ice. This 
consisted of 0.4mM NaVO4, 50mM NaF, 1mM Phenylmethanesulfonyl fluoride 
(PMSF), 20µM phenylarsine oxide, 10 mM sodium molybdate, 10µg/ml leupeptin and 
10µg/ml aprotinin, 50mM Tris, 5mM (Ethyleneglycol-O, O’ bis (2-aminoethyl) 
N,N,N’N’-tetraacetic acid) EGTA disodium salt, 150mM NaCl and 1% Triton dissolved 
in distilled water. 
 
Before the lysis buffer was added, the cell medium was removed from the wells, 
centrifuged at 1000g for 10 minutes and stored in aliquots at -20˚C. The TNFα 
concentration in the medium was measured at a later date (see ‘TNFα measurement’). 
The wells were then washed with 0.1M PBS to remove any remaining LPS. 125µl of 
lysis buffer was added to each well and left on ice for 15 minutes before scraping the 
cells from the bottom of the wells. The cell suspension was then centrifuged at 
13000rpm at 4˚C for 15 minutes. The supernatant was then removed and stored in 
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aliquots at -20˚C for up to 1 week. The protein concentration in this supernatant was 
measured at a later date (see ‘Protein measurement’). 
 
TNFα measurement 
 
The aliquots of cell medium (see ‘Cell lysis’ above) were thawed and the 
TNFα concentration was determined using the R and D systems mouse TNFα Duoset 
ELISA Development kit and following the kit protocol. 
 
Principle of assay: the assay employed the quantitative sandwich enzyme immunoassay 
technique. A polyclonal antibody (capture) specific for mouse TNFα was coated onto a 
96-well ELISA plate. Standards and samples were pipetted into wells and any mouse 
TNFα present was bound by the immobilized antibody. Another polyclonal antibody 
(detection) specific for mouse TNFα was then added to the wells which bound to the 
TNFα present. Streptavidin conjugated to horseradish peroxidise (streptavidin-HRP) 
was added to the wells which bound to the detection antibody. Substrate solution 
containing H2O2 and tetramethylbenzidine was added to the wells and converted to a 
coloured blue product by the HRP enzyme. This turned yellow when the H2SO4 stop 
solution was added. The absorbance was then measured at 450nm using a 
spectrophotometer (Sunset instruments, LLC, Hebron, USA). The plate was washed 
between steps to wash off any unbound substances. 
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Protein measurement 
 
Protein quantification was achieved by using the bicinchonic acid (BCA) assay. Bovine 
serum albumin (BSA) standards were prepared by serially diluting the BSA stock 
(2mg/ml) with distilled water. Aliquots of the cell lysate (see ‘Cell lysis’) were thawed 
and 10µl of lysate or standard was pipetted in duplicate onto a 96 well plate. BCA™ 
working reagent (WR) was prepared by mixing 50 parts of BCA™ reagent A with 1 
part of BCA™ reagent B. 200µl of the WR was added to each well and mixed by 
placing the plate on a plate shaker for 30 seconds. The plate was then incubated at 37˚C 
for 30 minutes. After cooling the plate for 5 minutes at room temperature, the 
absorbance was read at 562nm using a spectrophotometer (Sunset instruments, LLC, 
Hebron, USA). 
 
Principle of assay: When the working reagent (containing BCA™ reagents A and B) 
was added to the cell lysate, the protein present reduced the Cu2+ ions (BCA reagent B) 
to Cu1+ ions by forming light blue protein/copper chelates. The BCA™ reagent A 
provided the alkaline environment for this reaction to occur. In the next step, 
bicinchonic acid (BCA™ reagent A) reacted with the Cu1+ ions to form purple coloured 
BCA/copper complexes. The absorbance of these complexes could then be measured at 
the 562nm wavelength. 
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2.5 Data Analysis 
 
In the ileum experiments data was reported as percentage of baseline EFS or initial 
carbachol contractions (mean±SEM). Responses were measured once they had reached 
a plateau, before the next concentration of drug was added. 
 
IC25 and IC50 values calculated for drugs were defined as the drug concentrations 
required to inhibit baseline EFS/initial carbachol contractions by 25% and 50% 
respectively. Mean values with their 95% confidence intervals (shown in brackets) were 
calculated. 
 
To calculate an IC25 or IC50 value for a drug, concentration response curves were 
analysed individually. The concentration of drug corresponding to 25% or 50% 
inhibition was calculated by linear regression between the concentrations lying either 
side of the 25% or 50% inhibitory value. This was performed in Microsoft Excel 2007. 
The average IC25 or IC50 value was then calculated for each experimental group. 
 
95% confidence intervals (CI) were also calculated using Microsoft Excel 2007. The 
Excel formula was based on the equation: 
CI = x ± t* (s / √n) 
Where x = sample mean (mean IC25 or IC50), t*= test statistic, s= standard deviation, 
n=sample number. 
 
In the macrophage experiments the effect of each drug was expressed as a percentage of 
the media control. In the experiments examining TNFα release, results were also 
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expressed as pg TNFα / mg protein. Data were analysed in Microsoft Excel 2007 and 
displayed graphically using Graphpad Prism 5. 
 
2.6 Statistical analysis 
 
Statistical analysis was carried out using an unpaired Student’s T test (two groups) or 
one way ANOVA with post-hoc Dunnett’s test (more than two groups) using Instat. A P 
value of < 0.05 was considered significant 
 
2.7 Materials 
 
(S)-(-)-WIN 55,212-2 mesylate (Tocris, Bristol, UK). 
(R)-(+)-WIN 55,212-2 mesylate (Tocris, Bristol, UK). 
O-1602 (Tocris, Bristol, UK). 
Abnormal cannabidiol (Tocris, Bristol, UK). 
O-1918 (Tocris, Bristol, UK). 
Rimonabant (Tocris, Bristol, UK). 
AM281 (Tocris, Bristol, UK). 
AM630 (Tocris, Bristol, UK). 
Carbamoyl chloride (Sigma-Aldrich Company Ltd, Gillingham, UK).   
JWH007 (synthesised by Ghaith Al-Jayyoussi at the Welsh School of Pharmacy,Cardiff 
University, UK). 
GA001 (synthesised by Ghaith Al-Jayyoussi at the Welsh School of Pharmacy Cardiff 
University, UK). 
GA002 (synthesised by Ghaith Al-Jayyoussi at the Welsh School of Pharmacy Cardiff 
University, UK). 
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GA003 (synthesised  by Ghaith Al-Jayyoussi at the Welsh School of Pharmacy Cardiff 
University, UK). 
Tocrisolve (Tocris, Bristol, UK). 
SR144528 (Cambridge Biosciences Ltd,  Cambridge, UK). 
BCA™ protein assay reagent A (containing sodium carbonate, sodium bicarbonate, 
bicinchonic acid and sodium tartrate in 0.1M sodium hydroxide) (Thermo Fisher 
Scientific, Northumberland, UK). 
BCA™ protein assay reagent B (containing 4% cupric sulphate) (Thermo Fisher 
Scientific, Northumberland, UK). 
Methanethiosulphonate reagent (Promega Ltd, Southampton, UK). 
Lipolysaccharides from Escherichia Coli 055:B5, purified by gel filtration 
chromatography, gamma irradiated (Sigma-Aldrich Company Ltd, Gillingham, UK).   
Mouse TNFα Duoset ELISA Development kit (R and D systems, Abingdon, UK). 
DMEM (Invitrogen, Paisley, UK). 
Heat inactivated fetal bovine serum (Invitrogen). 
Penicillin/streptomycin, containing 5,000units/ml penicillin, 5000µg/ml streptomycin 
(Invitrogen, Paisley, UK). 
Isoton® ( Beckman Coulter Ltd, High Wycombe, UK). 
All other chemicals/reagents were purchased from Fisher-Scientific, UK or Sigma-
Aldrich. 
 
 
 
 
 
 
 
 
 
 
 
62 
 
 
 
 
 
 
                           CHAPTER 3: 
CANNABINOID PHARMACOLOGY OF  
THE GUINEA-PIG ILEUM 
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3. Cannabinoid pharmacology of the guinea-pig ileum 
 
3.1 Introduction 
 
As discussed in chapter 1, the currently held view is that cannabinoids reduce intestinal 
contractions in vitro and in vivo via activation of the CB1 receptor (Colombo et al., 
1998; Coutts et al., 1997; Izzo et al., 2000a; Pertwee et al., 1996). The literature 
suggests that cannabinoids activate pre-synaptic CB1 receptors on cholinergic nerve 
endings in the enteric nervous system, resulting in a reduction in acetylcholine release 
and hence ileum contractions (Colombo et al., 1998; Coutts et al., 1997; Izzo et al., 
2000a; Pertwee et al., 1996). However, much of the evidence for the involvement of the 
CB1 receptor relies on the use of the CB1 antagonist rimonabant, which is not as 
selective as first thought (see ‘Non-CB1 / CB2 targets for cannabinoid receptor ligands’, 
Chapter 1).  
 
Initially, the CB2 receptor was not thought to be involved in the inhibition of intestinal 
motility, but it is now thought that activation of this receptor may reduce contractions 
during inflammation (Izzo, 2007). There is also recent evidence that the CB2 receptor 
may be present in the normal gut of humans and rat, and may be involved in controlling 
motility (Wright et al., 2008; Storr et al., 2002; Ligresti et al., 2003; Duncan et al., 
2008; (Kurjak et al., 2008). Other studies have shown evidence that cannabinoids can 
activate non-CB1/CB2 receptors to inhibit acetylcholine release (Mang et al., 2001) and 
inhibit intestinal contractions (Duncan et al., 2005; Makwana et al., 2010a). There is 
also evidence for the presence of the putative cannabinoid receptors GPR55 and 
GPR119 in the intestine (Brown, 2007), although their role in motility is yet to be 
investigated. Together, these studies suggest that cannabinoid pharmacology in the 
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ileum may not be as straightforward as first thought and that other receptors, apart from 
CB1, may be involved in regulating intestinal motility. 
 
In this chapter, the cannabinoid pharmacology of the guinea-pig ileum was investigated 
using commercially available cannabinoid agonists and antagonists (listed in the 
following section). 
 
Cannabinoid agonists   
 
WIN 55,212-2 
 
The synthetic aminoalkylindole WIN 55,212-2 is available as two enantiomers, (R)-(+)-
WIN 55,212-2 and (S)-(-)-WIN 55,212-2 and exhibits stereoselectivity in its 
pharmacological effects. (S)-(-)-WIN 55,212-2 is a low potency CB2 antagonist and a 
partial CB1 inverse agonist (Savinainen et al., 2005) whereas (R)-(+)-WIN 55,212-2 is a 
potent, non-selective CB1/ CB2 agonist (D'Ambra et al., 1992) (see table 1.1, 
introduction). Some non-CB1/ CB2 effects have also been reported for the (R)-(+)-
isomer WIN 55,212-2 (see ‘Non-CB1 / CB2 targets for cannabinoid receptor ligands’, 
chapter 1).  
 
The non-selective agonist (R)-(+)-isomer WIN 55,212-2, referred to as (+)WIN, was 
used to investigate whether CB1 and/or CB2 receptors are involved in the inhibition of 
guinea-pig ileum contractions. This agonist was chosen due to its high potency at both 
receptors and lack of activity at TRPV1 and GPR55 receptors (Pertwee, 2010). The 
stereoisomer (S)-(-)-WIN 55,212-2, referred to as (-)WIN, was used as a negative 
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control to (+)WIN in these studies, as it does not activate the CB1 or CB2 receptor. The 
chemical structures of (+)WIN and (-)WIN are shown below (see figures 3.1 and 3.2). 
 
                                                
 
 
Figure 3.1 Chemical structure of (R)-(+)-WIN 55,212-2 
                                                                                                                                                                         
                                              
 Figure 3.2 Chemical structure of (S)-(-)-WIN 55,212-2 
 
  Arachidonylcyclopropylamide  
 
The synthetic analogue of anandamide, arachidonylcyclopropylamide (ACPA), is a 
potent, selective CB1 receptor agonist with greater affinity for CB1 over CB2 receptors 
(see table 1.1, introduction and figure 3.3). This selective CB1 agonist was used to 
investigate whether CB1 receptors are involved in the inhibition of guinea-pig ileum 
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contractions. ACPA was chosen as it is one of the most potent CB1 agonists, although it 
does not show resistance to hydrolysis, unlike the (R)-(+)-methandamide (a less 
efficacious CB1 agonist; Pertwee., 2010). ACPA has not been tested for any non-CB1/ 
CB2 effects (Hillard et al., 1999; Pertwee., 1999; Pertwee 2010). 
 
                                          
 
Figure 3.3 Chemical structure of ACPA 
 
 PSN 375963  
 
PSN 375963 (PSN) is a synthetic oxadiazole analogue which is an agonist at the 
proposed novel cannabinoid receptor GPR119 (see GPR119 receptor, chapter 1). 
Reported EC50s for the GPR119 receptor are in the micromolar range (in the yeast 
fluorimetric assay; Overton et al., 2006), suggesting it is a low potency agonist at this 
receptor. No activity has been reported at the CB1 receptor (see table 1.1, introduction) 
but this compound may have other non-GPR119 receptor mediated effects. This 
compound (see figure 3.4 overleaf) was chosen to investigate whether the GPR119 
receptor is involved in the inhibition of guinea-pig ileum contractions and, although it is 
not very potent and may not be highly selective, few GPR119 agonists are available and 
they all share similar limitations. As well as these issues, unfortunately no GPR119 
antagonist is available to confirm any effects seen by PSN (Pertwee, 2010; Ning et al., 
2008; Overton et al., 2006). 
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  Figure 3.4 Chemical structure of PSN 375963  
          
 
Abnormal cannabidiol 
 
Abnormal cannabidiol (abnormal-CBD) is a synthetic regioisomer of the 
phytocannabinoid cannabidiol (see figure 3.5). It was chosen to investigate whether the 
endothelial cannabinoid receptor (CBe) is present in the guinea-pig ileum and involved 
in inhibition of contractions. This compound was chosen as it is thought to be an agonist 
at the CBe receptor (EC50 ~3µM; Offertaler et al., 2003) and does not activate the CB1 or 
CB2 receptor (see table 1.1, introduction). However, it has also been shown to activate 
the GPR55 receptor (reported EC50s 2.5µM and 2.5nM; Ryberg et al., 2007 and Johns et 
al., 2007 respectively). The GPR55 receptor is now thought to be distinct from CBe (Ho 
et al., 2003; Jarai et al., 1999; Mo et al., 2004; Ryberg et al., 2007). 
 
   
                                              
 
Figure 3.5 Chemical structure of abnormal cannabidiol 
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 O-1602 
 
The synthetic analogue of cannabidiol O-1602 is a selective agonist for the suggested 
novel cannabinoid receptor GPR55 (see figure 3.6) and was used to investigate whether 
GPR55 is involved in inhibition of guinea-pig ileum contractions. This compound was 
chosen due to its high potency at the GPR55 receptor (EC50s 1.4 and 13nM; Johns et al., 
2007 and Ryberg et al., 2007 respectively) and because it activates GPR55 in a number 
of different assays (Johns et al., 2007; Ryberg et al., 2007; Waldeck-Weiermair et al., 
2008). In addition, no activity at the CB1 and CB2 receptor has been reported (see table 
1.1). There are some reports, however, that at higher concentrations (in the micromolar 
range) O-1602 activates the putative CBe receptor (EC50 2-3µM; Johns et al., 2007)  
                                             
 
Figure 3.6 Chemical structure of O-1602 
 
Cannabinoid antagonists  
 
Rimonabant and AM281 
 
The synthetic diarylpyrazole rimonabant and AM281 (structural analogue of 
rimonabant) are potent, competitive, relatively selective CB1 receptor antagonists (Lan 
et al., 1999a; Rinaldi-Carmona et al., 1994), showing greater affinity for CB1 over CB2 
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receptors (see table 1.1). There is also evidence that these antagonists are not simply 
neutral antagonists but also display inverse agonism (Hosohata et al., 1997; Pertwee et 
al., 1996). Both antagonists have been shown to act at the GPR55 receptor. AM281  
activates the receptor at 3-30µM (Henstridge et al., 2009a and b) whereas, reports of  
rimonabant’s effects on the receptor are conflicting (Godlewski et al., 2009; Pertwee., 
2010; Rinaldi-Carmona et al., 1994). Several non-CB1/ CB2 /GPR55 effects have been 
demonstrated with rimonabant use (see ‘Non-CB1 / CB2 targets for cannabinoid receptor 
ligands’, chapter 1). The two different CB1 antagonists were used with every agonist in 
this chapter to investigate if the effect was consistent regardless which CB1 antagonist 
was used. Therefore, if both antagonists attenuated a response to an agonist, it would be 
more convincing that the agonist effect was mediated through the CB1 receptor. The 
structures of AM281 and rimonabant are shown in figures 3.7 and 3.8.  
 
 
 
                
                                     
                                                     
Figure 3.7 Chemical structure of AM281 
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  Figure 3.8 Chemical structure of rimonabant 
 
SR144528 and AM630  
 
The diarylpyrazole SR144528 and aminoalkylindole AM630 (see figures 3.9 and 3.10) 
are potent, competitive, selective CB2 receptor antagonists (Hosohata et al., 1997; 
(Rinaldi-Carmona et al., 1998) showing greater affinity for CB2 over CB1 receptors (see 
table 1.1, introduction). These synthetic antagonists are also thought to act as inverse 
agonists at the CB2 receptor (Ross et al., 1999). Neither compound activates the GPR55 
receptor (Pertwee., 2010). 
 
 Two different CB2 antagonists were used for the same rationale as for the CB1 
antagonists; if both antagonists attenuated the agonist’s response, it would be more 
convincing that the agonist’s response was mediated through the CB2 receptor.  
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Figure 3.9 Chemical structure of AM630 
 
 
                                 
 
                                        
Figure 3.10 Chemical structure of SR144528 
 
 (-)cannabidiol 
 
(-) cannabidiol ((-)CBD) is one of the main phytocannabinoids found in cannabis. It was 
used to investigate whether any of the effects of the cannabinoid agonists were mediated 
through the GPR55 receptor as this is the only GPR55 antagonist available. This 
compound is, however, not very selective; the IC50 for the GPR55 receptor is only 
slightly lower than that for the CB1 receptor (0.4 and 3.4µM respectively; Petitet et al., 
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1998; Thomas et al., 2007., Ryberg et al., 2007). (-)CBD is also a CB2 receptor inverse 
agonist (Thomas et al., 2007), inhibitor of anandamide uptake (Bisogno et al., 2001) 
and an agonist at the TRPV1 receptor (Costa et al., 2004).  
                                                  
 
Figure 3.11 Chemical structure of (-) cannabidiol 
 
O-1918 
 
O-1918 is a synthetic analogue of CBD. It is a selective antagonist (≥ 1µM; Offertaler., 
2003) at the CBe receptor (Hoi et al., 2006; Mo et al., 2004; Offertaler et al., 2003) 
 and does not bind to the CB1 or CB2 receptor (see table 1.1; chapter 1). This was chosen 
to investigate whether any of the agonists mediated their effects through the CBe 
receptor as this was the only CBe receptor antagonist available.  
 
                                                           
 
 
Figure 3.12 Chemical structure of O-1918 
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3.2 Aims 
 
The aim of this chapter was to establish the identity of the receptors mediating 
inhibition of ileum contractions through the use of selective agonists and antagonists. 
 
3.3 Method 
 
 Construction of cannabinoid agonist concentration-response curves 
 
The ileum was prepared as in chapter 2 and was either subjected to EFS (see ‘Electrical 
field stimulation of the guinea-pig ileum’, chapter 2) or contracted with carbachol (see 
‘Carbachol-induced contraction of the ileum’, chapter 2). Once contractions had 
stabilised, concentrations of the cannabinoids ((+)WIN, (-)WIN, abnormal-CBD, PSN 
or O-1602) or ethanol vehicle were added in a cumulative manner. The organ bath 
concentration of the cannabinoids ranged from 1x10-11M to 3x10-6 M (1x10-4M for 0-
1602 and PSN). The concentration of the vehicle (absolute ethanol) varied depending on 
the cannabinoid used. The volumes of vehicle used and the final bath concentrations are 
shown in the results section (3.4). Enough time was allowed for each response to 
plateau before a subsequent agonist concentration was added. Only one concentration-
response curve was constructed per individual preparation. 
 
In the antagonist studies, the ileum was incubated with the antagonist (0-1918, (-)CBD, 
rimonabant, AM281, SR144528 or AM630) or vehicle for 30 minutes before the first 
concentration of agonist was added. Rimonabant, AM281 and AM630 were 
administered dissolved in DMSO, whereas absolute ethanol was used as the vehicle for 
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0-1918, SR144528 and (-)CBD. The final concentration of DMSO in the organ bath was 
0.02% where these antagonists were used. 
   
Drug solutions 
 
Drugs were dissolved in either absolute ethanol (WIN 55,212-2, PSN, SR144528,           
(-)CBD and 0-1918) or DMSO (AM630, AM281 and rimonabant). Abnormal-CBD and 
0-1602 were supplied pre-dissolved in methyl acetate. Due to the large inhibition of 
EFS-induced contractions induced by methyl acetate, the solvent was evaporated under 
vacuum using a rotary evaporator and the compounds were re-dissolved in absolute 
ethanol. Aliquots of drug solutions were frozen at -20˚C (for up to one month) and were 
thawed and diluted to the desired concentration on the day of the experiment. All 
cannabinoid agonists were serially diluted in ethanol. ACPA was the only drug supplied 
in TocrisolveTM, and was serially diluted with Krebs’ bicarbonate solution on the day of 
the experiment. The combined rimonabant and SR144528 solution was prepared by 
dissolving rimonabant in ethanol and then dissolving SR144528 in the rimonabant 
solution. This was then stored in aliquots as above and serially diluted in ethanol on the 
day of experiment. 
 
Data analysis 
 
The effect of each drug concentration on contraction size was reported as a percentage 
of baseline EFS or initial carbachol contraction. Data were reported as mean±SEM.  
 
An IC25 or IC50 was calculated for each drug, defined as the drug concentrations 
required to inhibit baseline EFS/initial carbachol contraction by 25% and 50% 
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respectively. Mean values with their 95% confidence intervals (shown in brackets) were 
calculated. 
 
Curve fitting was not carried out as the concentration-response curves did not fit the 
traditional sigmoidal shape and did not reach a maximum response at the concentrations 
used. 
 
Statistical analysis 
 
Mean values for the drug and its vehicle control were compared using unpaired 
Student’s t test (drug and vehicle) or one way ANOVA with post-hoc Dunnett’s Test 
(multiple drugs and vehicle). One sample Student’s t tests were used to determine the 
effects of the vehicle alone on contractions. Statistical differences between vehicle and 
drug were denoted with a star symbol.  P<0.05 was considered statistically significant. 
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3.4 Results 
 
3.4.1 The effect of cannabinoid agonists/antagonists on EFS-evoked contractions of 
the guinea-pig isolated ileum. 
 
The effect of (+)WIN on EFS-evoked contractions  
 
(+)WIN caused a concentration-dependent reduction in the size of EFS-induced 
contractions of the ileum (IC25: 2.8(0.1-56) x10-8M). (+)WIN had no effect at 
concentrations below 3x10-8M but caused (47.4 ± 5.5%; P < 0.01) inhibition at the 
highest concentration of 3µM (see figures 3.13 and 3.14). The ethanol vehicle had no 
significant effect on the size of contractions. 
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Figure 3.13 The effect of (+)WIN (n=6) and ethanol vehicle (n=5) on the size of EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The 
baseline size was measured immediately before the addition of (+)WIN. Each symbol represents the mean 
percentage; vertical bars indicate standard error of the mean (SEM); * P< 0.05, **P< 0.01 (one way 
ANOVA with post-hoc Dunnett’s test). The concentrations of ethanol vehicle used ranged from 0.02-
0.33% (shown as respective (+)WIN concentrations 10-11- 3x10-6M). The same vehicle control was used 
in several cannabinoid experiments. 
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Figure 3.14 Trace showing the effect of (+)WIN on EFS-induced contractions of the guinea-pig isolated 
ileum. Concentrations (M) shown below: 
 
1= 1x10-11                   4= 3x10-10               7= 1x10-8              10= 3x10-7                                                                             
2= 3x10-11                   5= 1x10-9                 8= 3x10-8              11= 1x10-6                                                                               
3= 1x10-10                   6= 3x10-9                 9= 1x10-7              12= 3x10-6                                                                                                               
 
 
The effect of rimonabant on (+)WIN-induced inhibition of EFS-evoked contractions  
 
Rimonabant alone (1µM) increased contraction size by 47.3 ± 8.7% (P < 0.05) (see 
figure 3.16 and table 3.1 overleaf). The antagonist vehicle alone had no significant 
effect on the EFS-induced response.  Rimonabant (1µM) did not antagonise the 
(+)WIN-induced inhibition (see figure 3.15 overleaf) of EFS-induced contractions and 
in fact increased the effect of 3µM (+)WIN. ((+)WIN reduced contraction size by 71.0 ± 
6.2 in the presence of rimonabant compared to 40.7 ± 7.6% in the presence of antagonist 
vehicle, P < 0.05).  
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Drugs n % of initial EFS 
response 
AM281 4 195.8 ± 9.0% * 
rimonabant 4 147.3 ± 8.7% * 
 
Table 3.1 The effect of rimonabant and AM281 alone (1µM) on EFS-induced contractions of the guinea-
pig isolated ileum. 
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Figure 3.15 The effect of (+)WIN on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM rimonabant (n=4) and antagonist vehicle (0.02% DMSO; n=5). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of (+)WIN. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); * P< 0.05 (one 
way ANOVA with post-hoc Dunnett’s test). The same antagonist vehicle was used in several (+)WIN 
experiments. 
 
 
 
 
 
79 
 
 
 
 
Figure 3.16 Trace showing the effect of (+)WIN (2-13) on EFS-induced contractions of the guinea-pig 
isolated ileum in the presence of rimonabant ( 1µM). Concentrations (M) shown below: 
 
1= rimonabant (1µM)                   4= 1x10-10                          7= 3x10-9                     10= 1x10-7        13 =  3x10-6                                                                                                                                     
2= 1x10-11                                      5= 3x10-10                           8= 1x10-8                     11= 3x10-7                                                                               
3= 3x10-11                                               6= 1x10-9                             9= 3x10-8                     12= 1x10-6                                                                                                               
 
 
The effect of AM281 on (+)WIN-induced inhibition of EFS-evoked contractions 
 
AM281 alone (1µM) increased contraction size by 95.8 ± 9.0% in a similar manner to 
rimonabant (see table 3.1). The antagonist vehicle alone had no significant effect on 
the EFS-induced response. AM281 (1µM) did not antagonise the (+)WIN-induced 
inhibition of EFS-evoked contractions (see figure 3.17 overleaf).  
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 Figure 3.17 The effect of (+)WIN on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM AM281 (n=6) and antagonist vehicle (0.02% DMSO; n=5). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of (+)WIN. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by one way ANOVA. The same antagonist vehicle control was used in several (+)WIN 
experiments. 
 
The effect of AM630 on (+)WIN-induced inhibition of EFS-evoked contractions 
 
AM630 (1µM) did not antagonise the (+)WIN-induced inhibition of EFS-induced 
contractions (see figure 3.18 overleaf) and, in fact, increased the response associated 
with low concentrations of (+)WIN (3x10-11 to 10-9M).(+)WIN at a concentration of 
10-9M was without effect in the absence of AM630 but caused a significant reduction 
in the presence of AM630, reducing contraction size by 22.2 ± 5.7% (P < 0.05). 
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 Figure 3.18 The effect of (+)WIN on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM AM630 (n=5) and antagonist vehicle (0.02% DMSO; n=5). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of (+)WIN. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); * P< 0.05 
(one way ANOVA with post-hoc Dunnett’s test). The same antagonist vehicle was used in several 
(+)WIN experiments. 
 
The effect of SR144528 on (+)WIN-induced inhibition of EFS-evoked contractions 
 
SR144528 (1µM) had no significant effect on (+)WIN-induced inhibition of EFS-
evoked contractions (see figure 3.19 overleaf). 
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Figure 3.19 The effect of (+)WIN on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM SR144528 (n=3) and antagonist vehicle (0.02% ethanol; n=5). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of (+)WIN. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by one way ANOVA. The same antagonist vehicle control was used in several (+)WIN 
experiments. 
 
 
The effect of O-1918 on (+)WIN-induced inhibition of EFS-evoked contractions 
 
O-1918 (1µM) had no significant effect on (+)WIN-induced inhibition of EFS-evoked 
contractions (see figure 3.20 overleaf). 
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Figure 3.20 The effect of (+)WIN on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM O-1918 (n=6) and antagonist vehicle (0.02% ethanol; n=5). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of (+)WIN. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by one way ANOVA. The same antagonist vehicle control was used in several (+)WIN 
experiments. 
 
The effect of rimonabant + SR144528 on (+)WIN-induced inhibition of EFS-
evoked contractions 
 
The combination of rimonabant (1µM) and SR144528 (1µM) had no significant effect 
on (+)WIN-induced inhibition of EFS-evoked contractions (see figure 3.21 overleaf). 
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Figure 3.21 The effect of (+)WIN on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM rimonabant+SR144528 (n=4) and antagonist vehicle (0.02% ethanol; 
n=5). The data were expressed as percentage of baseline EFS response. The baseline contraction size 
was measured after the addition of the antagonist and immediately before the addition of (+)WIN. 
Each symbol represents the mean percentage; vertical bars indicate standard error of the mean (SEM); 
data were analysed by one way ANOVA. The same antagonist vehicle control was used in several 
(+)WIN experiments. 
 
 
 
The effect of (-)WIN on EFS-evoked contractions 
 
(-)WIN did not significantly reduce contraction size at any concentration (see figure 
3.22 overleaf). The ethanol vehicle control caused a small reduction in contraction 
size at volumes required to achieve (-)WIN concentrations of 3x10-10, 1x10-8, 3x10-7, 
1x10-6and 3x10-6M. The largest reduction in contraction size by the ethanol vehicle 
was 16.8 ± 1.5% (P <0.05), exerted by the volume required to achieve a (-)WIN 
concentration of 1x10-8M. 
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(-)WIN increased contraction size at 3x10-10 and 1x10-8M (P < 0.05) compared to the 
ethanol vehicle alone.  Contractions size was measured as 101.2 ± 4.3% of baseline 
response in the presence of (-)WIN 3x10-10 M and only 85.3 ± 2.3% in the presence of 
the ethanol vehicle alone. Similarly, in the presence of 1x10-8M (-)WIN, contraction 
size was measured as 96.2 ± 3.5% of baseline response but only 83.2 ± 1.5% in the 
presence of ethanol vehicle alone. 
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Figure 3.22 The effect of (-) WIN (n=3) and ethanol vehicle (n=3) on the size of EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The 
baseline contraction size was measured immediately before the addition of (-)WIN. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); * P< 0.05 
(unpaired Student’s t test). The concentrations of ethanol vehicle used ranged from 0.02-0.33% (shown 
as respective (-)WIN concentrations 10-11- 3x10-6M).  
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The effect of ACPA on EFS-evoked contractions 
 
ACPA had no significant effect on the magnitude of EFS-evoked contractions of the 
ileum at concentrations of up to 10-4M (see figure 3.23). TocrisolveTM (the agonist 
vehicle) had no significant effect on the magnitude of EFS-evoked concentrations. 
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Figure 3.23 The effect of ACPA (n=4) and TocrisolveTM vehicle (n=4) on the size of EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The 
baseline contraction size was measured immediately before the addition of ACPA. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by unpaired Student’s t test. The concentrations of TocrisolveTM vehicle used ranged from  
2x10-6-0.33%. (shown as respective ACPA concentrations 10-10- 10-4M).  
 
The effect of abnormal-cannabidiol on EFS-evoked contractions 
 
The effect of abnormal-cannabidiol (abnormal-CBD) on EFS-evoked contractions 
was found to vary considerably. When abnormal-CBD was initially tested, it exhibited 
a concentration-dependent reduction in the size of EFS-induced contractions of the 
ileum (IC25: 9.8 (1.0 - 97) x 10-10M). The compound had no effect at concentrations 
below 3x10-10M but caused 58.3 ± 7.3%, (P < 0.01) inhibition of EFS-evoked 
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contractions at the highest concentration of 3µM (see figures 3.24a and 3.25a 
overleaf). The ethanol vehicle had no significant effect on the size of contractions.  
 
However, when abnormal-CBD was subsequently tested, it had no significant effect 
on EFS-evoked contractions up to 3x10-5M (see figures 3.24b and 3.25b overleaf). 
The ethanol vehicle had no significant effect when added in low volumes but inhibited 
contractions at the higher volumes required to achieve concentrations of abnormal-
CBD ≥ 1µM. The ethanol vehicle reduced contractions by 22.2 ± 2.9 % (P <0.01) at 
the highest volume added, which was required to achieve an abnormal-CBD 
concentration of 3x10-5M.  
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Figure 3.24a The effect of abnormal-CBD (n=5) and ethanol vehicle (n=5) on the size of EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The 
baseline contraction size was measured immediately before the addition of abnormal-CBD. Each 
symbol represents the mean percentage; vertical bars indicate standard error of the mean (SEM); * P< 
0.05, **P< 0.01 (one way ANOVA with post-hoc Dunnett’s test). The concentrations of ethanol vehicle 
used ranged from 0.02-0.33% (shown as respective abnormal-CBD concentrations 10-11-3x10-6M). The 
same vehicle control was used in several cannabinoid experiments. 
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Figure 3.24b The effect of abnormal-CBD (n=6) and ethanol vehicle (n=4) on the size of EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The 
baseline contraction size was measured immediately before the addition of abnormal-CBD. Each 
symbol represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data 
were analysed by unpaired Student’s t test. The concentrations of ethanol vehicle used ranged from 
0.02-0.29% (shown as respective abnormal-CBD concentrations 10-11-3x10-6M). 
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Figure 3.25a Trace showing the effect of abnormal-CBD on EFS-induced contractions of the guinea-
pig isolated ileum. Concentrations (M)  shown below: 
 
1= 1x10-11                   4= 3x10-10               7= 1x10-8              10= 3x10-7                                                                             
2= 3x10-11                   5= 1x10-9                 8= 3x10-8              11= 1x10-6                                                                               
3= 1x10-10                   6= 3x10-9                 9= 1x10-7              12= 3x10-6                                                                                                               
 
 
 
Figure 3.25b Trace showing the effect of abnormal-CBD on EFS-induced contractions of the guinea-
pig isolated ileum. Concentrations (M) shown below: 
1= 1x10-11                   4= 1x10-8              7= 1x10-5               
2= 1x10-10                   5= 1x10-7              8= 3x10-5               
3= 1x10-9                    6= 1x10-6                 
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The effect of O-1602 on EFS-evoked contractions 
 
O-1602 caused a concentration-dependent reduction in the size of EFS-induced 
contractions of the ileum (IC25: 6.7 (0.4 - 123) 10-7M and IC50: 3.1 (1.4 - 7.0) x 
10¯5M). O-1602 had no effect at concentrations below 10-7M but reached (90.8 ± 
1.3%, P < 0.001) inhibition at the highest concentration of 10-4M (see figures 3.26 and 
3.27). The ethanol vehicle had no significant effect on the EFS-induced response 
when added in low volumes but reduced contraction size by (16.0 ± 5.8%, P < 0.05) 
at the volume required to achieve an O-1602 concentration of 10-5M.  
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Figure 3.26 The effect of O-1602 (n=3) and ethanol vehicle (n=4) on the size of EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The 
baseline contraction size was measured immediately before the addition of O-1602. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); * P< 0.05, 
**P< 0.01, ***P<0.001 (unpaired Student’s t test). The concentrations of ethanol vehicle used ranged 
from 0.02-0.35% (shown as respective O-1602 concentrations 10-10-10-4M).  
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Figure 3.27 Trace showing the effect of O-1602 on EFS-induced contractions of the guinea-pig 
isolated ileum. Concentrations (M) shown below: 
1= 1x10-10                   4= 1x10-7              7= 3x10-5             
2= 1x10-9                     5= 1x10-6              8= 1x10-4               
3= 1x10-8                    6= 1x10-5                  
 
 
The effect of rimonabant on O-1602-induced inhibition of EFS-evoked  
contractions  
 
Rimonabant (1µM) had no significant effect on O-1602-induced inhibition of EFS-
evoked contraction (see figure 3.28 overleaf). 
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Figure 3.28 The effect of O-1602 on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM rimonabant (n=4) and antagonist vehicle (0.02% DMSO; n=4). The data 
was expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of O-1602. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by one way ANOVA. The same antagonist vehicle control was used in several O-1602 
experiments. 
 
The effect of AM281 on O-1602-induced inhibition of EFS-evoked contractions 
 
AM281 (1µM) had no significant effect on O-1602-induced inhibition of EFS-evoked 
contraction (see figure 3.29). 
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Figure 3.29 The effect of O-1602 on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM AM281 (n=3) and antagonist vehicle (0.02% DMSO; n=4). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of O-1602. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by one way ANOVA. The same antagonist vehicle control was used in several O-1602 
experiments. 
 
 The effect of SR144528 on O-1602-induced inhibition of EFS-evoked contractions 
 
SR144528 (1µM) had no significant effect on O-1602-induced inhibition of EFS-
evoked contraction (see figure 3.30 overleaf). 
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Figure 3.30 The effect of O-1602 on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM SR144528 (n=3) and antagonist vehicle (0.02% ethanol; n=5). The data 
was expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of O-1602. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data was 
analysed by one way ANOVA. The same antagonist vehicle control was used in several O-1602 
experiments. 
 
The effect of AM630 on O-1602-induced inhibition of EFS-evoked contractions 
 
AM630 (1µM) had no significant effect on O-1602-induced inhibition of EFS-evoked 
contraction (see figure 3.31 overleaf). 
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Figure 3.31 The effect of O-1602 on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM AM630 (n=3) and antagonist vehicle (0.02% DMSO; n=4). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of O-1602. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by one way ANOVA. The same antagonist vehicle control was used in several O-1602 
experiments. 
 
The effect of O-1918 on O-1602-induced inhibition of EFS-evoked contractions 
 
O-1918 (1µM) had no significant effect on O-1602-induced inhibition of EFS-evoked 
contractions (see figure 3.32 overleaf). 
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Figure 3.32 The effect of O-1602 on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 1µM O-1918 (n=3) and antagonist vehicle (0.02% ethanol; n=5). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of O-1602. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by one way ANOVA. The same antagonist vehicle control was used in several O-1602 
experiments. 
 
 
The effect of (-) CBD on O-1602-induced inhibition of EFS-evoked  contractions 
 
 (-) CBD (4µM) had no significant effect on O-1602-induced inhibition of EFS-
evoked contractions (see figure 3.33 overleaf). 
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Figure 3.33 The effect of O-1602 on the size of EFS-induced contractions of the guinea-pig isolated 
ileum, in the presence of 4µM (-)CBD (n=4) and antagonist vehicle (0.02% ethanol; n=5). The data 
were expressed as percentage of baseline EFS response. The baseline contraction size was measured 
after the addition of the antagonist and immediately before the addition of O-1602. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data were 
analysed by one way ANOVA. The same antagonist vehicle control was used in several O-1602 
experiments. 
 
The effect of PSN on EFS-evoked contractions 
 
PSN caused a concentration-dependent reduction in the size of EFS-induced 
contractions of the ileum (IC25: 3.9 (2.7 – 5.5) x 10-5 M). PSN had no significant 
effect at concentrations below 10-5M but caused 52.4 ± 6.9 % inhibition (P < 0.05) at 
the highest concentration of 10-4M (see figures 3.34 and 3.35). The ethanol vehicle 
had no significant effect at any concentration used. 
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Figure 3.34 The effect of PSN (n=3) and ethanol vehicle (n=3) on the size of EFS-induced contractions 
of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The baseline 
contraction size was measured immediately before the addition of PSN. Each symbol represents the 
mean percentage; vertical bars indicate standard error of the mean (SEM); * P< 0.05, **P< 0.01, 
(unpaired Student’s t test). The concentrations of ethanol vehicle used ranged from 0.02-0.28% (shown 
as respective PSN concentrations 10-6-10-4M).  
 
 
 
Figure 3.35 Trace showing the effect of PSN on EFS-induced contractions of the guinea-pig isolated 
ileum. Concentrations (M) shown below: 
1= 1x10-6              3= 3x10-5                                   
 2= 1x10-5             4= 1x10-4 
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3.4.2 The effect of cannabinoid agonists/antagonists on carbachol-induced 
contractions of the guinea-pig isolated ileum. 
 
The effect of (+)WIN on carbachol-induced contraction 
 
(+)WIN had no significant effect on carbachol-induced contraction of the ileum (see 
figure 3.36). The ethanol vehicle had no significant effect when added in low volumes 
but inhibited contractions at the higher volumes required to achieve concentrations of 
(+)WIN ≥ 1x10-7M. The ethanol vehicle reduced contractions by 37.7 ± 9.0 % (P 
<0.05) at the highest volume added, which was required to achieve 1µM (+)WIN. 
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Figure 3.36 The effect of (+)WIN (n=5) and ethanol vehicle (n=4) on the size of carbachol-induced 
contraction of the guinea-pig isolated ileum, expressed as percentage of initial carbachol contraction. 
The baseline contraction size was measured after the addition of carbachol and immediately before the 
addition of (+)WIN. Each symbol represents the mean percentage; vertical bars indicate standard 
error of the mean (SEM), data were analysed by unpaired Student’s t test. The concentrations of 
ethanol vehicle used ranged from 0.02-0.074% (shown as respective (+)WIN concentrations 10-9-10-
6M).  
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The effect of PSN on carbachol-induced contraction 
 
PSN showed a concentration-dependent reduction of the carbachol-induced 
contraction (IC50: 1.2 (0.2 – 1.2) x 10-5 M, see figures 3.37 and 3.38). PSN showed an 
effect from 10-5M upwards, abolishing contractions at the highest concentration of 
10¯4M (110.0 ± 7.3% inhibition, P < 0.001). The ethanol vehicle had no significant 
effect when added in low volumes but inhibited contractions at the higher volumes 
required to achieve concentrations of PSN ≥ 1x10-5M. The ethanol vehicle reduced 
contractions by 35.3 ± 7.9 % (P <0.05) at the highest volume added, which was 
required to achieve a PSN concentration of 1 x 10-4M . 
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Figure 3.37 The effect of PSN (n=4) and ethanol vehicle (n=5) on the size of carbachol-induced 
contraction of the guinea-pig isolated ileum, expressed as percentage of initial carbachol contraction. 
The baseline contraction size was measured after the addition of carbachol and immediately before the 
addition of PSN. Each symbol represents the mean percentage; vertical bars indicate standard error of 
the mean (SEM);; * P< 0.05, **P< 0.01(one way ANOVA with post-hoc Dunnett’s test).The 
concentrations of ethanol vehicle used ranged from 0.02-0.28% (shown as respective PSN 
concentrations 10-6-10-4M).  
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Figure 3.38 Trace showing the effect of PSN (2-5) on carbachol-induced contraction of the guinea-pig 
isolated ileum. Concentrations (M) shown below: 
1 = 3x10-7 carbachol                4 = 3 x10-5  
2 = 1 x10-6                                 5 = 1 x10-4  
3 = 1 x10-5  
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The effect of O-1602 on carbachol-induced contraction 
 
O-1602 had no significant effect on carbachol-induced contraction of the ileum (see 
figure 3.39). The ethanol vehicle had no significant effect when added in low volumes 
but inhibited contractions at the higher volumes required to achieve concentrations of 
O-1602 ≥ 1x10-5M. The ethanol vehicle reduced contractions by 35.3 ± 7.9 % (P < 
0.05) at the highest volume added, which was required to achieve an O-1602 
concentration of 1 x 10-4M . 
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Figure 3.39 The effect of O-1602 (n=3) and ethanol vehicle (n=5) on the size of carbachol-induced 
contraction of the guinea-pig isolated ileum, expressed as percentage of initial carbachol contraction. 
The baseline contraction size was measured after the addition of carbachol and immediately before the 
addition of O-1602. Each symbol represents the mean percentage; vertical bars indicate standard error 
of the mean (SEM), data were analysed by one way ANOVA. The concentrations of ethanol vehicle used 
ranged from 0.02-0.28% (shown as respective O-1602 concentrations 10-6-10-4M).  
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3.5 Discussion 
 
The main finding of these studies is that cannabinoid-mediated inhibition of ileal 
contractions was not mediated through the CB1 receptors, contrary to the currently held 
view (Colombo et al., 1998; Coutts et al., 1997; Izzo et al., 2000a; Pertwee et al., 1996). 
The cannabinoid responses were not blocked by either of the CB1 antagonists, 
rimonabant or AM281, and the selective CB1 agonist ACPA had no effect on EFS-
evoked contractions. Although ACPA does undergo hydrolysis by FAAH (Pertwee., 
2010), the concentration added to the bath (1 x 10-4M) was 50000 times higher than the 
its Ki (2.2 x 10-9 M; see table 1.1, chapter 1). Therefore, even in the face of significant 
degradation, a response would still be expected had it been mediated by CB1 receptors.  
 
One effect, which was consistent with the literature, was that rimonabant or AM281 
alone increased contraction size. The literature suggests that this response is due to 
inverse agonism or antagonism of endogenous cannabinoids at the CB1 receptor 
(Pertwee et al., 1996). The inability to be able to elicit a response with a selective CB1 
receptor agonist or of CB1 selective antagonists to block cannabinoid responses would 
suggest that, in the guinea-pig ileum, any inverse agonism would not be mediated by 
CB1 receptors.  
 
Another important finding is that cannabinoid-mediated inhibition of contractions may 
be exerted through the GPR119 receptor. Although GPR119 mRNA has been 
discovered in the intestine, this is the first indication that the receptor may be involved 
in controlling motility. In this research, the GPR119 agonist PSN was found to produce 
a concentration-dependent reduction in EFS-induced contractions (IC25: 3.9 (2.7 – 5.5) 
x 10-5 M), see figure 3.34). The response could be mediated through GPR119 as PSN 
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causes significant responses at 10-5M, only ten times higher than the EC50 reported for 
PSN at the human GPR119 receptor (~8.4 µM EC50 in the yeast fluorimetric assay; 
Overton et al., 2006). Unfortunately, this cannot be corroborated until a GPR119 
antagonist becomes available. 
 
Interestingly, PSN also reduced the carbachol-induced contraction of the guinea-pig 
ileum (IC50: 1.2 (0.2 – 1.2) x 10-5 M, see figure 3.37). This response could be mediated 
through GPR119 as the IC50 is in the same range as the EC50 reported for PSN at the 
GPR119 receptor (micromolar range in the yeast fluorimetric assay; Overton et al., 
2006). Although this requires corroboration with a GPR119 antagonist, it suggests that 
the GPR119 receptor may be present on smooth muscle. This is interesting as 
cannabinoid receptors are not thought to be expressed on intestinal smooth muscle 
(Lynn et al., 1994; Mang et al., 2001; Pertwee., 2001).  
 
The GPR119 receptor may also be present on neurones but this would need to be 
investigated by measuring neurotransmitter release. The GPR119 receptor does not 
seem to be involved in the other cannabinoid responses. O-1602 (selective GPR55 
agonist) and (+)WIN (non-selective agonist) reduced the size of EFS-evoked 
contractions but, as (+)WIN does not bind to the GPR119 receptor (see table 1.3, 
chapter 1) and neither agonist reduced carbachol-induced contraction, it is unlikely that 
the responses were mediated via GPR119. 
 
The CB2 receptor does not appear to mediate cannabinoid-mediated inhibition of 
contractions as O-1602 and (+)WIN responses were not blocked by the selective CB2 
antagonists, AM630 or SR144528. This is consistent with the literature, which suggests 
that inhibition of guinea-pig ileum contractions is not mediated through the CB2 
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receptor (Croci et al., 1998; Izzo et al., 2000a). Blocking the CB1 and CB2 receptors 
simultaneously, with the combination of SR144528 and rimonabant, also did not affect 
the cannabinoid response.  
 
Similarly, there is no evidence for the involvement of the GPR55 receptor in the 
cannabinoid responses. In this investigation, the selective GPR55 agonist O-1602 was 
found to reduce EFS-evoked contractions in a concentration-dependent manner (IC25: 
6.7 (0.4 - 123) 10-7M and IC50: 3.1 (1.4 - 7.0) x 10-5M, see figure 3.26). The IC50 was 
approximately 700 times higher than the reported EC50 for O-1602 (13 x 10-9M; Ryberg 
et al., 2007) at the GPR55 receptor. Although there is little information concerning the 
metabolism of O-1602, even if the compound undergoes extensive breakdown, it is 
unlikely this could account for such a discrepancy between the observed IC50 and the 
reported EC50 for the GPR55 receptor. In addition, the GPR55 antagonist (-) 
cannabidiol did not reduce the O-1602 response. As (+)WIN does not bind to GPR55 
(see table 1.2b, chapter 1), this receptor was not responsible for (+)WIN-mediated 
inhibition of contractions. Together, these results suggest that cannabinoid-responses 
are not mediated through the GPR55 receptor.  
 
It is unclear whether the putative CBe receptor is involved in cannabinoid-mediated 
inhibition of contractions. The effect of the selective CBe agonist abnormal-CBD was 
found to vary considerably. When it was initially tested, it reduced EFS-evoked 
contractions in a concentration-dependent manner (IC25: 9.8 (1.0 - 97) x 10-10M, see 
figure 3.24a) but, when it was tested subsequently, it had no effect, even at higher 
concentrations (see figure 3.24b). Due to the variability of abnormal-CBD effects, O-
1918 (CBe antagonist) could not be tested, so it is unclear whether abnormal-CBD acts 
through the CBe receptor. It may mediate its effect through this receptor but the 
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expression may vary between different guinea-pigs. The CBe receptor is not involved in 
O-1602 and (+)WIN mediated inhibition of contractions as O-1918 did not block their 
responses. It is possible that these cannabinoids do not bind to the CBe receptor but this 
can only be confirmed once that receptor has been cloned. 
 
As the responses to (+)WIN and O-1602 do not seem to be  mediated by any of the 
cloned or proposed cannabinoid receptors, this suggests the involvement of another 
receptor or a receptor-independent mechanism.  It is possible that the response to 
(+)WIN observed is not mediated through a receptor as it does not seem to have a 
traditional sigmoidal concentration-response curve seen for most receptors. This was 
investigated using the stereoisomer (-)WIN, which does not activate the CB1 or CB2 
receptor (activation of the receptor is stereoselective); (Savinainen et al., 2005). If the 
response to (+)WIN was non-receptor mediated, the stereoisomer (-)WIN would have 
been expected to replicate this response. Instead, (-)WIN did not inhibit EFS-induced 
contractions of the ileum, suggesting that the response to (+)WIN was mediated by a 
protein target such as a receptor.  
 
 (+)WIN has been shown, at the concentrations used in this thesis, to act on a number of 
non-cannabinoid receptors. It has been shown to antagonise 5-HT3 receptors (Pertwee., 
2010), and this could be significant as these receptors are known to mediate contraction 
in the guinea-pig ileum (Fox et al., 1990). (+)WIN also activates PPARα receptors 
(Pertwee, 2010) known to be present in the intestine (Sanderson et al., 2010), although 
it is not know whether they affect motility. It is possible that (+)WIN could act on one 
or several of these receptors/channels to inhibit contractions. As O-1602 is a relatively 
new compound, less is known about its interactions with non-cannabinoid receptors. It 
would be useful to investigate the effect of pertussis toxin (which inactivates Gi and Go 
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G proteins) on the inhibitory effect of O-1602 and (+)WIN in the ileum to give an 
indication of whether their effects is mediated through a Gi/o protein-coupled receptor.  
 
Another  noteworthy result from this study was that  (+) WIN was less potent (IC25: 
2.8(0.1-56) x10-8M) at inhibiting contractions than in the literature (IC50: 5.54 x 10-9M 
(Pertwee et al., 1996). The reason for this discrepancy is unclear. It may be due to 
differences in cannabinoid receptor expression between guinea-pig batches or the 
section of ileum used. It is unlikely that this is due to differences in guinea-pigs as the 
same species (Dunkin-Hartley) and similar size range was used in this research and the 
study by Pertwee (1996). Also, currently there is no evidence that cannabinoid receptor 
expression varies across the length of the ileum. The main difference between this study 
and the literature is that the whole guinea-pig ileum was used in this study whereas only 
the longitudinal muscle-myenteric plexus was used in the literature (Pertwee et al., 
1996). It is possible that it was more difficult for (+)WIN to access the receptors in the 
whole ileum as it had to cross through several layers of tissue though, again, this is 
unlikely as (+)WIN is lipophilic and should be able to cross the ileum. It also seems 
unlikely that (+)WIN was being broken down as it is resistant to hydrolysis by FAAH 
(Makwana et al., 2010b). 
 
To summarise, this study shows that cannabinoids reduce EFS-evoked guinea-pig ileum 
contractions and that these effects are not mediated through the CB1 receptor, contrary 
to the currently held view (Colombo et al., 1998; Coutts et al., 1997; Izzo et al., 2000a; 
Pertwee et al., 2006). The caveat of previous studies is the reliance on the CB1 
antagonist rimonabant, which is now known not to be as selective as first thought (see 
‘Non- CB1/ CB2 targets for cannabinoid receptor ligands’). This investigation showed 
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that cannabinoid responses could not be blocked by two different CB1 antagonists and 
that a selective CB1 agonist had no effect on the size of contractions. 
 
This study provides the first evidence that cannabinoids may activate the GPR119 to 
inhibit contractions and that this receptor may be present on smooth muscle. This is 
interesting as little evidence has been found this far for any post-synaptic effects of 
cannabinoids (Lynn et al., 1994; Mang et al., 2001; Pertwee., 2001).  This needs to be 
corroborated with a GPR119 antagonist, when one becomes commercially available. 
 
Neither the CB2 receptor nor the GPR55 receptor was involved in the cannabinoid-
mediated inhibition of contractions. The CBe receptor may be implicated but expression 
of this receptor may vary between animals. None of the known or putative cananbinoid 
receptors were involved in the responses to O-1602 and (+)WIN. However, the response 
to (+)WIN seemed to be mediated by a protein target such as a receptor, whereas it is 
not know whether this is the case for O-1602. 
 
This study has suggested that more extensive work is required to elucidate the 
mechanism by which cannabinoids intestinal inhibit contractions, since CB1 does not 
seem to be involved. Much of this work, however, cannot be carried out until more 
pharmacological tools are available, for example, a GPR119 receptor antagonist, and 
until more information is available concerning cannabinoid targets. 
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CHAPTER 4: 
INVESTIGATION OF CANNABINOID- 
MEDIATED  PROTECTION IN LPS AND  
H2O2 MODELS OF INFLAMMATORY 
DAMAGE IN THE GUINEA-PIG ISOLATED 
ILEUM 
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4. Investigation of cannabinoid-mediated protection in LPS and H2O2 
models of inflammatory damage in the guinea-pig isolated ileum 
 
4.1 Introduction 
 
Inflammatory bowel disease (IBD), as discussed in more detail in Chapter one, is 
characterised by the infiltration of white blood cells (neutrophils and macrophages) into 
the intestinal mucosa. This activation of these cells results in the production of 
inflammatory mediators such as reactive oxygen species (ROS), proteases and cytokines 
which cause the intestinal tissue damage and diarrhoea associated with IBD (Kruidenier 
et al., 2003; Saksena et al., 2008). 
 
Cannabinoids have been shown in the literature to possess several anti-inflammatory 
effects such as inhibiting the activity of immune cells (mainly CB2 mediated, Croxford 
et al., 2005) and reducing inflammation in animal models of IBD (CB1 and CB2 
mediated, Kimball et al., 2006). In addition, cannabinoids can aid tissue repair and have 
been shown to enhance epithelial wound healing in the colon (CB1 mediated, (Wright et 
al., 2005). 
 
Cannabinoids have also been shown to protect against inflammatory damage in several 
tissues (Montecucco et al., 2009) and nerves (Hampson et al., 1998) but their potential 
to protect the gut has not yet been investigated.  The purpose of this chapter was to 
investigate cannabinoid-mediated protection in LPS and H2O2 models of inflammatory 
damage in the guinea-pig isolated ileum.  
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H2O2 is a ROS which is continually produced by cells under normal conditions, 90% as 
a by-product of mitochondrial respiration. Leaked electrons from the respiratory 
electron transport train combine with oxygen to produce superoxide which 
spontaneously forms H2O2 or is converted to H2O2 by the enzyme superoxide dismutase 
(SOD). H2O2 is usually immediately neutralised by the antioxidant enzymes catalase 
and glutathione peroxidase, but the levels of these antioxidants have been reported to be 
impaired in IBD patients. In addition to this, under inflammatory conditions, H2O2 is 
produced in large amounts by white blood cells and bacteria as well as increased 
production in intestinal cells (Pravda, 2005). 
 
H2O2 in excess crosses cell membranes and reacts with iron to produce the highly 
reactive hydroxyl radical (Fenton reaction). This chemical reacts with lipids, proteins 
and DNA, causing tissue damage and apoptosis/necrosis. Several papers report H2O2-
induced damage to the intestinal epithelium and loss of barrier function (Shin et al., 
2010; Yamamoto, 2003). H2O2 has also been shown to increase the secretion of Cl- and 
inhibit NaCl absorption in the colon, which may contribute to diarrhoea (Saksena et al., 
2008). H2O2 can also induce intestinal dysmotility and has been shown to inhibit 
contraction of the sigmoid colonic circular muscle (Cao et al., 2004) and reduce 
excitability of myenteric neurones which control gastrointestinal motility (Pouokam et 
al., 2009). 
 
 LPS is an inflammatory stimulus present in the cell wall of Gram-negative bacteria 
such as E coli. LPS activates macrophages through binding to toll-like receptor 4, 
producing inflammatory mediators such as prostaglandins, nitric oxide, cytokines and 
ROS (Beutler et al., 2003). In the intestine, LPS produces diarrhoea and intestinal 
dysmotility (Duncan et al., 2008).  
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LPS has been used to induce inflammation in vitro and in vivo. Some in vitro 
experiments involved pre-treating animals with LPS and then investigating the 
contractility of dissected intestinal segments in an organ bath (Gonzalo et al., 2010; 
Gonzalo et al., 2011; Rebollar et al., 2002). Alternatively, intestinal sections were taken 
from normal animals and set up in an organ bath; LPS was added to the organ bath and 
the contractility measured (Rebollar et al., 2002). 
 
In vitro, LPS has been shown to inhibit contractions of duodenal longitudinal and 
circular muscle (Grasa et al., 2008), jejunal circular muscle (Eskandari et al., 1999) and 
ileal circular muscle (Rebollar et al., 2002). Prostaglandins and nitric oxide have been 
implicated in this inhibition (Chen et al., 2010; Grasa et al., 2008). LPS was also found 
to have a direct inhibitory effect on human colon smooth muscle cell contractility 
(Scirocco et al., 2010). 
 
The effects of LPS in vivo are conflicting. LPS has been shown to reduce 
gastrointestinal transit in some studies in mice (Chen et al., 2010; Liang et al., 2005) 
whilst other studies have reported that LPS increases gastrointestinal transit and 
diarrhoea in rats (Duncan et al., 2008). CB1 and CB2 agonists were found to reduce 
gastrointestinal motility in mice (Li et al., 2010) and rats (Duncan et al., 2008) treated 
with LPS.  The effect of cannabinoids was the same, regardless of whether LPS 
increased or decreased gastrointestinal motility. 
 
The cannabinoids tested in the in vitro LPS and H2O2 models have already been 
described in chapter 3. The damaging effects of LPS and H2O2 and the protective effects 
of cannabinoids were assessed by measuring tissue contractility. 
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  4.2 Aims 
 
• To investigate the protective effects of cannabinoids in models of LPS and H2O2 
inflammatory damage in the guinea-pig isolated ileum. 
 
4.3 Method 
 
The effect of LPS on EFS-induced contractions of the guinea-pig isolated ileum 
 
The ileum was prepared as in Chapter 2 and was subjected to EFS (see ‘Electrical field 
stimulation of the guinea-pig ileum’, Chapter 2). Once contractions had stabilised, LPS 
was added to the bath and left for 2 hours before washout. Contraction size was 
measured before the addition of LPS and then every 20 minutes for 2 hours after the 
addition. 
 
 
The effect of H2O2 on EFS-induced contractions of the guinea-pig isolated ileum 
 
The ileum was prepared as in Chapter 2 and was subjected to EFS (see ‘Electrical field 
stimulation of the guinea-pig ileum’, Chapter 2). Once contractions had stabilised, 0.3% 
H2O2 was added to the bath for 1 minute. This concentration and time period was 
chosen as it was found to substantially reduce but not completely abolish contractions. 
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The effect of cannabinoid agonists/antagonists on H2O2-induced damage of the 
isolated ileum 
 
In the first set of experiments, the ileum was prepared as in chapter 2 and was subjected 
to EFS (see ‘Electrical field stimulation of the guinea-pig ileum’, chapter 2). Once 
contractions had stabilised, the cannabinoid agonist/antagonist or ethanol vehicle was 
added as a 10µl or 100µl bolus dose for 30 minutes. The bath was then washed out and 
H2O2 was added to the bath for one minute before washout. The ileum was then left to 
recover for 2 hours (see figure 4.1). Contraction size was measured before the addition 
of H2O2 and every 20 minutes after the addition. The concentration of agonist and 
vehicle used are shown in the results section 4.4. Drugs were not re-added after 
washouts as it was shown that the drugs could not be removed even with multiple 
washes (see appendix 1). 
 
 
 
Figure 4.1 Protocol for H2O2 assay with cannabinoid agonists or antagonists alone 
 
The second set of experiments was carried out in the same way except that the ileum 
was incubated with the cannabinoid antagonist for 30 minutes before the addition of the 
cannabinoid agonist (see figure 4.2 overleaf).   
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Figure 4.2 Protocol for H2O2 assay with antagonist followed by agonist.  
 
 
Drug solutions 
 
Most drugs were dissolved in absolute ethanol ((+)WIN, PSN, SR144528, rimonabant  
and O-1918. Abnormal-CBD and O-1602 were supplied pre-dissolved in methyl 
acetate. Due to methyl acetate causing significant depression of ileum contraction, the 
solvent was evaporated under vacuum using a rotary evaporator and replaced with 
absolute ethanol. Aliquots of drug solutions were frozen at -20˚C (for up to one month) 
and were thawed and diluted to the desired concentration on the day of the experiment. 
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Data analysis 
 
The effect of each drug on recovery of contraction subsequent to H2O2 exposure was 
reported as a percentage of baseline EFS response at 20 minute intervals. Area under the 
curve was calculated for each drug and its vehicle. Data was reported as mean ± SEM. 
 
Data were excluded if drugs did not produce a pharmacological inhibition of EFS-
induced contractions response. The reason for this was that some cannabinoids did not 
always produce a pharmacological response (see abnormal-CBD cannabidiol responses, 
figures 3.25a and b in chapter 3.)  
 
Statistical analysis 
 
Mean values for the drug and its vehicle control were compared using unpaired 
Student’s T test (drug and vehicle) or one way ANOVA with post-hoc Dunnett’s Test 
(multiple drugs and vehicle). One sample Student’s t tests were used to determine the 
effects of the vehicle alone on contractions.  P<0.05 was considered statistically 
significant. 
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4.4 Results 
 
4.4.1 The effect of LPS on EFS-induced contractions  
 
LPS was found to have little effect on EFS-evoked contractions of the ileum ( see figure 
4.3). 
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Figure 4.3 The effect of LPS 200ng/ml (n=1), 800ng/ml (n=2) and 3µg/ml (n=2) on EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as a percentage of initial EFS response. The 
baseline contraction size was measured immediately before the addition of LPS. Each symbol represents 
the mean percentage; data were analysed by unpaired Student’s t test. 
 
 
 
4.4.2 The effect of H2O2 on EFS-induced contractions of the guinea-pig isolated 
ileum 
 
Following washout (time: 0 mins), contraction size returned to 20.0 ± 8.4% in H2O2-
treated tissues, compared to 82.2 ± 4.5% in non-treated tissues. After 60 minutes, 
contraction size plateaued in both treated and untreated tissues, reaching 62.1 ± 6.8% in 
treated tissues and 102.3 ± 6.5% in untreated tissues. The areas under the curves for 
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H2O2-treated and non-treated tissues were significantly different P < 0.05 (Student’s 
unpaired t test) (see figures 4.4 and 4.5 overleaf). 
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Figure 4.4 The Recovery of EFS-induced contractions of the guinea-pig isolated ileum following washout 
of 0.3% H2O2 (1 minute exposure; n=3) or washout (no treatment; n=5). The size of EFS-induced 
contractions is expressed as percentage of initial EFS response (A). The baseline contraction size was 
measured immediately before the addition of H2O2. Each symbol represents the mean percentage; vertical 
bars indicate standard error of the mean (SEM). The areas under the curves were calculated as 
%.minutes (B). * P<0.05, **P<0.01, ***P<0.001 (Student’s unpaired t test). 
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Figure 4.5 Trace showing the recovery of EFS-induced contractions of the guinea-pig isolated ileum 
following washout of 0.3% H2O2 (1 minute exposure). 
a = 0.3% H2O2 , b = washout. 
 
 
The effect of cannabinoid agonists/antagonists on H2O2-induced damage of the 
guinea-pig isolated ileum 
 
The effect of (+)WIN on H2O2-induced damage of the ileum  
 
Although (+)WIN had no significant effect on the total area under the curve for H2O2-
treated tissues, at 120 minutes the recovery of contraction in the (+)WIN-treated group 
was significantly better than vehicle (P < 0.05). Contraction returned to 154.6 ± 31.0% 
of baseline response in the presence of (+)WIN and only 70.3 ± 16.4% in the presence 
of vehicle alone (see figures 4.6 and 4.7 overleaf). The vehicle alone had no effect on 
the total area under the curve or on the size of EFS-contractions at any time point.  
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Figure 4.6 The effect of (+)WIN 10-7M (n=7) and ethanol vehicle 0.01% (n=7) on recovery of EFS-
induced contractions of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute 
exposure). The size of EFS-induced contractions is expressed as percentage of baseline EFS response 
(A). The baseline contraction size was measured after the addition of (+)WIN and before the addition of 
H2O2. Each symbol represents the mean percentage; vertical bars indicate standard error of the mean 
(SEM). The areas under the curves were calculated as %.minutes (B). * P<0.05 (one way ANOVA with 
post-hoc Dunnett’s test). ANOVA was used because the same vehicle control was used in several 
cannabinoid experiments. 
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Figure 4.7 Trace showing the effect of (+)WIN 10-7M on recovery of EFS-induced contractions of the 
guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute exposure). 
a = (+) WIN 10-7M               c = 0.3% H2O2 (1 minute exposure) 
b = washout                          d = washout 
 
 
 
The effect of rimonabant on H2O2-induced damage of the ileum  
 
Neither rimonabant (1µM) nor its vehicle control had a significant effect on the total 
area under the curve for H2O2-treated tissues (see figure) or the size of EFS-contractions 
at any time point (see figure 4.8 overleaf). 
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Figure 4.8 The effect of rimonabant 10-6M (n=6) and ethanol vehicle 0.01% (n=7) on recovery of EFS-
induced contractions of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute 
exposure). The size of EFS-induced contractions is expressed as percentage of baseline EFS response 
(A). The baseline contraction size was measured after the addition of rimonabant and before the addition 
of H2O2. Each symbol represents the mean percentage; vertical bars indicate standard error of the mean 
(SEM). The areas under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. 
ANOVA was used because the same vehicle control was used in several cannabinoid experiments. 
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The effect of rimonabant on (+)WIN-induced protection against H2O2 damage 
 
Rimonabant (1µM) had no significant effect on the area under the curve for (+)WIN-
induced contraction recovery in H2O2-treated tissues, or on the size of EFS-induced 
contractions at any time point (see figure 4.9). 
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Figure 4.9 The effect of rimonabant 10-6M (n=5) and ethanol vehicle 0.01% (n=4) on (+)WIN-induced 
protection of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute exposure). The size 
of EFS-induced contractions is expressed as percentage of baseline EFS response (A). The baseline 
contraction size was measured after the addition of (+)WIN and before the addition of H2O2. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM). The areas 
under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. ANOVA was used 
because the same vehicle control was used in several cannabinoid experiments. 
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The effect of SR144528 on H2O2-induced damage of the ileum  
 
Neither SR144528 (1µM) nor its vehicle control had a significant effect on the total area 
under the curve for H2O2-treated tissues or on the size of EFS-contractions at any time 
point (see figure 4.10). 
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Figure 4.10 The effect of SR144528 10-6M (n=4) and ethanol vehicle 0.01% (n=7) on recovery of EFS-
induced contractions of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute 
exposure). The size of EFS-induced contractions is expressed as percentage of baseline EFS response 
(A). The baseline contraction size was measured after the addition of SR144528 and before the addition 
of H2O2. Each symbol represents the mean percentage; vertical bars indicate standard error of the mean 
(SEM). The areas under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. 
ANOVA was used because the same vehicle control was used in several cannabinoid experiments. 
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The effect of SR144528 on (+)WIN-induced protection against H2O2 damage 
 
SR144528 (1µM) had no significant effect on the area under the curve for (+)WIN-
induced contraction recovery in H2O2-treated tissues, or on the size of EFS-induced 
contractions at any time point (see figure 4.11). 
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Figure 4.11 The effect of SR144528 10-6M (n=6) and ethanol vehicle 0.01% (n=4) on (+)WIN-induced 
protection of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute exposure). The size 
of EFS-induced contractions is expressed as percentage of baseline EFS response (A). The baseline 
contraction size was measured after the addition of (+)WIN and before the addition of H2O2. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM). The areas 
under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. ANOVA was used 
because the same vehicle control was used in several cannabinoid experiments 
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The effect of O-1918 on H2O2-induced damage of the ileum  
 
Neither O-1918 (1µM) nor its vehicle control had any effect on the total area under the 
curve for H2O2-treated tissues or on the size of EFS-contractions at any time point. (see 
figure 4.12). 
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Figure 4.12 The effect of O-1918 10-6M (n=7) and ethanol vehicle 0.01% (n=7) on recovery of EFS-
induced contractions of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute 
exposure). The size of EFS-induced contractions is expressed as percentage of baseline EFS response 
(A). The baseline contraction size was measured after the addition of O-1918 and before the addition of 
H2O2. Each symbol represents the mean percentage; vertical bars indicate standard error of the mean 
(SEM). The areas under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. 
ANOVA was used because the same vehicle control was used in several cannabinoid experiments. 
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The effect of O-1918 on (+)WIN-induced protection against H2O2 damage of the 
ileum 
 
O-1918 (1µM) had no significant effect on the area under the curve for (+)WIN-induced 
contraction recovery in H2O2-treated tissues, or on the size of EFS-induced contractions 
at any time point (see figure 4.13). 
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Figure 4.13 The effect of O-1918 10-6M (n=7) and ethanol vehicle 0.01% (n=4) on (+)WIN-induced 
protection of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute exposure). The size 
of EFS-induced contractions is expressed as percentage of baseline EFS response (A). The baseline 
contraction size was measured after the addition of (+)WIN and before the addition of H2O2. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM). The areas 
under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. ANOVA was used 
because the same vehicle control was used in several cannabinoid experiments. 
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The effect of ACPA on H2O2-induced damage of the ileum 
 
Neither ACPA (3x10-5M) nor its vehicle control had a significant effect on the total area 
under the curve for H2O2-treated tissues or on the size of EFS-contractions at any time 
point (see figure 4.14). 
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Figure 4.14 The effect of ACPA 3x10-5M (n=4) and ethanol vehicle 0.1% (n=6) on recovery of EFS-
induced contractions of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute 
exposure). The size of EFS-induced contractions is expressed as percentage of baseline EFS response 
(A). The baseline contraction size was measured after the addition of ACPA and before the addition of 
H2O2. Each symbol represents the mean percentage; vertical bars indicate standard error of the mean 
(SEM). The areas under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. 
ANOVA was used because the same vehicle control was used in several cannabinoid experiments. 
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The effect of abnormal-cannabidiol on H2O2-induced damage of the ileum 
 
Neither abnormal-CBD (3x10-5M) nor its vehicle control had a significant effect on the 
total area under the curve for H2O2-treated tissues or on the size of EFS-contractions at 
any time point (see figure 4.15). 
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Figure 4.15 The effect of abnormal-CBD 3x10-5M (n=3) and ethanol vehicle 0.1% (n=6) on recovery of 
EFS-induced contractions of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute 
exposure). The size of EFS-induced contractions is expressed as percentage of baseline EFS response 
(A). The baseline contraction size was measured after the addition of abnormal-CBD and before the 
addition of H2O2. Each symbol represents the mean percentage; vertical bars indicate standard error of 
the mean (SEM). The areas under the curves were calculated as %.minutes (B). Data were analysed by 
ANOVA. ANOVA was used because the same vehicle control was used in several cannabinoid 
experiments. 
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The effect of O-1602 on H2O2-induced damage of the ileum 
 
Neither O-1602 (1x10-5M) nor its vehicle control had any effect on the total area under 
the curve for H2O2-treated tissues or on the size of EFS-contractions at any time point. 
(see figure 4.16). 
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Figure 4.16 The effect of O-1602 1x10-5M (n=6) and ethanol vehicle 0.1% (n=6) on recovery of EFS-
induced contractions of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute 
exposure). The size of EFS-induced contractions is expressed as percentage of baseline EFS response 
(A). The baseline contraction size was measured after the addition of O-1602 and before the addition of 
H2O2. Each symbol represents the mean percentage; vertical bars indicate standard error of the mean 
(SEM). The areas under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. 
ANOVA was used because the same vehicle control was used in several cannabinoid experiments. 
 
 
 
 
 
131 
 
The effect of PSN on H2O2-induced damage of the ileum 
 
PSN (3x10-5M) nor its vehicle control had a significant effect on the total area under the 
curve for H2O2-treated tissues or on the size of EFS-contractions at any time point (see 
figure 4.17). 
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Figure 4.17 The effect of PSN 3x10-5M (n=5) and ethanol vehicle 0.1% (n=6) on recovery of EFS-
induced contractions of the guinea-pig isolated ileum following washout of 0.3% H2O2 (1 minute 
exposure). The size of EFS-induced contractions is expressed as percentage of baseline EFS response 
(A). The baseline contraction size was measured after the addition of ACPA and before the addition of 
H2O2. Each symbol represents the mean percentage; vertical bars indicate standard error of the mean 
(SEM). The areas under the curves were calculated as %.minutes (B). Data were analysed by ANOVA. 
ANOVA was used because the same vehicle control was used in several cannabinoid experiments. 
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4.5 Discussion 
 
The main finding of this chapter is that (+)WIN protects the ileum from inflammatory-
type damage but that this does not appear to be mediated through any of the classical or 
putative cannabinoid receptors. This is the first study which shows the protective effects 
of cannabinoids in the intestine. However, the limitation associated with these in vitro 
models of inflammatory damage is that immune cells are not recruited from the 
bloodstream to the tissue (which occurs during inflammation in vivo). 
 
LPS model of inflammatory damage in the ileum 
  
Studies have shown that LPS induces intestinal dysmotility in vivo (Chen et al., 2010; 
Duncan et al., 2008; Liang et al., 2005) and in vitro (Gonzalo et al., 2010; Gonzalo et 
al., 2011; Rebollar et al., 2002), although the effects in vivo are conflicting.Sometimes 
intestinal transit is decreased whereas other times it is increased (Chen et al., 2010; 
Duncan et al., 2008; Liang et al., 2005). Cannabinoids have been shown to inhibit LPS-
induced production of inflammatory mediators (Fischer-Stenger et al., 1993; Ross et al., 
2000) and attenuate LPS-induced dysmotility in vivo (Duncan et al., 2008). 
 
 Most of the in vitro studies examining the effect of LPS on normal intestinal segments 
have been carried out on rabbit intestine. These studies showed that LPS reduced the 
size of intestinal contractions and suggested that this involved the production of 
prostaglandins and nitric oxide (Chen et al., 2010; Grasa et al., 2008). In the guinea-pig 
ileum, however, LPS did not have a significant effect on contraction, even though a 
range of LPS concentrations were used. The highest concentration used exceeded the 
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concentrations previously reported as effective in the rabbit intestine (Chen et al., 2010; 
Grasa et al., 2008). It is possible that LPS had no effect in the guinea-pig ileum because 
the toll-like receptor 4 was not present. LPS would probably be more effective in vivo 
as the ileum would become infiltrated with immune cells from the bloodstream which 
express toll-like receptor 4. In future, it may be more effective to pre-treat the guinea-
pigs with LPS and then examine the contractility of the dissected ileum segments, as 
carried out previously in the rabbit (Gonzalo et al. 2010; Gonzalo et al., 2011; Rebollar 
et al., 2002).  
 
H2O2 model of inflammatory damage in the ileum 
 
H2O2 was used to produce oxidative stress, which is a major component of 
inflammation. Indeed, the intestinal inflammation that occurs in IBD involves excessive 
production of ROS. It has also been shown that the antioxidant balance is impaired in 
IBD patients, which leads to further oxidative damage. The impaired antioxidants 
include superoxide dismutases, catalase, glutathione peroxidase, glutathione and 
metallothionein (Kruidenier et al., 2003). H2O2 may contribute to dysmotility in IBD. 
The tissue damage caused by ROS such as H2O2 has been described in the Introduction, 
as well as the reduction in excitability of myenteric neurones which control 
gastrointestinal motility (Pouokam et al., 2009). In addition, H2O2 has been shown to 
reduce contractions of the colon (Cao et al., 2004). 
 
Cannabinoids have been shown to possess anti-oxidative properties. They have been 
shown to upregulate antioxidant enzymes such as superoxide dismutase (Garcia-
Arencibia et al., 2007) and reduce production of ROS from immune cells (Hao et al., 
2010). Cannabinoids have also been shown to be free radical scavengers (Velez-Pardo 
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et al., 2010). Although much of the literature suggests that cannabinoids reduce 
oxidative stress, there are a few studies which suggest in certain situations cannabinoids 
can induce ROS production (Massi et al., 2006a; Wu et al., 2008).  
 
The anti-oxidant activity have been shown to contribute to the neuroprotective 
(Hampson et al., 1998), cardioprotective (Montecucco et al., 2009) and 
hepatoprotective (Rajesh et al., 2007) effects of cannabinoids. The CB1 (Kessiova et al., 
2006) and CB2 (Montecucco et al., 2009) (Rajesh et al., 2007) receptors have previously 
been implicated in the anti-oxidant effects of cannabinoid as well as cannabinoid 
receptor independent effects (Chen et al., 2000; Kessiova et al., 2006). 
 
The recovery in the (+)WIN treated group from H2O2-induced damage was significantly 
better than the ethanol control group. Contraction returned to 154.6 ± 31.0% of the 
initial EFS response in the presence of (+)WIN compared with only 70.3 ± 16.4% in the 
presence of the ethanol vehicle alone. Antagonists for the CB1 (rimonabant), CB2 
(SR144528) or the putative CBe (O-1918) receptor had no effect on (+)WIN-induced 
recovery, suggesting these receptors are not involved in the protection by (+)WIN. This 
is supported by the lack of effect of the CB1 agonist ACPA and the putative CBe 
receptor agonist abnormal-CBD. As (+)WIN does not bind to the GPR55 receptor, this 
receptor would be unlikely to play a role in (+)WIN-induced protection from H2O2-
induced damage. This is further supported by the finding that the GPR55 agonist O-
1602 had no significant effect on recovery from H2O2-induced damage. GPR119 could 
be involved in the (+)WIN-induced protection but this is unlikely as the GPR119 
agonist PSN had no effect in the H2O2 assay. Unfortunately, corroboration could not be 
obtained as there is currently no selective antagonist of GPR119 available. 
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As the protective effect of (+)WIN does not seem to be due to any of the known 
cannabinoid receptors, it may either be mediated through a novel cannabinoid receptor 
or it is cannabinoid receptor independent effect. (+)WIN cannot be acting by   reducing 
ROS production as H2O2 is added directly to the bath to produce oxidative stress. It is 
also unlikely to be due to up-regulation of anti-oxidant enzymes as the timescale of the 
experiments was only two hours, whereas the up-regulation in the literature was 
reported after two weeks of cannabinoid treatment. It is possible that (+)WIN was 
acting as a free radical scavenger to prevent tissue damage. Although there was washout 
before and after H2O2 was added, (+)WIN could not be removed (see washout controls 
appendix 1) and would have been present to act as a scavenger. With (+)WIN reducing 
the amount of oxidative damage, the tissue would have been able to recover over time 
and contract effectively again. If (+)WIN were acting as a free radical scavenger, this 
would explain the cannabinoid receptor independent effect, which has been suggested in 
the literature (Chen et al., 2000; Kessiova et al., 2006; Underdown et al., 2005). 
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                                                      CHAPTER 5: 
IN VITRO TESTING OF THE 
PHARMACOLOGICAL ACTIVITY OF 
CANNABINOID-DENDRIMER 
CONJUGATES 
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5. In vitro testing of the pharmacological activity of cannabinoid-
dendrimer conjugates 
 
5.1 Introduction 
 
Cannabinoids have shown several pharmacological effects which may be beneficial in 
the treatment of inflammatory bowel disease (IBD). They have been shown to reduce 
gut inflammation in animal models of IBD via activation of CB1 and CB2 receptors 
(Kimball et al., 2006), enhance epithelial wound healing via CB1 activation (Wright et 
al., 2005) and reduce gut motility via CB1 activation (Heinemann et al., 1999; Izzo et 
al., 1998). The CB2 receptor may be involved in reducing motility under inflammation 
conditions (Izzo, 2007). 
 
The major barrier to the use of cannabinoids as therapeutics is their psychotropic 
effects, mediated by the CB1 receptor in the CNS (Xiong et al., 2011). However, CB1 
mediated effects are also desirable clinically, especially for the treatment of IBD (as 
shown above). Therefore, novel cannabinoids developed to treat IBD need to retain CB1 
and CB2 activity, but not act in the CNS.  
There are a number of strategies which could be adopted to prevent compounds from 
crossing the blood brain barrier. These include increasing the size of the compound, 
reducing its lipophilicity or creating a charged molecule. The strategy chosen in this 
thesis was to attach a large bulky group (dendrimer) to the cannabinoid.. Dendrimers are 
ideal for this purpose as they are polymers with bulky, tree-like branching structures 
(see figure 5.1). They differ in size depending on how many repeated branching cycles 
(known as the generation number) are performed during their synthesis. The more 
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cycles performed (the higher the generation number), the larger the dendrimer. The size 
of the dendrimer can be selected so that it is small enough to be absorbed across the 
intestine but large enough to prevent CNS penetration. 
In addition to increasing the size of the compound, conjugation to a dendrimer can also 
increase the hydrophilicity of the molecule and introduce a charge to the compound 
(cationic or anionic dendrimers). These combined properties should prevent the 
cannabinoid from crossing the blood brain barrier. 
Another reason for using the dendrimer conjugation strategy was because dendrimers 
have been shown to be non-toxic (Scharbin et al., 2010) and not to alter 
pharmacological activity in the literature (Khandare et al., 2005). 
 
  
 
Figure 5.1 The tree-like branching structure of dendrimers.  
 
 
dendritic 
wedge 
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Ghaith Al-Jayyoussi, from the Welsh School of Pharmacy has synthesised  a 
cannabinoid-dendrimer conjugate, which consists of the non-selective cannabinoid 
JWH007 (see figure 5.2), with a PAMAM dendrimer attachment (Al-Jayyoussi, 2011). 
JWH007 was the chosen cannabinoid due to its potency at the CB1 and CB2 receptor 
(see table 1.1, chapter 1). Also, JWH007 should be resistant to hydrolysis by FAAH as 
it lacks the required amide linkage (Makwana et al., 2010). The dendrimer chosen was 
the anionic generation 3.5 poly(amidoamine) (G3.5 PAMAM dendrimer) as it was 
thought that this would be large enough to prevent access to the CNS and these 
molecules have been shown to be biocompatible (Scharbin et al., 2010) . Before testing 
the final cannabinoid-dendrimer conjugate, preliminary studies were carried out on 
JWH007 with bulky group attachments. The purpose of this was to see how the 
pharmacological activity of JWH007 at the CB1 and CB2 receptor altered with the size 
of the attached group. 
 
The compounds were tested in two pharmacological assays, the Paton ileum (see 
‘Electrical field stimulation’, chapter 2) and LPS-stimulated macrophages (see ‘LPS-
stimulation of a macrophage cell line’, chapter 2).The Paton ileum preparation was used 
to screen the compounds for CB1 activity as inhibition of ileum contractions by 
cannabinoids was reported to be CB1 mediated (Izzo et al., 1998). However, although 
cannabinoid-induced inhibition of intestinal contractions was thought to be  CB1 
mediated, this thesis suggests that the inhibition is mediated through a non- CB1, non- 
CB2 receptor (see chapter 3). The Paton ileum model was still retained for the testing of 
novel cannabinoids, not as a CB1 assay, but to investigate the anti-motility effects of the 
drugs.  
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The macrophages were used to screen the compounds for CB2 activity as the reduction 
of inflammatory mediators from these LPS-stimulated cells by cannabinoids was 
reported to be CB2 mediated (Ross et al., 2000). 
 
The first compound to be tested in the assays was JWH007; the activity of the novel 
cannabinoids were subsequently compared to this. GA001 was the first novel 
cannabinoid to be tested. This compound was identical to JWH007, apart from a methyl 
group attachment to a napthoylene ring (see figure 5.3). The position of the methyl 
group attachment was decided based on literature detailing the structure-activity 
relationship (SAR) of cannabinoids as well as considering the difficulty of the 
attachment chemistry. The position chosen for the methyl group was a site of easy 
attachment which avoided areas of the JWH007 molecule important for 
pharmacological activity. The portions of JWH007 reported to be important to be for 
pharmacological activity at the CB1 and CB2 receptor (Huffman et al., 2005) have been 
circled in figure 5.2.     
 
                              
 
Figure 5.2 The chemical structure of JWH007. The circled regions are reported to be important for 
pharmacological activity (Huffman et al., 2005).. 
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Figure 5.3 The chemical structure of GA001. The site of the methyl group attachment is circled. 
 
The second compound to be tested was GA002, identical to GA001, but instead of the 
methyl group, a bulkier group was attached (similar to a portion of the dendrimer – a 
dendritic wedge). The site of attachment was the same (see figure 5.4).  
 
 
                        
 
Figure 5.4 The chemical structure of GA002. The site of the dendrimer wedge-like attachment is circled. 
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The third compound to be tested was GA003. GA003 was identical to GA001 but, 
instead of the methyl group, a longer chain was attached (a spacer). The site of 
attachment was the same (see figure 5.5 overleaf). This spacer is similar to the spacer 
used in the final cannabinoid-dendrimer conjugate. The purpose of the spacer in the 
final conjugated molecule was to provide the compound with flexibility to avoid the 
steric hinderence which could prevent receptor binding. 
 
 
 
                   
Figure 5.5 The chemical structure of GA003. The site of the spacer attachment is circled. 
 
 
 
The fourth compound to be tested was GA006 which was the final JWH007-PAMAM 
dendrimer conjugate. GA006 was identical to GA001 but with the spacer and dendrimer 
attached instead of the methyl group (see figure 5.6).  
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Figure 5.6 The chemical structure of GA006. The site of the spacer-dendrimer attachment is circled. 
 
 
 
 
5.2 Aims 
 
• To determine whether cannabinoids retain potency at the CB1 and CB2 receptor 
with the attachment of bulky groups such as dendrimers. 
 
• To investigate whether the selectivity of cannabinoids for the CB1 and CB2 
receptor is altered with the attachment of these bulky groups. 
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5.3 Method 
 
Although JWH007 and GA001 were tested in all experiments, due to limited drug 
supply, GA002, GA003 and GA006 were only tested in some experiments.  
 
Drug solutions 
 
Ileum experiments: GA001 and GA002 were dissolved in absolute ethanol and stored at 
20ºC for up to 1 month. GA003 was dissolved in DMSO and stored at 20ºC for up to 1 
month. GA001, GA002 and GA003 were serially diluted in ethanol on the day of the 
experiment. 
 
Macrophage experiments: The cannabinoids were dissolved in DMSO and stored at 
¯20˚C for up to 1 month. On the day of the experiment, the cannabinoids were thawed 
and diluted in media (90% DMEM, 10% FBS) which had been pre-warmed to 37˚C. 
 
The LPS was reconstituted in saline (0.9% sodium chloride) and aliquots were frozen at 
-20˚C for up to 1 month. The aliquots were thawed out on the day of the LPS 
experiments and serially diluted with media (90% DMEM, 10% FBS). 
 
5.3.1 The effect of novel cannabinoid compounds (based on the structure of JWH007) 
on EFS-evoked contractions of the guinea-pig isolated ileum 
 
This has been described in detail in Chapter 2. Cumulative concentration response 
curves for each cannabinoid was constructed (as in chapter 3 for (+) WIN ). 
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5.3.2 The effect of novel cannabinoid compounds (based on the structure of JWH007) 
on LPS-stimulated TNFα release from macrophages 
 
Cells were grown on a 24 well plate for 96 hours as in chapter 2 (see ‘LPS-induced 
TNFα release from RAW 264.6 macrophages’). Medium was then removed from each 
well and replaced with 1 ml of cannabinoid or DMSO vehicle solution (see ‘Drug 
solutions’ above).The concentrations of cannabinoid ranged from 1 to 30µM and the 
concentration of the DMSO vehicle was 0.02%. The plate was incubated at 37˚C for 30 
minutes to allow the drugs to reach equilibrium. After 30 minutes, LPS was prepared 
(see ‘Drug solutions’ above) and 10µl (500ng/ml) was added to each well to produce a 
final concentration of 5ng/ml. The plated was then incubated for 16 hours at 37˚C, After 
16 hours, the cell media was removed from the wells to be assayed for TNFα (see 
‘TNFα measurement’, Chapter 2) and the cells were lysed (see ‘Cell lysis’, Chapter 2) 
to remove and quantify their protein content (see ‘Protein measurement’, Chapter 2). 
 
 
 Investigation of the effect of the novel cannabinoids on RAW 264.7 macrophage 
viability 
 
Cells were grown for 96 hours as in chapter 2 (see ‘LPS-induced TNFα release from 
RAW 264.6 macrophages’) but were seeded onto a 96 well plate (0.32cm2/well) instead 
of a 24 well plate. Medium was then removed from each well and replaced with 200µl 
of cannabinoid or DMSO vehicle solution (see ‘Drug solutions’ above). The 
concentrations of cannabinoid ranged from 1 to 30µM and the concentration of the 
DMSO vehicle was 0.02%. The plate was incubated at 37˚C for 30 minutes to allow the 
drugs to reach equilibrium. After 30 minutes, LPS was prepared (see ‘Drug solutions 
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above’) and 2µl was added to each well to produce a final concentration of 5ng/ml. The 
plated was then incubated for 16 hours at 37˚C, after which the (Methanethiosulphonate 
reagent) MTS assay was performed.  
 
The MTS assay involved adding 20µl of MTS reagent to 100µl of media in the wells 
and incubating for 2 hours 30 minutes. The absorbance of the plate was then read at 
490nm using a spectrophotometer. The purpose of this assay was to investigate whether 
the cannabinoids would affect cell viability at any of the concentrations used.  This was 
important as a reduction in cell viability could affect the concentration of TNFα in the 
media and make it difficult to interpret the effects of the cannabinoids. 
 
 Data analysis 
 
Ileum experiments: The effect of each drug concentration on contraction size was 
reported as a percentage of baseline EFS or initial carbachol contraction. Data were 
reported as mean ± SEM.  
 
An IC25 or IC50 was calculated for each drug, defined as the drug concentrations 
required to inhibit baseline EFS/initial carbachol contraction by 25% and 50% 
respectively. Mean values with their 95% confidence intervals (shown in brackets) were 
calculated. 
 
Curve fitting was not carried out as the concentration-response curves did not fit the 
traditional sigmoidal shape and did not reach a maximum response at the concentrations 
used. 
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Macrophage experiments: The effect of each drug was expressed as a percentage of the 
media control. In the experiments examining TNFα release, results were also expressed 
as pg TNFα / mg protein. 
 
Statistical analysis 
 
Mean values for the drug and its vehicle control were compared using unpaired 
Student’s t test (drug and vehicle) or one way ANOVA with post-hoc Dunnett’s Test 
(multiple drugs and vehicle). One sample Student’s t tests were used to determine the 
effects of the vehicle alone on contractions. P<0.05 was considered statistically 
significant. 
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5.4. Results 
 
5.4.1 The effect of novel cannabinoid compounds (based on the structure of JWH007) 
on EFS-evoked contractions of the guinea-pig isolated ileum 
 
The effect of JWH007 on EFS-evoked contractions  
 
JWH007 showed a concentration-dependent reduction in the size of EFS-induced 
contractions of the ileum (IC25: 2.0 (0.1 - 45) x 10-10M and IC50:1.5 (0.02 – 100) x10-
8M; see table 5.1). JWH007 started to exert an effect at 3x10-11M, reaching 72 ± 8.07% 
inhibition (P < 0.01) at the highest concentration of 3x10-6M (see figures 5.7 and 5.8). 
The ethanol vehicle had no significant effect when added in low volumes but inhibited 
contractions at the higher volumes required to achieve concentrations of JWH007 ≥ 
3x10-7M. The ethanol vehicle reduced contractions by 18.23 ± 5.5 % (P <0.05) at the 
highest volume added, which was required to achieve JWH007 3x10-6M. 
-11 -10 -9 -8 -7 -6 -5
0
20
40
60
80
100
120
JWH007
vehicle
*
*
**
log [JWH007] M
%
 b
as
el
in
e 
E
FS
 r
es
po
ns
e
 
Figure 5.7 The effect of JWH007 (n=4) and ethanol vehicle (n=6) on the size of EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The 
baseline contraction size was measured immediately before the addition of JWH007 or ethanol vehicle. 
Each symbol represents the mean percentage; vertical bars indicate standard error of the mean (SEM); * 
P< 0.05, **P< 0.01 (one way ANOVA with post-hoc Dunnett’s test). The concentration of ethanol vehicle 
ranged from 0.02-0.33% (shown as respective JWH007 concentrations 10-11-3x10-6M). The same vehicle 
control was used in several cannabinoid experiments. 
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Figure 5.8 Trace showing the effect of JWH007 on EFS-induced contractions of the guinea-pig isolated 
ileum. Concentrations (M) shown below: 
1= 1x10-11                   4= 3x10-10               7= 1x10-8              10= 3x10-7                                                                             
2= 3x10-11                   5= 1x10-9                 8= 3x10-8              11= 1x10-6                                                                               
3= 1x10-10                   6= 3x10-9                 9= 1x10-7              12= 3x10-6                                                                                                               
 
The effect of GA001 on EFS-evoked contractions 
 
GA001 caused a concentration-dependent reduction in the size of EFS-induced 
contractions of the ileum (IC25: 3(0.01 – 910) x 10-10 M and IC50: 4.9 (0.03 – 700) x 
10¯9M; see table 5.1). GA001 started to exert an effect at 1x10-11M, causing 63.9 ± 
2.3% inhibition (P < 0.01) at the highest concentration of 3x10-6M (see figures 5.9 and 
5.10 overleaf). The ethanol vehicle had no significant effect when added in low volumes 
but inhibited contractions at the higher volumes required to achieve concentrations of 
GA001 ≥ 3x10-7M. The ethanol vehicle reduced contractions by 18.23 ± 5.5 % (P 
<0.05) at the highest volume added, which was required to achieve GA001 3x10-6M. 
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Figure 5.9 The effect of GA001 (n=3) and ethanol vehicle (n=6) on the  size of EFS-induced contractions 
of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The baseline  
contraction  size was measured immediately before the addition of GA001 or ethanol vehicle. Each 
symbol represents the mean percentage; vertical bars indicate standard error of the mean (SEM); * P< 
0.05, **P< 0.01 (one way ANOVA with post-hoc Dunnett’s test). The concentration of ethanol vehicle 
ranged from 0.02-0.33% (shown as respective GA001 concentrations 10-11-3x10-6M). The same vehicle 
control was used in several cannabinoid experiments. 
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Figure 5.10 Trace showing the effect of GA001 on EFS-induced contractions of the guinea-pig isolated 
ileum. Concentrations (M) shown below: 
1= 1x10-11                   4= 3x10-10               7= 1x10-8              10= 3x10-7                                                                             
2= 3x10-11                   5= 1x10-9                 8= 3x10-8              11= 1x10-6                                                                               
3= 1x10-10                   6= 3x10-9                 9= 1x10-7              12= 3x10-6                                                                                                               
 
 
 
The effect of GA002 on EFS-evoked contractions 
 
GA002 showed a concentration-dependent reduction in the size of EFS-induced 
contractions of the ileum (IC25: 1.8 (0.1 – 39) x 10-8 M; see table 5.1). GA002 had no 
effect at concentrations below 1x10-6M,  but reached 51.39 ± 7.03% inhibition (P < 
0.01)  at the highest concentration of 3x10-6M (see figures 5.11and 5.12 overleaf). The 
ethanol vehicle had no significant effect when added in low volumes but inhibited 
contractions at the higher volumes required to achieve concentrations of GA002 ≥ 3x10-
7M. The ethanol vehicle reduced contractions by 18.23 ± 5.5 % (P <0.05) at the highest 
volume added, which was required to achieve GA002 3x10-6M.  
 
Figure 5.14 shows the percentage inhibition of EFS-induced contractions of the guinea-
pig isolated ileum by JWH007, GA001 and GA002 at the maximum concentration used 
(3 x 10-6 M). 
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Figure 5.11 The effect of GA002 (n=4) and ethanol vehicle (n=6) on the size of EFS-induced 
contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. The 
baseline   contraction size was measured immediately before the addition of GA002 or ethanol vehicle. 
Each symbol represents the mean percentage; vertical bars indicate standard error of the mean (SEM); * 
P< 0.05, **P< 0.01 (one way ANOVA with post-hoc Dunnett’s test). The bath concentration of ethanol 
vehicle ranged from 0.02-0.33% (shown as respective GA002 concentrations 10-11-3x10-6M). The same 
vehicle control was used in several cannabinoid experiments. 
 
 
 
Figure 5.12 Trace showing the effect of GA002 on EFS-induced contractions of the guinea-pig isolated 
ileum. Concentrations (M)  shown below: 
1= 1x10-11                   4= 3x10-10               7= 1x10-8              10= 3x10-7                                                                             
2= 3x10-11                   5= 1x10-9                 8= 3x10-8              11= 1x10-6                                                                               
3= 1x10-10                   6= 3x10-9                 9= 1x10-7              12= 3x10-6                                                                                                               
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The effect of GA003 on EFS-evoked contractions 
 
Neither GA003 nor the DMSO/ethanol control affected the size of EFS-evoked 
contractions at the concentrations used (see figure 5.13). 
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Figure 5.13 The effect of GA003 (n=4) and mixed ethanol/DMSO vehicle (n=5) on the size of EFS-
induced contractions of the guinea-pig isolated ileum, expressed as percentage of baseline EFS response. 
The baseline  contraction size was measured immediately before the addition of GA003. Each symbol 
represents the mean percentage; vertical bars indicate standard error of the mean (SEM); data was 
analysed by unpaired Student’s t test. The bath concentration of DMSO ranged from 4x10-8-0.012% and 
ethanol from 0.02-0.32% (shown as respective GA003 concentrations 10-11-3x10-6M) 
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Figure 5.14 The percentage inhibiton of EFS-induced contractions of the guinea-pig isolated ileum by 
JWH007, GA001 and GA002 at the maximum concentration used (3 x 10-6 M). 
 
 
 
Agonist IC25 mean (M) IC25 95% 
confidence 
limits (M) 
IC50 mean (M) IC50  95% 
confidence 
limits (M) 
JWH007 2 x 10-10 (0.1 – 45) x 10-
10 
1.5 x 10-8 (0.02 - 100) x 
10-8 
 
GA001 3 x 10-10  (0.01 – 910) x 
10-10 
4.9 x 10-9 (0.03 – 700) x 
10-9 
GA002 1.8 x 10-8 (0.1 – 39) x 10-
8 
             _           _ 
 
Table 5.1 IC25 and IC50 values are shown for JWH007, GA001 and GA002. IC50s were not calculated for 
GA002 because the inhibition did not reach 50% in all experiments. 
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5.4.2 The effect of novel cannabinoid compounds (based on the structure of JWH007) 
on LPS-stimulated TNFα release from macrophages 
 
The effect of JWH007, GA001 and GA006 on macrophage viability 
 
JWH007, GA001 and their vehicle (DMSO 0.02%) had no effect on macrophage 
viability after 16 hours in the presence of 5ng.ml LPS. 5ng/ml LPS alone (GA006 
control) also did not affect cell viability. 30µM GA006, however, reduced cell viability 
by  97.1 ± 1.4% (see figure 5.15). 
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Figure 5.15 The effect of JWH007, GA001, their DMSO vehicle and GA006 (n=3-7) on RAW 264.7 
macrophage viability after 16 hours in the presence of 5ng/ml LPS. The control for JWH007 and GA001 
was DMSO (0.02%) in the presence of LPS, whereas the control for GA006 (dissolved in water) was LPS 
5ng/ml alone. Results are expressed as percentage of media control; vertical bars indicate standard error 
of the mean (SEM); *** P<0.001 (Student’s unpaired t test). 
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The effect of JWH007, GA001 and GA003 on macrophage protein concentration 
 
None of the drugs or their vehicle (DMSO 0.02%) had any effect on macrophage 
concentration after 16 hours in the presence of 5ng/ml LPS. 5ng/ml LPS alone also did 
not affect macrophage protein concentration (see figure 5.16). 
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 Figure 5.16 The effect of JWH007, GA001, GA003 (n=3) and their DMSO vehicle (n=3) on RAW 264.7 
macrophage protein concentration after 16 hours in the presence of 5ng/ml LPS. The effect of LPS 
5ng/ml alone is also shown. Results are expressed as percentage of media control; vertical bars indicate 
standard error of the mean (SEM); data were analysed by one-way ANOVA with post-hoc Dunnett’s test. 
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The effect of JWH007, GA001 and GA003 on LPS-stimulated TNFα release from 
macrophages 
 
This experiment was carried out three times, on three different passages (n=3). Due to 
inter-experiment variability, the results for each passage are shown separately – i.e. each 
graph represents n = 1. Results were expressed as TNFα release in pg/mg protein (figure 
A) and as percentage of LPS stimulation (figure B). Results were not collated and 
statistical tests were not carried out due to the inter-experiment variability. 
 
 
The effect of JWH007, GA001 and GA003 on LPS-stimulated TNFα release from 
macrophages (results from the first passage) 
 
Figure 5.17A overleaf shows the effects of JWH007, GA001 and GA003 on TNFα 
release from RAW 264.7 macrophages. The vehicle (DMSO 0.02%) seemed to have a 
small effect on LPS stimulation of TNFα release, reducing the LPS effect by 27.6% (see 
figure 5.17B overleaf). 10µM JWH007 reduced LPS stimulation by 29.6% (no more 
than its DMSO vehicle), whereas 30µM JWH007 reduced LPS stimulation by 54.8 %. 
10µM GA001 reduced LPS stimulation by 54.9% whereas 30µM GA001 reduced LPS 
stimulation by 68.1 %. 30µM GA003 reduced LPS stimulation by 29.0 % (no more than 
its DMSO vehicle). 
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Figure 5.17A The effect of JWH007, GA001, GA003 and their vehicle (DMSO 0.02%) (replicate 
number=1-3) on RAW 264.7 TNFα release after 16 hours in the presence of 5ng/ml LPS. The effect of 
LPS 5ng/ml alone is also showed. Results are expressed as TNFα release (pg/mg protein).  
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Figure 5.17B The effect of JWH007, GA001, GA003 and their vehicle (DMSO 0.02%) (replicate 
number=1-3) on RAW 264.7 TNFα release after 16 hours in the presence of 5ng/ml LPS. The effect of 
LPS 5ng/ml alone is also showed. Results are expressed as % of LPS 5ng/ml stimulation. 
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The effect of JWH007, GA001 and GA003 on LPS-stimulated TNFα release from 
macrophages (results from the second passage) 
 
Figure 5.18A overleaf shows the effects of JWH007, GA001 and GA003 on TNFα 
release from RAW 264.7 macrophages. The vehicle (DMSO 0.02%) had a substantial 
effect on LPS stimulation of TNFα release, reducing the LPS effect by 72.3% (see 
figure 5.18B overleaf). 10µM JWH007 reduced LPS stimulation by 64.5%, whereas 
30µM JWH007 reduced LPS stimulation by 52.8%. 10µM GA001 reduced LPS 
stimulation by 54.64% whereas 30µM GA001 reduced LPS stimulation by 56.8%. 
30µM GA003 reduced LPS stimulation by 9.0%. The effect of the DMSO vehicle alone 
was greater than the effect of any of the cannabinoids tested. 
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Figure 5.18A The effect of JWH007, GA001, GA003 and their vehicle (DMSO 0.02%) (replicate 
number=2-3) on RAW 264.7 TNFα release after 16 hours in the presence of 5ng/ml LPS. The effect of 
LPS 5ng/ml alone is also showed. Results are expressed as TNFα release (pg/mg protein). 
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Figure 5.18B The effect of JWH007, GA001, GA003 and their vehicle (DMSO 0.02%) (replicate 
number=2-3) on RAW 264.7 TNFα release after 16 hours in the presence of 5ng/ml LPS. The effect of 
LPS 5ng/ml alone is also showed. Results are expressed as % of LPS 5ng/ml stimulation. 
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The effect of JWH007, GA001 and GA003 on LPS-stimulated TNFα release from 
macrophages (results from the third passage) 
 
Figure 5.19A overleaf shows the effects of JWH007, GA001 and GA003 on TNFα 
release from RAW 264.7 macrophages. The vehicle (DMSO 0.02%) seemed to have a 
substantial effect on LPS stimulation of TNFα release, reducing the LPS effect by 
84.1% (see figure 5.19B overleaf). 10µM JWH007 reduced LPS stimulation by 68.2%, 
whereas 30µM JWH007 reduced LPS stimulation by 63.5%. 10µM GA001 reduced 
LPS stimulation by 57.3% whereas 30µM GA001 reduced LPS stimulation by 34.7%. 
30µM GA003 reduced LPS stimulation by 41.0%. The effect of the DMSO vehicle 
alone was greater than the effect of any of the cannabinoids tested. 
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Figure 5.19A The effect of JWH007, GA001, GA003 and their vehicle (DMSO 0.02%) (replicate 
number=2-3) on RAW 264.7 TNFα release after 16 hours in the presence of 5ng/ml LPS. The effect of 
LPS 5ng/ml alone is also showed. Results are expressed as TNFα release (pg/mg protein). 
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Figure 5.19B The effect of JWH007, GA001, GA003 and their vehicle (0.02 DMSO%) (replicate 
number=2-3) on RAW 264.7 TNFα release after 16 hours in the presence of 5ng/ml LPS. The effect of 
LPS 5ng/ml alone is also showed. Results are expressed as % of LPS 5ng/ml stimulation. 
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5.5 Discussion 
 
The aim of this chapter was to set-up two reproducible pharmacological assays to test 
the efficacy of the novel cannabinoid compounds (based on the structure of JWH007) 
and compare them to the parent cannabinoid, the non-selective CB1,CB2 agonist 
JWH007. One assay was designed to test for potency at the CB1 receptor and the other 
to test for CB2 efficacy. Activity at both of these receptors was thought to be important 
as the literature at the time suggested that the CB1 receptor was involved in inhibiting 
intestinal motility and enhancing wound healing (Heinemann et al., 1999; Izzo et al., 
1998; Wright et al., 2005) and the CB2 receptor was involved in reducing inflammation 
(Patel et al., 2010). All of these actions are considered to be therapeutically desirable as 
inflammatory bowel disease (IBD) is characterised by inflammation of sections of the 
GI tract, accompanied by increased intestinal motility, leading to symptoms such as 
cramps and diarrhoea (Kumar and Clark., 2009). 
 
The Paton ileum model was used to investigate the CB1 activity of the novel 
cannabinoids. In this model, the effects on intestinal motility were determined by 
measuring the size of electrically-stimulated contractions in the guinea-pig isolated 
ileum before and after the addition of the cannabinoids (see ‘Electrical field 
stimulation’, chapter 2). The rationale for using this as a CB1 assay was that previous 
studies had reported that cannabinoids inhibited ileal contractions through activation of 
the CB1 receptor (Heinemann et al., 1999; Izzo et al., 1998). 
 
Although cannabinoid-induced inhibition of intestinal contractions was thought to be  
CB1 mediated, this thesis has produced evidence that the inhibition is mediated through 
a non- CB1, non- CB2 receptor. The mechanisms involved, therefore, require further 
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investigation and this has been discussed in more detail in chapter 3. The Paton ileum 
model was still retained for the testing of novel cannabinoids, not as a CB1 assay but to 
investigate the anti-motility effects of the drugs. It is important for a new therapeutic for 
IBD/IBS to reduce motility in order to alleviate intestinal cramps and diarrhoea. 
 
 
In the Paton ileum model, JWH007 (the parent cannabinoid) was found to reduce the 
size of EFS-stimulated contractions in a concentration-dependent manner  reaching 72 ± 
8.07% inhibition at the highest concentration of 3x10-6M. The novel cannabinoid 
GA001 and GA002 found to show the same concentration-dependent inhibitory effect 
as JWH007 and to be of similar potency (see IC25s and IC50s and responses at the 
maximum concentration used; figure 5.14 and table 5.1). GA003 on the other hand had 
no effect on the size of EFS-induced contractions at any concentration used. These 
results show that, when JWH007 is modified with just a methyl group attachment 
(GA001) or a dendritic wedge (GA002), pharmacological activity in the Paton ileum 
model does not alter. However, activity is abolished when a longer spacer chain is 
attached to JWH007 (GA003), probably due to steric hinderence preventing receptor 
binding. Unfortunately, due to a short supply of GA006 (the final cannabinoid-
dendrimer conjugate), this could not be tested in the ileum. As GA003 had no effect on 
the ileal contractions, this could mean that GA006 would also have no effect, since it is 
an even larger compound. Alternatively, the addition of the dendrimer may stabilise the 
spacer, prevent the interference with binding and restore activity. 
 
The effects of cannabinoids their vehicles in the second pharmacological assay (TNFα 
release) are more complicated. Initially, the cannabinoids were screened to make sure 
they were not toxic to the macrophages.This was assessed by looking at the effects of 
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the cannabinoids on macrophage protein concentration and the MTS assay (cell 
viability) results. The results show that DMSO 0.02%, 10µM and 30µM JWH007 and 
have no effect on cell viability or macrophage protein concentration. GA003, though 
not tested in the MTS assay, had no effect on macrophage protein concentration. These 
results suggest that these drugs are not toxic to the macrophages. However, 30µM 
GA006 has a substantial effect on cell viability in the MTS assay, reducing viability by 
97.1± 1.4%. This suggests that the cannabinoid-dendrimer conjugate is toxic to this 
macrophage cell line. This is an interesting result as JWH007 was not shown to be toxic 
and dendrimers are reportedly non toxic (Scharbin et al., 2010). Ideally, the dendrimer 
alone would have been tested in the cell viability assay but, due to time constraints, this 
could not be carried out. 
 
When the cannabinoids JWH007, GA001 and GA003 were tested in the LPS stimulated 
macrophages, there was a great deal of inter-experiment variability. The three 
experiments were carried out on three different cell passages at different times. Due to 
the variability, the results for each passage are shown separately but cannot be 
statistically analysed as each passage is only counted as n =1. 
 
 In the first experiment, the DMSO vehicle seemed to have a small effect on LPS 
stimulation of TNFα release, reducing the LPS effect by 27.6%. JWH007 and GA001 
inhibited LPS-stimulated TNFα release but GA003 had no more effect than its DMSO 
control. GA001 seemed to be more potent than JWH007 (30µM GA001 reduced LPS 
stimulation by 68.1%, whereas 30µM JWH007 only reduced LPS stimulation by 54.8 
%). This suggested that the methyl group attachment to JWH007 enhanced activity in 
this assay. However, conjugation to a longer spacer chain (GA003) abolished activity, 
which supports the results obtained in the ileum. As in the ileum, the spacer probably 
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produces steric hindrance to prevent receptor binding. It is important to note though, as 
this was only an n of 1, statistical analysis could not be carried out. 
 
The two subsequent experiments in the macrophages, however, did not show the same 
results. In these experiments, the DMSO vehicle (0.02%) had a substantial effect on the 
LPS stimulated TNFα release, reducing the release by 73-85%. In comparison, none of 
the cannabinoids reduced TNFα release to the extent of the control alone. 
 
The macrophage assay clearly needs further optimisation. The inter-experiment 
variability may be due to differences in cell confluency because this was estimated by 
observing the cells through a microscope, and is open to human error. When the assay 
has been optimised, the cannabinoids need to be tested again and also the cannabinoid-
dendrimer conjugate, GA006 (which was not tested here). However, from the cell 
viability assay, it seems as though GA006 is highly toxic to cells, so this may skew the 
results for GA006 in this assay.  
 
 
In conclusion, JWH007 was active in both assays and this activity did not seem to be 
adversely affected by conjugation to the small methyl group (GA001). In fact, in the 
cell-based assay, conjugation to the methyl group seemed to enhance the activity of 
JWH007. However, conjugation to the longer spacer chain (GA003) seemed to abolish 
activity, which may be due to steric hindrance preventing receptor binding. As GA003 
had no effect on the ileal contractions or TNFα release, this could mean that GA006 
would also have no effect, since it is an even larger compound. Alternatively, the 
addition of the dendrimer may stabilise the spacer, allow binding to the receptor (s) and 
restore activity. 
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Although GA006 still needs to be tested in the macrophage and ileum assay, the cell 
viability assay suggested that GA006 was extremely toxic to macrophages. Even if 
activity is restored, its toxicity is likely to preclude its use as a therapeutic entity.  
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6. General Discussion 
 
Cannabinoids show great promise in the treatment of inflammatory bowel disease. They 
have been found to reduce intestinal secretions, motility and inflammation (Izzo et al., 
2010). They have also been shown to reduce visceral pain and enhance wound healing 
in the gut (Wright et al., 2005). The mechanisms involved in these effects have not been 
fully elucidated, however, and cannabinoid pharmacology in the gut may not be as 
straightforward as first thought. The major problem with a cannabinoid-based 
therapeutic would be the resulting psychotropic side effects. It may be possible to 
overcome this by conjugating the cannabinoid with a dendrimer, in order to prevent the 
cannabinoid from reaching the CNS whilst retaining absorption across the intestine. 
 
The aims of this thesis were to investigate the cannabinoid receptors involved in 
intestinal motility and also to examine the protection afforded by cannabinoids against 
the type of tissue damage caused by inflammation, as this has not previously been 
studied in the intestine. Another aim was to determine whether cannabinoids retain their 
potency when conjugated to a bulky group such as a dendrimer. 
 
There are several issues concerning the pharmacological tools available to study 
cannabinoid responses in the gut. Firstly, cannabinoid agonists and antagonists are 
highly lipophilic. As they are poorly soluble in water, organic solvents such as DMSO 
or ethanol must be used to dissolve these compounds. DMSO and ethanol however, 
were both found to inhibit EFS-induced contractions in the ileum (see ‘Choice of 
cannabinoid vehicle in the ileum, chapter 2). Ethanol was chosen as the vehicle where 
possible as this had the least effect on contractions, providing the concentrations were 
kept to a minimum. DMSO was used as the cannabinoid vehicle in the macrophage 
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experiments but the effect of this vehicle was variable. In some experiments it had little 
effect but in others the effect was substantial. This may have been due to differences in 
cell confluency. Another problem with the high lipophilicity of cannabinoids is that they 
cannot be washed out of tissues even with multiple washes (see appendix 1). For this 
reason, cannabinoid was not re-added after the washout stages in chapter 5. 
 
An additional issue is that the antagonists available are not highly selective. For 
example, the supposedly selective CB1 antagonists, rimonabant and AM251 have been 
shown to act at several other receptors at concentrations used in pharmacological 
studies (see table 1.4, chapter 1 and Pertwee et al., 2010). Also, there are few 
antagonists available for the putative cannabinoid receptors. There is only one receptor 
antagonist for the putative CBe receptor as this receptor has not been cloned yet. 
Similarly, one antagonist is available for the GPR55 receptor, (-) cannabidiol, but this is 
not very selective (Petitet et al., 1998; Thomas et al., 2007., Ryberg et al., 2007). No 
antagonist has been developed for the GPR119 receptor, so it was difficult to establish 
whether this receptor was involved in any of the effects observed in this study. 
 
The currently held view is that cannabinoids inhibit intestinal motility through 
activation of the CB1 receptor (Colombo et al., 1998; Coutts et al., 1997; Izzo et al., 
2000a; Pertwee et al., 1996). However, much of this evidence relies on the use of one 
CB1 receptor antagonist, rimonabant, which does not seem to be as selective as first 
thought (see table 1.4, chapter 1). In addition, the effects of selective CB1 agonists on 
intestinal motility do not seem to have been explored. This, together with new evidence 
for non-CB1, non-CB2 effects on intestinal motility (Mang et al., 2001; Smid et al., 
2007), suggests that cannabinoid pharmacology of the gut may be more complicated 
than first thought.  
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Results from this thesis suggest, contrary to current opinion, that the CB1 receptor is not 
involved in cannabinoid-mediated inhibition of EFS-evoked contractions of the guinea-
pig ileum. All cannabinoids were found to reduce the size of contractions in a 
concentration-dependent manner but this was not blocked by either of the CB1 receptor 
antagonists (AM281 and rimonabant) used. This was further supported by the fact that 
ACPA had no effect on EFS contractions, even though the concentration added to the 
bath (1 x 10-4M) was 50000 times higher than its Ki value (2.2 x 10-9 M) for the CB1 
receptor (see table 1.1, chapter 1). The CB1 antagonists (AM281 and rimonabant) alone 
increased EFS-induced contraction size in this study, which supports the literature. 
However, researchers have suggested that this is due to inverse agonism or antagonism 
of endogenous agonists at the CB1 receptor (Pertwee et al., 1996). The results found in 
this study however, suggest that this is not the case as the CB1 receptor does not seem to 
be involved in the inhibition of contraction. Therefore, AM281 and rimonabant would 
appear to be acting via a different mechanism other than inverse agonism of CB1 
receptors; a mechanism that is currently unknown. 
 
This thesis provides preliminary evidence that GPR119 is present on ileal smooth 
muscle and that this receptor may be involved in controlling motility. This was 
suggested by the inhibition of EFS and carbachol-induced contractions by the GPR119 
agonist PSN. These responses were observed at similar concentrations to the agonist’s 
EC50 at the GPR119 receptor (in the yeast fluorimetric assay; Overton et al., 2006), 
although the involvement of GPR119 in the responses needs to be confirmed when a 
GPR119 antagonist becomes available. 
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This study also suggests that at least one other receptor may be involved in contractile 
inhibition. Both O-1602 and (+)WIN caused a reduction in the size of EFS-induced 
contractions, but these responses were not blocked by any antagonist, suggesting that 
the responses were not mediated by any of the classical receptors, GPR55 or the CBe 
receptor. Simultaneous blockade of the CB1 and CB2 receptor also had no effect on the 
(+)WIN-induced inhibition of contractions. GPR119 does not seem to be involved as 
(+)WIN does not bind to GPR119 and neither (+)WIN nor O-1602 reduced carbachol-
induced contraction.  
 
As (-)WIN had no effect on contractility of the ileum, this strongly suggests that the 
response to (+)WIN is mediated by a protein target such as a receptor. It is unclear 
whether this is the case for O-1602. In the future, the effect of pertussis toxin (which 
inactivates Gi and Go G proteins) on cannabinoid-mediated inhibition of ileal 
contractions could be investigated. This would give an indication of whether the effects 
of these compounds are mediated through a Gi protein-coupled receptor. 
 
With regard to cannabinoid-mediated protection against inflammatory damage, the 
cardioprotection and hepatoprotection (Montecucco et al., 2009; Raj et al., 2007) is 
thought to be CB2 receptor mediated whereas cannabinoid receptor-independent 
mechanisms may be involved in the neuroprotective effects (Hampson et al., 1998). The 
studies reported in this thesis are the first to investigate potential protective effects of 
cannabinoids in the ileum.  
 
(+)WIN effectively limited the contractile dysfunction induced by H2O2, demonstrating 
cannabinoid-mediated tissue protection. The receptors CB1, CB2 and CBe do not seem to 
be involved in cannabinoid-mediated protection of the ileum as (+)WIN’s protective 
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effect was not blocked by rimonabant, SR144528 or O-1918. This was supported by the 
lack of effect of ACPA and abnormal-CBD cannabidiol. The GPR119 and GPR55 
receptors are unlikely to be involved as the GPR119 and GPR55 agonists, PSN and O-
1602 respectively, had no effect on the H2O2-induced damage.  
 
As the protective effect of (+)WIN does not seem to be due to any of the classical or 
putative cannabinoid receptors, it may either be mediated through a novel receptor or it 
may be a cannabinoid receptor independent effect. 
 
 (+)WIN could be acting as a free radical scavenger to prevent tissue damage. As 
(+)WIN could not be washed out, the cannabinoid would have been present to act as a 
scavenger and reduce oxidative damage. Anti-oxidant effects have been shown to 
contribute to the neuroprotective (Hampson et al., 1998), cardioprotective (Montecucco 
et al., 2009) and hepatoprotective (Rajesh et al., 2007) effects of cannabinoids. The CB1 
(Kessiova et al., 2006) and CB2 (Montecucco et al., 2009; Rajesh et al., 2007) receptors 
have previously been implicated in the anti-oxidant effects of cannabinoid as well as 
cannabinoid receptor independent effects (Chen et al., 2000; Kessiova et al., 2006). If 
(+)WIN were acting as a free radical scavenger, this would be consistent with the 
cannabinoid receptor independent effect observed in this study and reported in some of 
the literature (Chen et al., 2000; Kessiova et al., 2006).  
 
In the literature, cannabinoids were shown to be neuroprotective through non-
cannabinoid-receptor mediated antioxidant effects (Hampson et al., 1998). This could 
be the case in the gut, i.e. the antioxidant effect of (+)WIN may protect cholinergic 
neurones in the myenteric plexus. As it is not clear with the EFS-evoked contractions 
whether the H2O2-damage is to the myenteric neurones or smooth muscle it would be 
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interesting to look at the effects of H2O2 on carbachol-induced contractions of the ileum, 
to see if it affects smooth muscle directly and to look at the effect of (+)WIN in this 
assay. 
 
One of the aims of the current studies was to attempt to conjugate a cannabinoid to a 
large dendrimer such that it would be excluded from the CNS. It was not known if such 
a dendrimer would retain pharmacological activity and so had to be tested in 
cannabinoid receptor assay systems. The Paton ileum model was still retained for the 
testing of novel cannabinoids, even though it was shown not to be a CB1 assay, to 
investigate the anti-motility effects of the drugs. It is important for a new therapeutic for 
IBD to reduce motility in order to alleviate intestinal cramps and diarrhoea. 
 
The cannabinoid JWH007 was active in both assays and this activity did not seem to be 
reduced by conjugation to the small methyl group (GA001). However, conjugation to 
the longer spacer chain (GA003) seemed to abolish activity in the assays, possibly due 
to steric hindrance preventing receptor binding. This could mean that the bulkier GA006 
would also have no effect, as addition of the dendrimer could increase steric hindrance. 
It is possible, however, that activity of the cannabinoid may be restored by the addition 
of the dendrimer as this may stabilise the spacer and allow binding to the receptor (s). 
Unfortunately, due to a shortage of GA006, the pharmacological activity of this 
compound could not be tested. Surprisingly, GA006 was shown to be highly toxic in the 
cell viability assay which may limit its potential as a therapeutic. This result was 
unexpected as the cananbinoid (JWH007) alone did not affect cell viability and 
PAMAM dendrimers are reportedly non-toxic (Scharbin et al., 2010), suggesting it is 
the conjugation of these compounds which is noxious to cells. 
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In summary, this thesis has shown that cannabinoids reduce contractions and protect 
against inflammatory damage in the ileum, which are two desirable effects in the 
treatment of IBD. However, contrary to the current held view (Colombo et al., 1998; 
Coutts et al., 1997; Izzo et al., 2000a; Pertwee et al., 1996), the CB1 receptor was not 
shown to be involved in cannabinoid-mediated inhibition of contraction. This study has 
instead provided preliminary evidence that GPR119 may be present on smooth muscle 
and is involved in inhibiting contractions. This contrasts findings in the literature which 
suggest that cannabinoids do not act post-synaptically to exert their effects (Lynn et al., 
1994; Mang et al., 2001; Pertwee., 2001). There is also evidence for a pre-synaptic 
receptor distinct from any of the classical or putative cannabinoid receptors.  
 
The cannabinoid-mediated protection against inflammatory-type damage also did not 
seem to be mediated by any of the known or putative cannabinoid receptors which 
compares with cannabinoid receptor-independent effects supported in the literature. It is 
possible that this protection could be due to free radical scavenging, as this would be 
consistent with a receptor-independent effect. However, both cannabinoid-mediated 
protection against inflammatory damage as well as inhibition of contraction require 
more extensive research. 
 
Although cannabinoids have shown effects which may be beneficial in the treatment of 
IBD, the psychotropic side effects are a major drawback. Conjugation to a dendrimer 
may prevent the psychotropic side effects associated with cannabinoids, but this thesis 
has shown that the toxicity of the cannabinoid-dendrimer GA006 will limit its use as a 
therapeutic for IBD. In the future, other conjugations could be tested, for example, using 
different cannabinoids, dendrimers or attachment strategy. However, as the 
pharmacology of cannabinoids in the gut progresses, the CB1 receptor may emerge as a 
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less important target for IBD therapeutics than other receptors. It may then be possible 
to develop a therapeutic using a cannabinoid which does not bind to CB1. This would 
avoid the psychotropic effects of cannabinoids without the need to conjugate the 
compounds to bulkier molecules. 
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Appendix 1 
 
The effects of cannabinoid washout in the isolated guinea-pig ileum 
 
The effect of washout on WIN 
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WIN 10-7M was added to the bath and then washed out after 30 minutes. 
 
The effect of washout on rimonabant 
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Rimonabant 10-6M was added to the bath and then washed out after 30 minutes. 
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The effect of washout on O-1602 
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O-1602 1x10-5M was added to the bath and then washed out after 30 minutes. 
 
 
 
The effect of washout on PSN 
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 PSN 3x10-5M was added to the bath and then washed out after 30 minutes. 
